

CURRICULUM VITAE

Name: Jay Arthur Berzofsky

June 21, 2019

Education:

1967 - A.B., Harvard University (Summa Cum Laude in Chemistry)
 1971 - Ph.D., Albert Einstein College of Medicine, Molecular Biology
 1973 - M.D., Albert Einstein College of Medicine, Medical Scientist
 Training Program

Brief Chronology of Employment:

| | |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1973 - 1974 | Medical Internship (Straight Medicine), Massachusetts General Hospital, Boston, Massachusetts |
| 1974 - 1976 | Research Associateship, Laboratory of Chemical Biology National Institute of Arthritis, Metabolism, and Digestive Diseases, National Institutes of Health |
| 1976 - 1979 | Investigator ("Expert"), Metabolism Branch, National Cancer Institute, National Institutes of Health |
| 1979 - 1987 | Senior Investigator (tenured), Metabolism Branch, National Cancer Institute, National Institutes of Health |
| 1987 - 2003 | Chief, Molecular Immunogenetics and Vaccine Research Section, Metabolism Branch, National Cancer Institute, National Institutes of Health |
| 2004 – Date | Chief, Vaccine Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health |

Honors/Awards:

Detur Prize, Harvard University, 1964
 Harvard College Scholarship, Harvard University, 1964
 Phi Beta Kappa, Junior Year, Harvard University, 1966
 Summa Cum Laude in Chemistry, Harvard University, 1967
 Sophia Freund Prize for Graduate with Highest Cumulative Grade Point Average, Harvard College, 1967
 NIH Special Achievement Award, 1982
 Hollister - Stier's Distinguished Lectureship, Washington State University, 1986
 J. W. McLaughlin Fund Distinguished Contributions to Immunology Lectureship, University of Texas Medical School, Galveston, 1987
 U. S. Public Health Service Superior Service Award, 1988
 31st Michael Heidelberger Award and Lecture, Columbia University, 1992

McLaughlin Visiting Professorship, University of Texas Medical School,
Galveston, 1992
 American Society for Clinical Investigation, President (elected) 1993-94
 Fellow of the American Association for the Advancement of Science, 1995
 Cytokine Interest Group Best Paper of 2000 Award to fellow in lab, 2001
 The 2004 Tadeusz J. Wiktor Memorial Lecture, Wistar Institute, University of
 Pennsylvania, Philadelphia, PA., November 17, 2004
 Chair (elected), Medical Sciences Section, American Association for the Advancement of
 Science, 2007-2008
 The Herschel Zackheim Lectureship Award, International Society for Cutaneous
 Lymphomas, 2007
 Distinguished Alumnus of the Year Award 2007, Albert Einstein College of Medicine
 NIH Director's Award, 2008
 NIH/NCI Merit Award, 2008
 NIH/NCI Merit Award, 2011
 The 2012 Iris Fisher Memorial Lecture, Yale University Cancer Center, April 24, 2012
 NCI Certificate of Appreciation for Outstanding Contributions to Research Innovation,
 2012
 Federal Technology Transfer Awards—2011, 2012, 2013, 2014, 2015, 2016, 2017
 European Academy of Tumor Immunology, elected 2016.
 2018 EATI Career Award “for his important contribution to tumor immunotherapy” and
 Honorary Lecture, European Academy of Tumor Immunology, 2018

Professional Society Memberships:

Association of Harvard Chemists, 1967 - present
 New York Academy of Sciences, 1971 - present
 American Association of Immunologists, 1977 - present
 Undersea Medical Society, 1978 - 1988
 American Federation for Clinical Research, 1979 - present
 American Society of Biological Chemists, 1980 - present
 American Society for Clinical Investigation, 1983 - present,
 Secretary-Treasurer, 1989 - 1992
 President-elect, 1992-1993
 President, 1993-94
 Association of American Physicians, 1990 – present
 American Association for the Advancement of Science, Fellow 1995-present;
 Chair of Medical Sciences Section, 2007-2008
 Clinical Immunological Society, 2002-present
 American Association for Cancer Research, 2006 - present
 Faculty of 1000, 2006-present
 Society for the Immunotherapy of Cancer (SITC), 2015-present
 European Academy of Tumor Immunology, 2016-present

Editorial Positions:

Associate Editor, *Journal of Immunology*, 1980 - 1984
 Editorial Advisory Board, *Journal of Molecular and Cellular Immunology*, 1983-88

Advisory Editor, *Molecular Immunology*, 1985 - 1988
 Editorial Board, *Peptide Research*, 1987 - present
 Transmitting Editor, *International Immunology*, 1988 - 2000
 Editorial Board, *Journal of Human Virology*, 1997-present
 Consulting Editor, *Journal of Clinical Investigation*, 1998-2005
 Section Editor, *Clinical Immunology*, 2002-2007
 Associate Editor, *Clinical Cancer Research*, 2002-present
 Editorial Board, *Cancer Research*, 2010—present
 Editorial Board, *Cancer Immunology, Immunotherapy*, 2013-present.

Professional Committees and Activities:

American Association of Immunologists, Membership Committee, 1981 - 1988
 American Association of Immunologists, Chairman of Membership Committee, 1983 - 1988
 NIH Clinical Center Compensable Events Committee, 1982 - present
 American Society for Clinical Investigation, Council, 1989-1994 (President, 1993-94)
 NCI Division of Clinical Sciences Promotion and Tenure Committee, 1995-2001.
 NCI Division of Clinical Sciences Research Advisory Group, 1995-2001
 NCI Director's Intramural Advisory Board, 1997-99
 NIH AIDS Vaccine Research Center Steering Committee, 1997-present
 NIH Search Committee for Director of Office of AIDS Research, 1997-98
 NIAID Malaria Vaccine Task Force, 1998-present
 NCI Vaccine Working Group, Chairman/Organizer, 1998-present
 NCI/CCR Immunology Faculty Steering Committee, 2001-present
 NCI/CCR HIV & Virology Faculty Steering Committee, 2001-present
 NCI/CCR Frontiers in Science Newsletter Editorial Board, 2001-present.
 NCI/NIH Committee for Biodefense, founding member, 2001-present.
 NCI Center of Excellence in Immunology, Steering Committee, 2003-present.
 NIH CRADA 01361 with Genzyme Corporation. Co-principal Investigator, 2003-present
 Advisory Committee, Harvard Blood Center, 2004-present
 External Advisory Committee, University of London, 2006-present.
 NCI Center of Excellence in HIV & Cancer Viruses, Executive Committee, 2006-present
 NIAID AIDS Vaccine Research Subcommittee, 2007-present
 NIH Director's Biennial Report to Congress, 2007, Team Leader for Cancer topic.
 NCI Cancer & Inflammation Program Tenure Track Search Committee, Chair, 2007-2008.
 NIAID Laboratory of Malaria Immunology & Vaccines Lab Chief Search Committee, 2008.
 NIAID Vaccine Research Center Bioinformatics PI Search Committee, 2017

Military Service:

Commissioned Corps, United States Public Health Service, 1974 - 1976

Other Research Experience:

Summers, 1962 - 1965 Research Assistant, Pediatric Research Unit (H. M. Nitowsky), Sinai Hospital, Baltimore, Maryland

Summer, 1966 Research Assistant, Organic Synthesis Laboratory
 C. H. Robinson), Department of Pharmacology, Johns
 Hopkins School of Medicine, Baltimore, Maryland
 Summer, 1967 Visiting Scientist, Laboratoire d'Enzymologie (G. N.
 Cohen), Centre National de la Recherche Scientifique, Gif-sur-Yvette, France

Medical Licensure: Maryland

Major Outside Activities (Not permitted by NIH after 2005)

Medimmune, Inc.—Scientific Founder and Chair, Scientific Advisory Board, 1989-2002
 Magainin Pharmaceuticals, Inc.—Member, Scientific Advisory Board, 1991-97
 Diacrin, Inc.—Member, Scientific Advisory Board, 1993-2002
 Pharmadyne, Inc.—Scientific Co-Founder and Chair, Scientific Advisory Board, 1997-
 2004
 Boston University Community Technology Fund—Consultant, 1997-1999
 Health Care Ventures, Inc.—consultant, 1998
 EMD Pharmaceuticals, Inc.—consultant, 2000-2003
 Epivax, Inc.—Member, Scientific Advisory Board, 2000-2004
 Therapeutic Devices, Inc.—consultant, 2002-2004
 Transform Pharmaceuticals, Inc.—consultant 2002-2005
 Celera Genomics, Inc.—consultant 2002-2004
 Genencor International, Inc.—consultant 2003-2004.

Major areas of research:

1. Molecular basis of antigen recognition by T lymphocytes
2. Processing of antigens and their presentation by major histocompatibility molecules
3. Structure of antigenic sites on protein antigens
4. Genetic regulation of the immune response
5. Design and development of artificial vaccines based on immunological principles and peptide synthesis or recombinant DNA technology
6. AIDS vaccines and diagnostic techniques
7. Malaria vaccines
8. Cancer vaccines
9. Antigen-antibody interactions
10. Structure-function relationships in proteins and protein conformation.
11. Regulation of tumor immunosurveillance and T cell function by cytokines and regulatory cells
12. NKT cells in the regulation of tumor immunity
13. Mucosal immunity and vaccines
14. Cytokines, chemokines, and TLR ligands as immune modulators and vaccine adjuvants.

**CURRENT POSITIONS HELD BY FORMER LAB MEMBERS AND TRAINEES
(CHRONOLOGICAL ORDER – PAST TO MOST RECENT)**

| <u>Alumna/Alumnus</u> | <u>Title</u> | <u>Current Position</u> |
|-------------------------------|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Yoichi Kohno, M.D., Ph.D. | Postdoctoral Fellow | Professor & Chair, Dept. of Pediatrics, Chiba University School of Medicine, and Director, Chiba University Hospital, Chiba, Japan |
| Ira J. Berkower, M.D., Ph.D. | Postdoctoral Fellow | Chief, Lab of Immunoregulation, Division of Viral Products, Office of Vaccine Research and Review at the Center for Biologics Evaluation & Research, FDA, emeritus |
| Shoichi Ozaki, M.D., Ph.D. | Postdoctoral Fellow | University President, St. Marianna University Former Professor & Chair, Dept. of Rheumatic & Allergic Diseases, & Dean of the St. Marianna University Medical School St. Marianna University School of Medicine, Kawasaki, Japan; |
| Howard Streicher, M.D. | Postdoctoral Fellow | Sr. Investigator and Head of Vaccine Research Investigational Drug Branch, Cancer Therapy Evaluation Program, NCI |
| Kemp B. Cease, M.D., M.B.A. | Postdoctoral Fellow | Chief, Hematology-Oncology Section, VA Ann Arbor Healthcare System Associate Professor, Department of Internal Medicine, University of Michigan (also Associate Chair in the Department of Internal Medicine, U. of Michigan, from September 1996 - May 2002) |
| Hidemi Takahashi, M.D., Ph.D. | Postdoctoral Fellow | Professor & Chair, Dept. of Immunology and Microbiology Nippon Medical School, Tokyo, Japan |
| Anne Hosmalin, M.D., Ph.D. | Postdoctoral Fellow | Director of Research, Dendritic Cell Laboratory, & Director of International Relations, Institut Cochin de Génétique Moléculaire (ICGM) and INSERM, Paris, France; recent past President, French Society for Immunology |

| | | |
|----------------------------------|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Michael F. Good, M.D., Ph.D. | Postdoctoral Fellow | Emeritus Director, Queensland Institute for Medical Research, Brisbane, Australia, now Professor and Australia Fellow, Institute for Glycomics, Griffith University, Queensland, Australia |
| Toshiyuki Takeshita, M.D., Ph.D. | Postdoctoral Fellow | Professor & Chair, Dept. of Obstetrics and Gynecology First Hospital of Nippon Medical School Tokyo, Japan |
| Mutsunori Shirai, M.D., Ph.D. | Postdoctoral Fellow | Professor & Chair, Department of Microbiology, Yamaguchi University School of Medicine Yamaguchi, Japan |
| Akahiko Kurata, M.D., Ph.D. | Postdoctoral Fellow | First Dept of Internal Medicine, Nagasaki University School of Medicine Nagasaki, Japan |
| Kazutaka Kurokohchi, M.D., Ph.D. | Postdoctoral Fellow | Dept of Gastroenterology & Neurology Kagawa University, Kagawa, Japan |
| Sara J. Brett, Ph.D. | Postdoctoral Fellow | Dept of Immunology, GlaxoSmithKline, Brentford, London, UK |
| Jeffrey Ahlers, Ph.D. | Staff Scientist | Chief Scientific Officer/Manager, PI, Vaccine & Gene Therapy Institute- Port St. Lucie, FL |
| Anne S. De Groot, M.D. | Postdoctoral Fellow | Associate Professor, Department of Medicine, University of Rhode Island; President & CEO, EpiVax, Inc. |
| Pablo Sarobe, Ph.D. | Postdoctoral Fellow | Associate Professor of Immunology, Center for Applied Medical Research, University of Navarra, Pamplona, Spain |
| Masaki Terabe, Ph.D. | Postdoctoral Fellow | Senior Associate Scientist and Deputy Section Chief, MIVR Section Vaccine Branch, CCR, NCI |
| Richard D. England, M.D., Ph.D. | Clinical Associate | Director, Pfizer Clinical Sciences, Groton, CT |
| Chuck Smith, M.D., Ph.D. | Clinical Associate | Senior Director, Clinical Development Genencor International, Inc. Palo Alto, CA |

| | | |
|-------------------------------|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Margaret Marshall, M.D. | Clinical Associate | Senior Director, Clinical Development, Kite Pharma, Inc., Los Angeles, CA |
| Martha Alexander-Miller | Postdoctoral Fellow | Full Professor and Chair, Dept. of Microbiology and Immunology Wake Forest Univ School of Medicine Graduate Program Director & Director, Institutional Flow Cytometry Facility Clemmons, NC |
| Graham Leggatt, Ph.D. | Postdoctoral Fellow | Assistant Professor/Senior Lecturer, Dept of Immunology, University of Queensland, Brisbane, Australia |
| Theresa J. Goletz, Ph.D. | Postdoctoral Fellow | Global Head, NBE Drug Disposition, EMD Serono, Inc., Boston, MA |
| Takahiro Okazaki, M.D., Ph.D. | Postdoctoral Fellow | Associate Professor, Division of Rheumatology, Department of Medicine St. Marianna University School of Medicine, Kawasaki, Japan |
| Taku Tskukui | Postdoctoral Fellow | Assistant Professor, Dept. of Immunol., Nippon Medical School, Tokyo, Japan |
| SangKon Oh, Ph.D. | Postdoctoral Fellow | Professor and Director, Center for Transplantation Immunology, Baylor Institute for Immunology Research & Baylor University, Dallas, TX |
| Shun Takaku | Postdoctoral Fellow | Assistant Professor, Dept. of Immunol., Nippon Medical School, Tokyo, Japan |
| Qing Zhu, M.D., Ph.D. | Postdoctoral Fellow | Associate Professor, Chinese Academy of Medical Sciences, Beijing, China |
| Igor M. Belyakov, M.D., Ph.D. | Staff Scientist | Research Assistant Professor, Dept. of Internal Medicine, University of Michigan, and Michigan Nanotechnology Institute for Medicine and Biological Sciences |
| Amiran Dzutsev, Ph.D. | Research Fellow | Staff Scientist II, (Staff Scientist equivalent) Leidos, Cancer & Inflammation Program, CCR, NCI, Bethesda, MD |
| Dmitry Isakov | Postdoctoral Fellow | University of Michigan, Department of Internal Medicine |

| | | |
|------------------------------|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Elena Ambrosino | Postdoctoral Fellow | Assistant Professor, Inst. for Public Health Genomics, Dept. of Genetics and Cell Biology, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands |
| Yi-Hsiang Huang, M.D., Ph.D. | Postdoctoral Fellow | Professor, Institute of Clinical Medicine, National Yang-Ming University. Attending Physician, Division of Gastroenterology Taipei Veterans General Hospital Taipei, Taiwan |
| Jessica O’Konek, Ph.D. | Postdoctoral Fellow | Research Lab Specialist Lead, Michigan Nanotechnology Inst. for Med. and Biological Sciences, University of Michigan School of Medicine |
| Huifeng Yu, Ph.D. | Postdoctoral Fellow | Staff Fellow, Center for Biologics Evaluation and Research FDA, White Oak, MD |
| Karen Muindi, Ph.D. | Postdoctoral Fellow | Center for Biologics Evaluation & Research, FDA, White Oak, MD |
| Satomi Takao, Ph.D. | Postdoctoral Fellow | Research Associate/Acting Instructor, Center for Intelligent Materials and Systems Dept. of Mechanical Engineering, University of Washington |
| Stanley Parish, Ph.D. | Postdoctoral Fellow | Manager, ILSI Health & Environmental Sciences Institute, Washington, DC |
| Liat Izhak, Ph.D. | Postdoctoral Fellow | Senior Research Scientist, Janssen Pharmaceutical Companies of Johnson & Johnson, Philadelphia area, PA |
| Alison Hogg, Ph.D. | Postdoctoral Fellow | Senior Manager, Scientific Affairs, Emergent BioSciences, Gaithersburg, MD |
| Yichuan Wang, M.D., Ph.D. | Postdoctoral Fellow | Staff Scientist, NCI Frederick/Leidos |
| Shingo Kato, M.D., Ph.D. | Postdoctoral Fellow | Assistant Professor, Yokohama City University School of Medicine. |
| Rolf Billeskov, Ph.D. | Visiting Postdoctoral Fellow | Postdoctoral Fellow, Serum Statens Institute, Copenhagen, Denmark |

| | | |
|-----------------|---------------------------|--------------------------------------------------------------|
| Hannah Weber | Post-baccalaureate Fellow | MD-PhD Student, NYU School of Medicine |
| Faith Robertson | Post-baccalaureate Fellow | Medical student, Harvard Medical School |
| Katharine Clark | Post-baccalaureate Fellow | Medical student, Johns Hopkins University School of Medicine |
| Blake Frey | Post-baccalaureate Fellow | MD-PhD Student, University of Alabama, Birmingham. |
| Shweta Kulkarni | Post-baccalaureate Fellow | Graduate student, University of Florida |
| Salil Ojha | Post-baccalaureate Fellow | Medical student, University of Texas |

BIBLIOGRAPHY

Jay Arthur Berzofsky

1. Nitowsky, H.M., L. Matz, and J.A. Berzofsky. 1966. Studies on oxidative drug metabolism in the full-term newborn infant. *J. Pediatrics* 69:1139-1149.
2. Berzofsky, J.A., J. Peisach, and W.E. Blumberg. 1971. Sulfheme proteins. I. Optical and magnetic properties of sulfmyoglobin and its derivatives. *J. Biol. Chem.* 246:3367-3377.
3. Peisach, J., J.A. Berzofsky, and W.E. Blumberg. 1973. Electronic control of oxygen binding to heme proteins. In Proceedings of the Second International Symposium on Oxidases and Related Oxidation-Reduction Systems. T.E. King, H.S. Mason, and M. Morrison, editors. University Park Press, Baltimore. 265-278.
4. Berzofsky, J.A. 1971. The nature of sulfmyoglobin: Chemical, physical, and oxygen-binding properties. Albert Einstein College of Medicine, New York.
5. Berzofsky, J.A., J. Peisach, and W.E. Blumberg. 1971. Sulfheme proteins II. The reversible oxygenation of ferrous sulfmyoglobin. *J. Biol. Chem.* 246:7366-7372.
6. Berzofsky, J.A., J. Peisach, and J.O. Alben. 1972. Sulfheme proteins. III. Carboxysulfmyoglobin: The relation between electron withdrawal from iron and ligand binding. *J. Biol. Chem.* 247:3774-3782.
7. Berzofsky, J.A., J. Peisach, and B.L. Horecker. 1972. Sulfheme proteins. IV. The stoichiometry of sulfur incorporation and the isolation of sulfhemin, the prosthetic group of sulfmyoglobin. *J. Biol. Chem.* 247:3783-3791.
8. Berzofsky, J.A., A.N. Schechter, and H. Kon. 1976. Does Freund's adjuvant denature protein antigens? EPR studies of emulsified hemoglobin. *J. Immunol.* 116:270-273.
9. Berzofsky, J.A., J.G. Curd, and A.N. Schechter. 1976. Probability analysis of the interaction of antibodies with multideterminant antigens in radioimmunoassay: application to the amino terminus of the beta chain of hemoglobin S. *Biochem* 15:2113-2121.
10. Berzofsky, J.A., A.N. Schechter, G.M. Shearer, and D.H. Sachs. 1977. Genetic control of the immune response to staphylococcal nuclease III. Time course and correlation between the response to native nuclease and the response to its polypeptide fragments. *J. Exp. Med.* 145:111-112.
11. Berzofsky, J.A., A.N. Schechter, G.M. Shearer, and D.H. Sachs. 1977. Genetic control of the immune response to staphylococcal nuclease IV. H-2-linked control of the relative proportions of antibodies produced to different determinants of native nuclease. *J. Exp. Med.* 145:123-145.

12. Sachs, D.H., J.A. Berzofsky, C.G. Fathman, D.S. Pisetsky, A.N. Schechter, and R.H. Schwartz. 1976. The immune response to staphylococcal nuclease: A probe of cellular and humoral antigen specific receptors. *Cold Spring Harbor Symp. Quant. Biol.* 41:295-306.
13. Berzofsky, J.A., R.H. Schwartz, A.N. Schechter, and D.H. Sachs. 1978. H-2 linked control of the antibody and cellular immune response to nuclease at the level of individual regions of the molecule. In *Ir Genes and Ia Antigens* (Proceedings of the Third Ir Gene Workshop, December, 1976, Asilomar, CA). H.O. McDevitt, editor. Academic Press, New York. 423-431.
14. Berzofsky, J.A. 1978. Genetic control of the immune response to mammalian myoglobins in mice I. More than one I-region gene in H-2 controls the antibody response. *J. Immunol.* 120(2):360-369.
15. Pisetsky, D.S., J.A. Berzofsky, and D.H. Sachs. 1978. Genetic control of the immune response to staphylococcal nuclease. VII. Role of non-H-2-linked genes in the control of the anti-nuclease antibody response. *J. Exp. Med.* 147(2):396-408.
16. Berzofsky, J.A. 1978. The assessment of antibody affinity from radioimmunoassay. *Clinical Chem.* 24(3):419-421.
17. Berzofsky, J.A. 1978. Genetic control of the antibody response to sperm whale myoglobin in mice. *Adv. Exp. Med. Biol.* 98:225-240.
18. Berzofsky, J.A., D.S. Pisetsky, R.H. Schwartz, A.N. Schechter, and D.H. Sachs. 1978. Genetic control of the immune response to staphylococcal nuclease in mice. *Adv. Exp. Med. Biol.* 98:241-258.
19. Schwartz, R.H., J.A. Berzofsky, C.L. Horton, A.N. Schechter, and D.H. Sachs. 1978. Genetic control of the T-lymphocyte proliferative response to staphylococcal nuclease. Evidence for multiple MHC-linked Ir gene control. *J. Immunol.* 120:1741-1749.
20. Sachs, D.H., J.A. Berzofsky, D.S. Pisetsky, and R.H. Schwartz. 1978. Genetic control of the immune response to staphylococcal nuclease. In *Seminars in Immunopathology* Vol.I. B. Benacerraf, editor. Springer-Verlag, New York. 51-83.
21. Berzofsky, J.A., L.K. Richman, and D.J. Killion. 1979. Distinct H-2-linked Ir genes control both antibody and T cell responses to different determinants on the same antigen, myoglobin. *Proc. Natl. Acad. Sci. U. S. A.* 76:4046-4050.
22. Richman, L.K., R.J. Klingenstein, J.A. Richman, W. Strober, and J.A. Berzofsky. 1979. The murine Kupffer cell. I. Characterization of the cell serving accessory function in antigen-specific T cell proliferation. *J. Immunol.* 123:2602-2609.

23. Richman, L.K., W. Strober, and J.A. Berzofsky. 1980. Genetic control of the immune response to myoglobin: III. Determinant-specific, two Ir gene phenotype is regulated by the genotype of reconstituting Kupffer cells. *J. Immunol.* 124:619-624.
24. Berzofsky, J.A. 1980. Immune response genes in the regulation of mammalian immunity. In *Biological Regulation and Development*. R.F. Goldberger, editor. Plenum Press, New York. 467-594.
25. Berzofsky, J.A., G. Hicks, J. Fedorko, and J. Minna. 1980. Properties of monoclonal antibodies specific for determinants of a protein antigen, myoglobin. *J. Biol. Chem.* 255:11188-11191.
26. Berzofsky, J.A., L.K. Richman, and W. Strober. 1982. Determinant-specific antigen presentation by liver Kupffer cells under control of H-2-linked Ir genes. In *Recent Advances in Mucosal Immunity*. W. Strober, L.A. Hanson, and K.W. Sell, editors. Raven Press, New York. 213-223.
27. Berzofsky, J.A., and A.N. Schechter. 1981. The concepts of crossreactivity and specificity in immunology. *Molec. Immunol.* 18:751-763.
28. Berzofsky, J.A., and L.K. Richman. 1981. Genetic control of the immune response to myoglobins. IV. Inhibition of determinant-specific Ir-gene-controlled antigen presentation and induction of suppression by pretreatment of presenting cells with anti-Ia antibodies. *J. Immunol.* 126:1898-1904.
29. Berzofsky, J.A., G.K. Buckenmeyer, G. Hicks, F.R.N. Gurd, R.J. Feldmann, and J. Minna. 1982. Topographic antigenic determinants recognized by monoclonal antibodies to sperm whale myoglobin. *J. Biol. Chem.* 257:3189-3198.
30. Berzofsky, J.A., D.S. Pisetsky, D.J. Killion, G. Hicks, and D.H. Sachs. 1981. Ir genes of different high responder haplotypes for staphylococcal nuclease are not allelic. *J. Immunol.* 127:2453-2455.
31. Berzofsky, J.A., G.K. Buckenmeyer, G. Hicks, D.J. Killion, I. Berkower, Y. Kohno, M.A. Flanagan, M.R. Busch, R.J. Feldmann, J. Minna, and F.R.N. Gurd. 1983. Topographic antigenic determinants detected by monoclonal antibodies to myoglobin. In *Protein Conformation as Immunological Signal*. F. Celada, E. Sercarz, and V. Shumaker, editors. Plenum Press, New York. 165-180.
32. Berkower, I., G.K. Buckenmeyer, F.R.N. Gurd, and J.A. Berzofsky. 1983. A possible immunodominant domain of myoglobin for murine T lymphocytes. In *Protein Conformation as Immunological Signal*. F. Celada, E. Sercarz, and V. Shumaker, editors. Plenum Press, New York. 289-302.
33. Berzofsky, J.A., G.K. Buckenmeyer, and G. Hicks. 1982. Genetics control of the immune response to myoglobins. VI. Distinct Ir genes for different myoglobins: Complementing genes in I-A and H-2D for equine myoglobin. *J. Immunol.* 128:737-741.

34. Kohno, Y., I. Berkower, J. Minna, and J.A. Berzofsky. 1982. Idiotypes of anti-myoglobin antibodies: Shared idiotypes among monoclonal antibodies to distinct determinants of sperm whale myoglobin. *J. Immunol.* 128:1742-1748.
35. Berzofsky, J.A., and I. Berkower. 1983. Antigen-Antibody Interaction. In *Fundamental Immunology*. W.E. Paul, editor. Raven Press, New York. 595-644.
36. Kohno, Y., and J.A. Berzofsky. 1982. Genetic control of the immune response to myoglobin. V. Antibody production in vitro is macrophage and T cell-dependent and is under control of two determinant-specific Ir genes. *J. Immunol.* 128:2458-2464.
37. Lando, G., J.A. Berzofsky, and M. Reichlin. 1982. Antigenic structure of sperm whale myoglobin: I. Partition of specificities between antibodies reactive with peptides and native protein. *J. Immunol.* 129:206-211.
38. Berkower, I., G.K. Buckenmeyer, F.R.N. Gurd, and J.A. Berzofsky. 1982. A possible immunodominant epitope recognized by murine T lymphocytes immune to different myoglobins. *Proc. Natl. Acad. Sci. U. S. A.* 79:4723-4727.
39. Kohno, Y., and J.A. Berzofsky. 1982. Genetic control of the immune response to myoglobins. Both low and high responder T cells tolerant to the other MHC help high but not low responder B cells. *J. Exp. Med.* 156:791-809.
40. Simmerman, H.K.B., C.C. Wang, E.M. Horwitz, J.A. Berzofsky, and F.R.N. Gurd. 1982. Semisynthesis of sperm whale myoglobin by fragment condensation. *Proc. Natl. Acad. Sci. U. S. A.* 79:7739-7743.
41. Kohno, Y., and J.A. Berzofsky. 1982. Genetic control of immune response to myoglobin. Ir gene function in genetic restriction between T and B lymphocytes. *J. Exp. Med.* 156:1486-1501.
42. Berzofsky, J.A., Y. Kohno, and H. Kawamura. 1983. Both low and high responder myoglobin-specific T cells, tolerant to F1, help high but not low responder B cells. In *Ir Genes: Past, Present, and Future*. C.W. Pierce, S.E. Cullen, J.A. Kapp, B.D. Schwartz, and D.C. Shreffler, editors. Humana Press, New Jersey. 269-275.
43. Berzofsky, J.A. 1983. T-B reciprocity: An Ia-restricted epitope-specific circuit regulating T cell-B cell interaction and antibody specificity. *Survey of Immunol. Res.* 2:223-229.
44. Berzofsky, J.A. 1984. Monoclonal antibodies as probes of antigenic structure. In *Monoclonal Antibodies as Probes of Antigenic Structure, Receptor Biochemistry and Methodology* Vol. 4. J.C. Venter, C.M. Fraser, and J.M. Lindstrom, editors. Alan R. Liss, Inc., New York. 1-19.
45. Berzofsky, J.A. 1983. T cell activation by antigen. *Immunol. Today* 4:299-301.

46. Venter, J.C., J.A. Berzofsky, J. Lindstrom, S. Jacobs, C.M. Fraser, L.D. Kohn, W. Schnieder, G.L. Greene, A.D. Strosberg, and B.F. Erlanger. 1984. Monoclonal and anti-idiotypic antibodies as probes for receptor structure and function. *Fed. Proc.* 43:2534-2539.
47. Berzofsky, J.A. 1984. Mechanisms of antigen-specific, genetically restricted, T cell-B cell interaction. *Survey of Immunol. Res.* 3:103-106.
48. Benjamin, D.C., J.A. Berzofsky, I.J. East, F.R.N. Gurd, C. Hannum, S.J. Leach, E. Margoliash, J.G. Michael, A. Miller, E.M. Prager, M. Reichlin, E.E. Sercarz, S.J. Smith-Gill, P.E. Todd, and A.C. Wilson. 1984. The antigenic structure of proteins: A reappraisal. *Annu. Rev. Immunol.* 2:67-101.
49. Berkower, I., L.A. Matis, G.K. Buckenmeyer, F.R.N. Gurd, D.L. Longo, and J.A. Berzofsky. 1984. Identification of distinct predominant epitopes recognized by myoglobin-specific T cells under control of different Ir genes and characterization of representative T-cell clones. *J. Immunol.* 132:1370-1378.
50. Kawamura, H., Y. Kohno, M. Busch, F.R.N. Gurd, and J.A. Berzofsky. 1984. A major anti-myoglobin idio type: Influence of H-2-linked Ir genes on idio type expression. *J. Exp. Med.* 160:659-678.
51. Streicher, H.Z., I.J. Berkower, M. Busch, F.R.N. Gurd, and J.A. Berzofsky. 1984. The role of antigen conformation in determining requirements for antigen processing for T cell activation. In *Regulation of the Immune System*. E. Sercarz, H. Cantor, and L. Chess, editors. Alan R. Liss, Inc., New York. 163-180.
52. Berzofsky, J.A., and H.M. Grey. 1984. MHC-restricted specific antigen presentation to different T cell sets (Th, Ts, Tc). In *Regulation of the Immune System*. E. Sercarz, H. Cantor, and L. Chess, editors. Alan R. Liss, Inc., New York. 189-193.
53. Streicher, H.Z., I.J. Berkower, M. Busch, F.R.N. Gurd, and J.A. Berzofsky. 1984. Antigen conformation determines processing requirements for T-cell activation. *Proc. Natl. Acad. Sci. U. S. A.* 81:6831-6835.
54. Berzofsky, J.A., and K. Yokomuro. 1985. Antigen presenting cells: Workshop Summary. In *Immune Regulation*. M. Feldmann, and N.A. Mitchison, editors. Humana Press, NJ. 369-374.
55. Kohno, Y., H. Kawamura, and J.A. Berzofsky. 1985. A unidirectional carrier effect. *Cellular Immunol.* 92:226-234.
56. Berzofsky, J.A. 1985. The nature and role of antigen processing in T cell activation. In *The Year in Immunology 1984-1985*. J.M. Cruse, and R.E. Lewis, Jr., editors. Karger, Basel. 18-24.

57. Morrissey, P.J., S.O. Sharrow, Y. Kohno, J.A. Berzofsky, and A. Singer. 1985. Correlation of intrathymic tolerance with intrathymic chimerism in neonatally tolerized mice. *Transplant.* 40:68-72.
58. Kawamura, H., S.A. Rosenberg, and J.A. Berzofsky. 1985. Immunization with antigen and interleukin-2 in vivo overcomes Ir genetic low responsiveness. *J. Exp. Med.* 162:381-386.
59. Berkower, I., H. Kawamura, L.A. Matis, and J.A. Berzofsky. 1985. T cell clones to two major T cell epitopes of myoglobin: Effect of I-A/I-E restriction on epitope dominance. *J. Immunol.* 135:2628-2634.
60. Delisi, C., and J.A. Berzofsky. 1985. T cell antigenic sites tend to be amphipathic structures. *Proc. Natl. Acad. Sci. U. S. A.* 82:7048-7052.
61. Berzofsky, J.A. 1985. Intrinsic and extrinsic factors in protein antigenic structure. *Science* 229:932-940.
62. Darst, S.A., C.R. Robertson, and J.A. Berzofsky. 1986. Myoglobin adsorption onto crosslinked polydimethylsiloxane. *Journal of Colloid and Interface Science* 111:466-474.
63. Berzofsky, J.A., I.J. Berkower, K.B. Cease, G.K. Buckenmeyer, H.Z. Streicher, and C. Delisi. 1986. Structural and conformational requirements for protein antigen recognition by MHC class II - restricted T cells and clones. In *Modern Approaches to Vaccines*. F. Brown, R. Chanock, and R. Lerner, editors. Cold Spring Harbor Laboratory, New York. 123-127.
64. Berzofsky, J.A., K.B. Cease, G.K. Buckenmeyer, H.Z. Streicher, C. Delisi, and I.J. Berkower. 1986. Structural and conformational requirements for Ir-gene-controlled myoglobin epitope recognition by Ia-restricted T cells and clones. In *Regulation of Immune Gene Expression*. M. Feldmann, and A. McMichael, editors. Humana Press, Clifton, NJ. 225-234.
65. Kawamura, H., and J.A. Berzofsky. 1986. Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. *J. Immunol.* 136:58-65.
66. Streicher, H.Z., F. Cuttitta, G.K. Buckenmeyer, H. Kawamura, J. Minna, and J.A. Berzofsky. 1986. Mapping the idiotopes of a monoclonal anti-idiotypic antibodies: Detection of a common idiotope. *J. Immunol.* 136:1007-1014.
67. Berzofsky, J.A. 1987. *Ir* genes: antigen-specific genetic regulation of the immune response. In *The Antigens*. M. Sela, editor. Academic Press, New York. 1-146.
68. Berkower, I., G.K. Buckenmeyer, and J.A. Berzofsky. 1986. Molecular mapping of a histocompatibility - restricted immunodominant T cell epitope with synthetic and natural peptides: Implications for antigenic structure. *J. Immunol.* 136:2498-2503.

69. Berzofsky, J.A. 1986. Structural features of protein antigenic sites recognized by helper T cells: What makes a site immunodominant? In *The Year in Immunology 1985-1986*. J.M. Cruse, and R.E. Lewis, Jr., editors. Karger, Basel. 28-38.
70. Simpson, E., R. Lieberman, I. Ando, D.H. Sachs, W.E. Paul, and J.A. Berzofsky. 1986. How many class II Immune Response Genes? A reappraisal of the evidence. *Immunogenetics* 23:302-308.
71. Delisi, C., J. Cornette, H. Margalit, K. Cease, J. Spouge, and J.A. Berzofsky. 1987. The role of amphipathicity as an indicator of T cell antigenic sites on proteins. In *Immunogenicity of Protein Antigens: Repertoire and Regulation*. E. Sercarz, and J.A. Berzofsky, editors. CRC Press, Boca Raton. 35-42.
72. Berzofsky, J.A., J. Cornette, H. Margalit, I. Berkower, K. Cease, and C. Delisi. 1986. Molecular features of class II MHC-restricted T cell recognition of protein and peptide antigens: the importance of amphipathic structures. In *Current Topics in Microbiology and Immunology* Vol. 130. F. Melchers, and H. Koprowski, editors. Springer-Verlag, New York. 14-24.
73. Kawamura, H., S.O. Sharrow, D.W. Alling, D. Stephany, J. York-Jolley, and J.A. Berzofsky. 1986. IL-2 receptor expression in unstimulated murine splenic T cells: Localization to L3T4+ cells and regulation by non-H-2-linked genes. *J. Exp. Med.* 86:1376-1390.
74. Wagner, D.K., J. York-Jolley, T.R. Malek, J.A. Berzofsky, and D.L. Nelson. 1986. Antigen-specific murine T cell clones produce soluble interleukin 2 receptor on stimulation with specific antigens. *J. Immunol.* 137:592-596.
75. Good, M.F., J.A. Berzofsky, W.L. Maloy, Y. Hayashi, N. Fujii, W.T. Hockmeyer, and L.H. Miller. 1986. Genetic control of the immune response in mice to a Plasmodium faciparum sporozoite vaccine: Widespread non-responsiveness to a single malaria T epitope in highly repetitive vaccine. *J. Exp. Med.* 164:655-660.
76. Berzofsky, J.A., K.B. Cease, I.J. Berkower, H. Margalit, J. Cornette, J. Spouge, C. Spencer, G. Buckenmeyer, H. Streicher, M. Kojima, and C. Delisi. 1988. The role of MHC and amphipathic structures in T cell recognition: Features determining immunodominance. In *Antigen Processing and Presentation*. H. Vogel, B. Pernis, and S. Silverstein, editors. Columbia University Press, New York. 125-131.
77. Finnegan, A., M.A. Smith, J.A. Smith, J.A. Berzofsky, D.H. Sachs, and R.J. Hodes. 1986. The T cell repertoire for recognition of a phylogenetically distant protein antigen: peptide specificity and MHC restriction of staphylococcal nuclease specific T cell clones. *J. Exp. Med.* 164:897-910.
78. Kawamura, H., and J.A. Berzofsky. 1987. Influence of MHC-linked genes on idiotype expression. In *Immunogenicity of Protein Antigens: Repertoire and Regulation* Vol.2. E.E. Sercarz, and J.A. Berzofsky, editors. CRC Press, Boca Raton. 121-127.

79. Berzofsky, J.A., K.B. Cease, I.J. Berkower, H. Margalit, J. Cornette, and C. Delisi. 1986. Immunodominance of amphipathic peptides and their localization on the cell surface for antigen presentation to helper T cells. In *Progress in Immunology V*. B. Cinader, and R.G. Miller, editors. Academic Press, New York. 255-265.
80. Cease, K.B., I. Berkower, J. York-Jolley, and J.A. Berzofsky. 1986. T cell clones specific for an amphipathic alpha helical region of sperm whale myoglobin show differing fine specificities for synthetic peptides: A multi-view/single structure interpretation of immunodominance. *J. Exp. Med.* 164:1779-1784.
81. Cease, K.B., G. Buckenmeyer, I. Berkower, J. York-Jolley, and J.A. Berzofsky. 1986. Immunologically relevant peptide antigen exists on the presenting cell in a manner accessible to macromolecules in solution. *J. Exp. Med.* 164:1440-1454.
82. Berzofsky, J.A., and K.B. Cease. 1986. Peptide antigenic structure and localization on the surface of the presenting cell for antigen presentation. *Annales de l'Institut Pasteur* 137D:312-316.
83. Berzofsky, J.A., K.B. Cease, S. Ozaki, H. Margalit, J.L. Cornette, J. Spouge, and C. Delisi. 1987. Helper T cell immunity: Implications for vaccines. In *Vaccines '87*. R. Chanock, F. Brown, H. Ginsberg, and R. Lerner, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. 26-32.
84. Finnegan, A., and J.A. Berzofsky. 1986. Antigen recognition by T cells. *Immunol. Today* 7:317-319.
85. Spouge, J.L., H.R. Guy, J.L. Cornette, H. Margalit, K. Cease, J.A. Berzofsky, and C. Delisi. 1987. Strong conformational propensities enhance T-cell antigenicity. *J. Immunol.* 138:204-212.
86. Good, M.F., I.A. Quakyi, A. Saul, J.A. Berzofsky, R. Carter, and L.H. Miller. 1987. Human T clones reactive to the sexual stages of *Plasmodium falciparum* malaria: High frequency of gamete-reactive T cells in peripheral blood of non-exposed donors. *J. Immunol.* 138:306-311.
87. Coico, R.F., J.A. Berzofsky, J. York-Jolley, S. Ozaki, G.W. Siskind, and G.J. Thorbecke. 1987. Physiology of IgD. VII. Induction of receptors for IgD on cloned T cells by IgD and Interleukin 2. *J. Immunol.* 138:4-6.
88. Ozaki, S., J. York-Jolley, H. Kawamura, and J.A. Berzofsky. 1987. Cloned protein antigen-specific, Ia-restricted T cells with both helper and cytolytic activities: Mechanisms of activation and killing. *Cellular Immunol.* 105:301-316.
89. Good, M.F., J.A. Berzofsky, L. Maloy, M.N. Lunde, Y. Hayashi, N. Fujii, W.T. Hockmeyer, B. Moss, and L.H. Miller. 1987. Genetic control of the immune response to a *Plasmodium falciparum* sporozoite vaccine and to the Cirumsporozoite (CS) protein. In

- Vaccines`87*. R. Chanock, F. Brown, H. Ginsberg, and R. Lerner, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. 81-85.
90. Margalit, H., J.L. Spouge, J.L. Cornette, K. Cease, C. Delisi, and J.A. Berzofsky. 1987. Prediction of immunodominant helper T-cell antigenic sites from the primary sequence. *J. Immunol.* 138:2213-2229.
 91. Takacs, L., J.A. Berzofsky, J. York-Jolley, T. Akahoshi, E. Blasi, and S.K. Durum. 1987. IL 1-Induction by murine T cell clones: Detection of an IL 1-inducing lymphokine. *J. Immunol.* 138:2124-2131.
 92. Good, M.F., W.L. Maloy, M.N. Lunde, H. Margalit, J.L. Cornette, G.L. Smith, B. Moss, L.H. Miller, and J.A. Berzofsky. 1987. Construction of a synthetic immunogen: use of a new T-helper epitope on malaria circumsporozoite protein. *Science* 235:1059-1062.
 93. Hoffman, S.L., L.T. Cannon, J.A. Berzofsky, W.R. Majarian, J.G. Young, W.L. Maloy, and W.T. Hockmeyer. 1987. Plasmodium falciparum: Increased immunity with T cell epitope on sporozoite vaccine. *Exp. Parasitology* 64:64-70.
 94. Cornette, J.L., K.B. Cease, H. Margalit, J.L. Spouge, J.A. Berzofsky, and C. Delisi. 1987. Hydrophobicity scales and computational techniques for detecting amphipathic structures in proteins. *J. Mol. Biol.* 195:659-686.
 95. Cease, K.B., H. Margalit, J.L. Cornette, S.D. Putney, W.G. Robey, C. Ouyang, H.Z. Streicher, P.J. Fischinger, R.C. Gallo, C. Delisi, and J.A. Berzofsky. 1987. Helper T cell antigenic site identification in the AIDS virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. *Proc. Natl. Acad. Sci. USA* 84:4249-4253.
 96. Ozaki, S., and J.A. Berzofsky. 1987. Antibody conjugates mimic specific B cell presentation of antigen: Relationship between T and B cell specificity. *J. Immunol.* 138:4133-4142.
 97. Berzofsky, J.A., K.B. Cease, J.L. Cornette, J.L. Spouge, H. Margalit, I.J. Berkower, M.F. Good, L.H. Miller, and C. Delisi. 1987. Protein antigenic structures recognized by T cells: Potential applications to vaccine design. *Immunol. Rev.* 98:9-52.
 98. Berzofsky, J.A. 1988. Features of T-cell recognition and antigen structure useful in the design of vaccines to elicit T-cell immunity. *Vaccines* 6:89-93.
 99. Berzofsky, J.A., and S. Ozaki. 1988. Antibody conjugates mimic specific B-cell presentation of antigen: epitope restrictions in specific T-B interaction. In *Antigen Presenting Cells: Diversity, Differentiation and Regulation*. L.B. Schook, and J.G. Tew, editors. Alan R. Liss, Inc., New York. 41-48.
 100. Good, M.F., D. Pombo, I.A. Quakyi, E.M. Riley, R.A. Houghten, A. Menon, D.W. Alling, J.A. Berzofsky, and L.H. Miller. 1988. Human T cell recognition of the circumsporozoite

- protein of *Plasmodium falciparum*. Immunodominant T cell domains map to the polymorphic regions of the molecule. *Proc. Natl. Acad. Sci. USA* 85:1199-1203.
101. Good, M.F., J.A. Berzofsky, and L.H. Miller. 1988. The T-cell response to the malaria circumsporozoite protein: an immunological approach to vaccine development. *Annu. Rev. Immunol.* 6:663-688.
 102. Lin, J., J.A. Berzofsky, and T.L. Delovitch. 1988. Ultrastructural study of internalization and recycling of antigen by antigen presenting cells. *J. Mol. Cell. Immunol.* 3:321-343.
 103. Kojima, M., K.B. Cease, G.K. Buckenmeyer, and J.A. Berzofsky. 1988. Limiting dilution comparison of the repertoires of high and low responder MHC-restricted T cells. *J. Exp. Med.* 167:1100-1113.
 104. Good, M.F., D. Pombo, W.L. Maloy, V.F. De la Cruz, L.H. Miller, and J.A. Berzofsky. 1988. Parasite polymorphism present within minimal T-cell epitopes of Plasmodium falciparum circumsporozoite protein. *J. Immunol.* 140:1645-1650.
 105. Takahashi, H., J. Cohen, A. Hosmalin, K.B. Cease, R. Houghten, J. Cornette, C. Delisi, B. Moss, R.N. Germain, and J.A. Berzofsky. 1988. An immunodominant epitope of the HIV gp160 envelope glycoprotein recognized by class I MHC molecule-restricted murine cytotoxic T lymphocytes. *Proc. Natl. Acad. Sci. USA* 85:3105-3109.
 106. Darst, S.A., C.R. Robertson, and J.A. Berzofsky. 1988. Adsorption of the protein antigen myoglobin affects the binding of conformation specific monoclonal antibodies. *Biophysical Journal* 53:533-539.
 107. Pombo, D., W.L. Maloy, J.A. Berzofsky, and M.F. Good. 1988. Neonatal exposure to immunogenic peptides. Differential susceptibility to tolerance induction of helper T cells and B cells reactive to malarial circumsporozoite peptide epitopes. *J. Immunol.* 140:3594-3598.
 108. Berzofsky, J.A. 1988. T-cell recognition of protein and peptide antigens: applications to vaccines development. In *Technological Advances in Vaccine Development*. L. Laskey, editor. Alan R. Liss, Inc., New York, 587-602.
 109. Berzofsky, J.A. 1988. Immunodominance in T lymphocyte recognition. *Immunol. Letters* 18:83-92.
 110. Ozaki, S., S.K. Durum, K. Muegge, J. York-Jolley, and J.A. Berzofsky. 1988. Production of T-T hybrids from T cell clones: Direct comparison between cloned T cells and T hybridoma cells derived from them. *J. Immunol.* 141:71-78.
 111. Brett, S.J., K.B. Cease, and J.A. Berzofsky. 1988. Influences of antigen processing on the expression of the T cell repertoire: Evidence for MHC-specific hindering structures on the products of processing. *J. Exp. Med.* 168:357-373.

112. Good, M.F., D. Pombo, M.N. Lunde, W.L. Maloy, R. Halenbeck, K. Koths, L.H. Miller, and J.A. Berzofsky. 1988. Recombinant human interleukin-2 (IL-2) overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biological activity of IL-2. *J. Immunol.* 141:972-977.
113. Cease, K.B., and J.A. Berzofsky. 1990. T cell immunity and vaccine engineering: Application to the AIDS virus. In *AIDS Vaccine Research and Clinical Trials*. S. D. Putney, and D. P. Bolognesi, editors. Marcell Dekker, New York, pp. 139-156.
114. Kumar, S., L.H. Miller, I.A. Quakyi, D.B. Keister, R.A. Houghten, W.L. Maloy, B. Moss, J.A. Berzofsky, and M.F. Good. 1988. Cytotoxic T cells specific for the circumsporozoite protein of *Plasmodium falciparum*. *Nature* 334:258-260.
115. Berzofsky, J.A., A. Bensussan, K.B. Cease, J.F. Bourge, R. Cheynier, Z. Lurhuma, J.-J. Salaün, R.C. Gallo, G.M. Shearer, and D. Zagury. 1988. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. *Nature* 334:706-708.
116. Margalit, H., C. Delisi, and J.A. Berzofsky. 1990. Computer predictions of T-cell epitopes. In *New Generation Vaccines*. G.C. Woodrow, and M.M. Levine, editors. Marcel Dekker, New York, 109-116.
117. Berzofsky, J.A. 1989. Structural features of T-cell recognition: Applications to vaccine design. *Phil. Trans. Roy. Soc. London B.*, 323: 535-544.
118. Cease, K.B., and J.A. Berzofsky. 1988. Antigenic structures recognized by T cells: Toward the rational design of an AIDS vaccine. *AIDS* 2:(suppl.1) S95-S101.
119. Berzofsky, J.A., S.J. Brett, H.Z. Streicher, and H. Takahashi. 1988. Antigen processing for presentation to T lymphocytes: Function, mechanisms, and implications for the T-cell repertoire. *Immunol. Rev.* 106: 5-31.
120. Good, M.F., L.H. Miller, S. Kumar, I.A. Quakyi, D. Keister, J. Adams, B. Moss, J.A. Berzofsky, and R. Carter. 1988. Limited immunological recognition of critical malaria vaccine candidate antigens. *Science* 242: 574-577.
121. Berzofsky, J.A., and I.J. Berkower. 1989. Immunogenicity and antigen structure. In *Fundamental Immunology* 2nd Edition. W.E. Paul, editor. Raven Press, New York, pp. 169-208.
122. Berzofsky, J.A., S.L. Epstein, and I.J. Berkower. 1989. Antigen-antibody interactions and monoclonal antibodies. In *Fundamental Immunology* 2nd edition. W.E. Paul, editor. Raven Press, New York, pp. 315-356.
123. Dontfraid, F., M.A. Cochran, D. Pombo, J.D. Knell, I. Quakyi, S. Kumar, R.A. Houghten, J.A. Berzofsky, L.H. Miller, and M.F. Good. 1988. Human and murine CD4 T-cell epitopes map to the same region of the malaria circumsporozoite protein: Limited

- immunogenicity of sporozoites and circumsporozoite protein. *Mol. Biol. Med.*, 5: 185-196.
124. Hosmalin, A.M., P.L. Nara, M. Zweig, K.B. Cease, E. Gard, P.D. Markham, S.D. Putney, M.D. Daniel, R.C. Desrosiers, and J.A. Berzofsky. 1989. Enhancement of an antibody response to the envelope glycoprotein of HIV-1 in primates by priming with helper T-cell epitope peptides. In *Vaccines 89*. R. Lerner, H. Ginsberg, R. Chanock, and F. Brown, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, 121-124
125. Takahashi, H., J. Cohen, A. Hosmalin, K.B. Cease, R. Houghten, J.L. Cornette, C. Delisi, S. Merli, B. Moss, R.N. Germain, and J.A. Berzofsky. 1989. Limited epitope repertoire recognized with class I MHC molecules by murine cytotoxic lymphocytes on the HIV gp160 envelope glycoprotein. In *Vaccines 89*. R. Lerner, H. Ginsberg, R. Chanock, and F. Brown, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor., 109-114.
126. Berzofsky, J.A. 1989. Immunodominance of T-cell epitopes: Applications to vaccine design. In *Vaccines 89*. R. Lerner, H. Ginsberg, R. Chanock, and F. Brown, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, 27-31.
127. Berzofsky, J.A. 1988. The structural basis of antigen recognition by T lymphocytes: Implications for vaccines. *J. Clin. Invest.* 82: 1811-1817.
128. Berzofsky, J.A. 1989. Mechanisms of immunodominance in T-cell recognition, with applications to vaccine design. In *Immune System and Cancer: Proceedings of the Nineteenth International Symposium of the Princess Takamatsu Cancer Research Fund*. T. Hamaoka, R.J. Hodes, G. Klein, T. Sugimura, S. Takayama, and Y. Yamamura, editors. The Princess Takamatsu Cancer Research Fund, Tokyo, 161-177.
129. Takahashi, H., K.B. Cease, and J. A. Berzofsky. 1989. Identification of proteases that process distinct epitopes on the same protein. *J. Immunol.* 142: 2221-2229.
130. Brett, S. J., D. McKean, J. York-Jolley, and J. A. Berzofsky. 1989. Antigen presentation to specific T cells by Ia molecules selectively altered by site-directed mutagenesis. *Internat. Immunol.* 1: 130-140.
131. Berzofsky, J. A., and Y. Paterson. 1990. Discussion summary: Antigen structure: B cell and T cell determinants and immunogenicity. In *Immunogenicity (UCLA Symposia on Molecular and Cellular Biology, New Series, Vol. 113)*. C. Janeway, J. Sprent, and E. Sercarz, editors. Alan R. Liss, New York, pp. 65-67.
132. Hoffman, S. L., J. A. Berzofsky, D. Isenbarger, E. Zeltzer, W. R. Majarian, M. Gross, and W. R. Ballou. 1989. Immune response gene regulation of immunity to *Plasmodium berghei* sporozoites and circumsporozoite protein vaccines: Overcoming genetic restriction with whole organism and subunit vaccines. *J. Immunol.* 142: 3581-3584.

133. Cornette, J. L., H. Margalit, C. DeLisi, and J. A. Berzofsky. 1989. Concepts and methods in the identification of T cell epitopes and their use in the construction of synthetic vaccines. *Methods in Enzymol.* 178: 611-634.
134. Sanui, H., T. M. Redmond, S. Kotake, B. Wiggert, L.-H. Hu, H. Margalit, J. A. Berzofsky, G. J. Chader, and I. Gery. 1989. Identification of an immunodominant and highly immunopathogenic determinant in the retinal interphotoreceptor retinoid-binding protein (IRBP). *J. Exp. Med.* 169: 1947-1960.
135. DeGroot, A. S., A. H. Johnson, W. L. Maloy, I. A. Quakyi, E. M. Riley, A. Menon, S. M. Banks, J. A. Berzofsky, and M. F. Good. 1989. Human T cell recognition of polymorphic epitopes from malaria circumsporozoite protein. *J. Immunol.* 142: 4000-4005.
136. Palker, T. J., T. J. Matthews, A. Langlois, M. E. Tanner, M. E. Martin, R.M. Scearce, J. E. Kim, J. A. Berzofsky, D. P. Bolognesi, and B. F. Haynes. 1989. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. *J. Immunol.* 142: 3612-3619.
137. Sanza, L. R., L.M.Gierasch, J. A. Berzofsky, G. K. Buckenmeyer, K. B. Cease, and C. S. Ouyang. 1988. Formation of amphipathic secondary structure is correlated to T-cell antigenicity in a series of synthetic peptides from sperm whale myoglobin. In *Peptides: Chemistry and Biology*. G. R. Marshall, editor, ESCOM, Leiden, pp. 549-550.
138. Palker, T. J., T. J. Matthews, A. Langlois, J. E. Kim, J. A. Berzofsky, D. P. Bolognesi, and B. F. Haynes. 1989. Multivalent synthetic peptide inoculum induces neutralizing antibodies to divergent HIV isolates and anamnestic T-cell responses to HIV gp120. In *Early Human Retroviruses*. J. E. Groopman, I. Chen, M. Essex, and R. Weiss, editors. Alan R. Liss, New York, in press.
139. Clerici, M., N. I. Stocks, R. A. Zajac, R. N. Boswell, D. C. Bernstein, D. L. Mann, G. M. Shearer, and J. A. Berzofsky. 1989. IL-2 production used to detect antigenic peptide recognition by T helper lymphocytes from asymptomatic, HIV seropositive individuals. *Nature* 339: 383-385.
140. Williams, W.V., S.D. London, D.B. Weiner, S. Wadsworth, J.A. Berzofsky, F. Robey, D.H. Rubin, and M.I. Greene. 1989. Immune response to a molecularly defined internal image idiotope. *J. Immunol.* 142: 4392-4400.
141. Brett, S.J., K.B. Cease, C.S. Ouyang, and J.A. Berzofsky. 1989. Fine specificity of T cell recognition of the same peptide in association with different I-A molecules. *J. Immunol.* 143: 771-779.
142. Hale, P.M., K.B. Cease, R.A. Houghten, C. Ouyang, S. Putney, K. Javaherian, H. Margalit, J.L. Cornette, J.L. Spouge, C. Delisi, and J.A. Berzofsky. 1989. T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction. *Internat. Immunol.* 1: 409-415.

143. Berzofsky, J.A., A. Kurata, H. Takahashi, S.J. Brett, and D.J. McKean. 1989. Molecular studies of antigen processing and presentation to T cells by class II MHC molecules. In Cold Spring Harbor Symposium on Quantitative Biology LIV: Immunological Recognition. J.D. Watson, and J. R. Inglis, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, pp. 417-430.
144. Kurata, A., T.J. Palker, R.D. Streilein, R.M. Scearce, B.F. Haynes, and J.A. Berzofsky. 1989. Immunodominant sites of human T-cell lymphotropic virus type 1 envelope protein for murine helper T cells. *J. Immunol.* 143: 2024-2030.
145. Redmond, T.M., H. Sanui, L.H. Hu, B. Wiggert, H. Margalit, J.A. Berzofsky, G.J. Chader, and I. Gery. 1989. Immune responses to peptides derived from the retinal protein IRBP: immunopathogenic determinants are not necessarily immunodominant. *Clinical Immunology and Immunopathology* 53: 212-224.
146. Lark, L.R., J.A. Berzofsky, and L.M. Gierasch. 1989. T-Cell antigenic peptides from sperm whale myoglobin fold as amphipathic helices: a possible determinant for immunodominance? *Peptide Research* : 2: 314-321.
147. Vacchio, M.S., J.A. Berzofsky, U. Krzych, J.A. Smith, R.J. Hodes, and A. Finnegan. 1989. Sequences outside a minimal immunodominant site exert negative effects on recognition by staphylococcal nuclease-specific T-cell clones. *J. Immunol.* 143: 2814-2819.
148. Vajda, S., H. Margalit, R. Kataoka, J. L. Cornette, J. A. Berzofsky, and C. DeLisi. 1990. Molecular structure and vaccine design. *Ann. Rev. Biophys. Biophys. Chem.* 19: 69-82..
149. Takahashi, H., S. Merli, S.D. Putney, R. Houghten, B. Moss, R.N. Germain, and J.A. Berzofsky. 1989. A single amino acid interchange yields reciprocal CTL specificities for HIV gp160. *Science* 246: 118-121.
150. Takahashi, H., R. Houghten, S.D. Putney, D.H. Margulies, B. Moss, R.N. Germain, and J.A. Berzofsky. 1989. Structural requirements for class-I MHC molecule-mediated antigen presentation and cytotoxic T-cell recognition of an immunodominant determinant of the HIV envelope protein. *J. Exp. Med.* 170: 2023-2035.
151. Weiss, W.R., M.F. Good, M.R. Hollingdale, L.H. Miller, and J.A. Berzofsky. 1989. Genetic control of immunity to *Plasmodium yoelii* sporozoites. *J. Immunol.* 143: 4263-4266.
152. Berzofsky, J.A., P.M. Hale, M. Clerici, K.B. Cease, R.A. Houghten, S.D. Putney, R.A. Zajac, R.N. Boswell, H. Margalit, J.L. Cornette, J.L. Spouge, C. Delisi, and G.M. Shearer. 1990. Multideterminant regions of the HIV-1 envelope with sites seen by murine and human helper T cells: circumventing the MHC restriction problem. In *Vaccines 90*. F. Brown, R.M. Chanock, H.S. Ginsberg, and R.A. Lerner, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, pp. 307-312.

153. Takahashi, H., R. Houghten, S. Merli, S.D. Putney, B. Moss, R.N. Germain, and J.A. Berzofsky. 1990. Immunodominant CTL epitope of HIV-1 envelope protein: the relationship between viral mutation and CTL specificity. In *Vaccines 90*. F. Brown, R.M. Chanock, H.S. Ginsberg, and R.A. Lerner, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, pp 269-276.
154. Vinetz, J.M., S. Kumar, M.F. Good, B.J. Fowlkes, J.A. Berzofsky, and L.H. Miller. 1990. Adoptive transfer of CD8⁺ T cells from immune animals does not transfer immunity to blood stage *Plasmodium yoelii* malaria. *J. Immunol.* 144: 1069-1074.
155. Takahashi, H., R.N. Germain, B. Moss, and J.A. Berzofsky. 1990. An immunodominant class I-restricted CTL determinant of HIV-1 induces CD4 class II-restricted help for itself. *J. Exp. Med.* 171: 571-576.
156. Weiss, W.R., S. Mellouk, R.A. Houghten, M. Sedegah, S. Kumar, M.F. Good, J.A. Berzofsky, L.H. Miller, and S.L. Hoffman. 1990. Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria infected hepatocytes. *J. Exp. Med.* 171: 763-773.
157. Kotake, S., B. Wiggert, T.M. Redmond, D.E. Borst, J.M. Nickerson, H. Margalit, J.A. Berzofsky, G.J. Chader, and I. Gery. 1990. Repeated determinants within the retinal interphotoreceptor retinoid-binding protein (IRBP). Immunological properties of the repeats of an immunodominant determinant. *Cellular Immunol.*, 126: 331-342.
158. Hosmalin, A., M. Clerici, R. Houghten, C.D. Pendleton, C. Flexner, D.R. Lucey, B. Moss, R.N. Germain, G.M. Shearer, and J.A. Berzofsky. 1990. An epitope in HIV-1 reverse transcriptase recognized by both mouse and human CTL. *Proc. Natl. Acad. Sci. U. S. A.* 87: 2344-2348.
159. Ahlers, J., M. Clerici, A. Hosmalin, G.M. Shearer, and J.A. Berzofsky. 1990. Host immune response: T helper cell responses. In *Techniques in HIV Research*. A. Aldovini, and B. Walker, editors. Stockton Press, New York, pp. 211-222.
160. Berzofsky, J.A. 1990. Immunogenicity of antigens recognized by T cells. In *Cellular Immunity and the Immunotherapy of Cancer*. M.T. Lotze, and O.J. Finn, editors. Wiley-Liss, Inc., New York, 1-22.
161. Takahashi, H., T. Takeshita, B. Morein, S.D. Putney, R.N. Germain, and J.A. Berzofsky. 1990. Induction of specific CD8⁺ class I-MHC restricted CTL against HIV envelope protein by immunization with purified whole protein in ISCOMs. *Nature* , 344: 873-875.
162. Kim, J.E., M. Kojima, R. Houghten, C.D. Pendleton, J.L. Cornette, C. Delisi, and J.A. Berzofsky. 1990. Characterization of a helper T-cell epitope recognized by mice of a low responder major histocompatibility type. *Molec. Immunol.* 27: 941-946.
163. Weiner, D.B., W.V. William, M.J. Merva, K. Huebner, J.A. Berzofsky, and M.I. Greene. 1990. HIV Infectivity analysis of viral envelope determinants and target cell requirements

- for infectivity by HIV-1. In *Vaccines 90*. F. Brown, R.M. Chanock, H.S. Ginsberg, and R.A. Lerner, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. 339-345.
164. Kurata, A., and J.A. Berzofsky. 1990. Analysis of peptide residues interacting with MHC molecule or T-cell receptor: can a peptide bind in more than one way to the same MHC molecule?. *J. Immunol.* 144: 4526-4535.
 165. Kumar, S., J. Gorden, J.L. Flynn, J.A. Berzofsky, and L.H. Miller. 1990. Immunization of mice against *Plasmodium vinckei* with a combination of attenuated *Salmonella typhimurium* and malarial antigen. *Infect. Immun.* 58: 3425-3429.
 166. Kozlowski, S., T. Takeshita, W. -H. Boehncke, H. Takahashi, L. F. Boyd, R. N. Germain, J. A. Berzofsky, and D. H. Margulies. 1991. Excess β_2 -microglobulin promotes functional peptide association with purified soluble class I MHC molecules. *Nature* 349: 74-77.
 167. Hosmalin, A., P. L. Nara, M. Zweig, N. W. Lerche, K. B. Cease, E. A. Gard, P. D. Markham, S. D. Putney, M. D. Daniel, R. C. Desrosiers, and J. A. Berzofsky. 1991. Priming with helper T-cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV 1 in primates. *J. Immunol.* 146: 1667-1673.
 168. Berzofsky, J.A. 1991. Progress towards an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization. *Biotech. Therapeutics.* 2: 123-135.
 169. Berzofsky, J.A. 1991. Approaches and issues in the development of vaccines against HIV. *J. Acq. Immune Defic. Syndromes* 4: 451-459.
 170. Clerici, M., D. R. Lucey, R. A. Zajac, R. N. Boswell, H. M. Gebel, H. Takahashi, J. A. Berzofsky, and G. M. Shearer. 1991. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. *J. Immunol.* 146: 2214-2219.
 171. Culver, K.W., C. Able, R. Toper, S. Freeman, J. A. Berzofsky, and R. M. Blaese. 1990. Lymphocytes as vehicles for gene therapy. In *Cellular Immunity and the Immunotherapy of Cancer*. M.T. Lotze and O.J. Finn, editors. Wiley-Liss, Inc., New York. 129-137.
 172. Clerici, M., C. O. Tacket, C. S. Via, D. R. Lucey, S. C. Muluk, R. A. Zajac, R. N. Boswell, J. A. Berzofsky, and G. M. Shearer. 1991. Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection. *Eur. J. Immunol.* 21: 1345-1349.
 173. Takahashi, H., T. Takeshita, B. Moreln, S. Putney, R. N. Germain, and J. A. Berzofsky. 1991. A unique subunit immunogen, ISCOM-gp160, can elicit MHC class-I-restricted HIV envelope-specific CD8⁺CTLs. In *Vaccines 91*. R.M. Chanock, H.S. Ginsberg, F. Brown, and R.A. Lerner, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. 1-7.

174. Lipham, W.J., T. M. Redmond, H. Takahashi, J. A. Berzofsky, B. Wiggert, G. J. Chader, and I. Gery. 1991. Recognition of peptides that are immunopathogenic but cryptic: Mechanisms that allow lymphocytes sensitized against cryptic peptides to initiate pathogenic autoimmune processes. *J. Immunol.* 146: 3757-3762.
175. Clerici, M., J. A. Berzofsky, G. M. Shearer, and C. O. Tacket. 1991. Exposure to HIV-1 indicated by HIV-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies. *J. Infect. Dis.* 164: 178-182.
176. Berzofsky, J.A. 1991. Mechanisms of T cell recognition with application to vaccine design. *Molec. Immunol.* 28:217-223.
177. Berzofsky, J.A. 1991. Development of artificial vaccines against HIV using defined epitopes. *FASEB J.* 5: 2412-2418.
178. Berzofsky, J.A. 1991. Antigenic peptide interaction with MHC molecules: implications for the design of artificial vaccines. *Seminars in Immunology* 3: 203-216.
179. Goodman-Snitkoff, G., M. F. Good, J. A. Berzofsky, and R. J. Mannino. 1991. Role of intrastructural/intermolecular help in immunization with peptide-phospholipid complexes. *J. Immunol.* 147: 410-415.
180. Berzofsky, J.A., C. D. Pendleton, M. Clerici, J. Ahlers, D. R. Lucey, S. D. Putney, and G. M. Shearer. 1991. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T-cell responses in mice and humans of multiple MHC types. *J. Clin. Invest.* 88: 876-884.
181. Berzofsky, J.A. 1991. Human immunodeficiency virus: structural features of T-cell epitopes and their use in vaccine development. In *Viruses and the Cellular Immune Response*. D.B. Thomas, editor. Marcel Dekker, Inc., New York.
182. Berzofsky, J.A., C. D. Pendleton, M. Clerici, J. Ahlers, D. R. Lucey, S. D. Putney, and G. M. Shearer. 1991. Peptides containing multideterminant clusters of Human Immunodeficiency Virus envelope induce murine and human T -cell responses in diverse histocompatibility types. *Transac. Assoc. Amer. Phys.* 104: 69-77.
183. Ida, H., A. Kurata, K. Eguchi, A. Kawakami, K. Migita, T. Fukuda, T. Nakamura, Y. Kusumoto, J. A. Berzofsky, and S. Nagataki. 1991. Different B-cell responses to human T-cell lymphotropic virus type I (HTLV-I) envelope synthetic peptides in HTLV-I-infected individuals. *Journal of Clinical Immunology* 11:143-151.
184. DeGroot, A. S., M. Clerici, A. Hosmalin, S. H. Hughes, D. Barnd, C. W. Hendrix, R. A. Houghten, G. M. Shearer, and J. A. Berzofsky. 1991. Human immunodeficiency virus (HIV-1) reverse transcriptase T helper epitopes identified in mice and humans: Correlation with a cytotoxic T cell (CTL) epitope. *J. Infect. Dis.* 164: 1058-1065.

185. Takahashi, H., Y. Nakagawa, C. D. Pendleton, R. A. Houghten, K. Yokomuro, R. N. Germain, and J. A. Berzofsky. 1992. Analysis of CTL crossreactivity to an HIV-1 immunodominant determinant: elicitation of widely crossreactive CTL. In *Vaccines 92*. F. Brown, R. Chanock, H. Ginsberg, and R. Lerner, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. 69-74.
186. Shirai, M. and J. A. Berzofsky. 1992. Promiscuity of cytotoxic T-cell epitopes from the HIV-1 envelope . In *Vaccines 92*. F. Brown, R. Chanock, H. Ginsberg, and R. Lerner, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. 243-246.
187. Berzofsky, J. A. 1992. Progress towards artificial vaccines for HIV. In *Vaccines 92*. F. Brown, R. Chanock, H. Ginsberg, and R. Lerner, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. 41-50.
188. Takahashi, H., Y. Nakagawa, C. D. Pendleton, R. A. Houghten, K. Yokomuro, R. N. Germain, and J. A. Berzofsky. 1992. Induction of broadly crossreactive cytotoxic T cells recognizing an HIV-1 envelope determinant. *Science* , 255: 333-336.
189. Shirai, M., C. D. Pendleton, and J. A. Berzofsky. 1992. Broad recognition of cytotoxic T-cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. *J. Immunol.* 148: 1657-1667.
190. Cornette, J. L., H. Margalit, C. DeLisi, and J. A. Berzofsky. 1993. The amphipathic helix as a structural feature involved in T-cell recognition. In *The Amphipathic Helix*. R.M. Epanand, editor. CRC Press, Boca Raton., 333-346.
191. Clerici, M., J. V. Giorgi, C. -C. Chou, V. K. Gudeman, J. A. Zack, P. Gupta, H. -N. Ho, P. G. Nishanian, J. A. Berzofsky, and G. M. Shearer. 1992. Cell mediated immune response to human immunodeficiency virus type I (HIV-1) in seronegative homosexual men with recent sexual exposure to HIV-1. *J. Infect. Dis.* 165: 1012-1019.
192. Kozlowski, S., M. Corr, T. Takeshita, L. F. Boyd, C. D. Pendleton, R. N. Germain, J. A. Berzofsky, and D. H. Margulies. 1992. Serum angiotensin-1 converting enzyme activity processes an HIV 1 gp160 peptide for presentation by MHC class I molecules. *J. Exp. Med.* 175: 1417-1422.
193. Kullberg, M. C., E. J. Pearce, S. E. Hieny, A. Sher, and J. A. Berzofsky. 1992. Infection with *Schistosoma mansoni* alters Th1/Th2 cytokine responses to a non-parasite antigen. *J. Immunol.* 148: 3264-3270.
194. Sher, A., R. T. Gazzinelli, I. P. Oswald, M. Clerici, M. Kullberg, E. J. Pearce, J. A. Berzofsky, T. R. Mosmann, S. L. James, H. C. Morse, III, and G. M. Shearer. 1992. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. *Immunological Reviews* 127: 183-204.
195. Shirai, M., T. Akatsuka, C. D. Pendleton, R. Houghten, C. Wychowski, K. Mihalik, S. Feinstone, and J. A. Berzofsky. 1992. Induction of cytotoxic T cells to a crossreactive

- epitope in the hepatitis C viral nonstructural RNA polymerase-like protein. *J. Virol.* 66: 4098-4106.
196. Clerici, M., J. A. Berzofsky, G. M. Shearer, J. V. Giorgi, and C. Tacket. 1992. On HIV-serologic testing of blood and tissue donors. *New Engl. J. Med.* 327: 564-565 (letter).
 197. Quakyi, I. A., D. W. Taylor, A. H. Johnson, J. B. Allotey, J. A. Berzofsky, L. H. Miller, and M. F. Good. 1992. Development of a malaria T-cell vaccine for blood stage immunity. *Scand. J. Immunol.* 36 (Suppl. 11):9-16.
 198. Hosmalin, A., S. Kumar, D. Barnd, R. Houghten, G. E. Smith, S. H. Hughes, and J. A. Berzofsky. 1992. Immunization with soluble protein-pulsed spleen cells induces class I-restricted CTL that recognize immunodominant epitopic peptides from *P. falciparum* and HIV-1. *J. Immunol.* 149: 1311-1318.
 199. Weiss, W. R., J. A. Berzofsky, R. A. Houghten, M. Sedegah, M. Hollindale, and S. L. Hoffman. 1992. A T cell clone directed at the circumsporozoite protein which protects mice against both *Plasmodium yoelii* and *Plasmodium berghei*. *J. Immunol.* 149: 2103-2109.
 200. Actor, J. K., M. Shirai, M. C. Kullberg, R. M. L. Buller, A. Sher, and J. A. Berzofsky. 1993. Helminth infection results in decreased virus-specific CD8⁺ cytotoxic T-cell and Th1 cytokine responses as well as delayed virus clearance. *Proc. Natl. Acad. Sci. USA* 90: 948-952.
 201. Boehncke, W. -H., T. Takeshita, C. D. Pendleton, S. Sadegh-Nasseri, L. Racioppi, R. A. Houghten, J. A. Berzofsky, and R. N. Germain. 1993. The importance of dominant negative effects of amino acids side chain substitution in peptide-MHC molecule interactions and T cell recognition. *J. Immunol.* 150: 331-341.
 202. Takahashi, H., Y. Nakagawa, M. Takeuchi, K. Yokomuro, and J. A. Berzofsky. 1993. Elicitation of CD8⁺ class-I-restricted CTLs by immunization with syngeneic irradiated HIV-1 envelope-derived peptide-pulsed splenic dendritic cells. In *Vaccines 93*. F. Brown, R.M. Chanock, H.S. Ginsberg, and R.A. Lerner, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
 203. Berzofsky, J. A. and I. J. Berkower. 1993. Immunogenicity and antigen structure. In *Fundamental Immunology*. 3rd Edn. W.E. Paul, editor. Raven Press, New York., pp. 235-282.
 204. Berzofsky, J. A., I. J. Berkower, and S. L. Epstein. 1993. Antigen-antibody interactions and monoclonal antibodies. In *Fundamental Immunology*. 3rd Edn. W.E. Paul, editor. Raven Press, New York. , pp. 421-465.
 205. Berzofsky, J. A. 1995. Immunogenicity and Antigenicity. In *Samter's Immunological Diseases*. M.M. Frank, K.F. Austen, H.N. Claman, and E.R. Unanue, editors. Little, Brown, and Company, Boston, pp. 17-32..

206. Berzofsky, J. A. 1993. Epitope selection and design of synthetic vaccines: molecular approaches to enhancing immunogenicity and crossreactivity of engineered vaccines. *Annals of the New York Academy of Sciences* , 690: 256-264.
207. Ahlers, J. D., C. D. Pendleton, N. Dunlop, A. Minassian, P. L. Nara, and J. A. Berzofsky. 1993. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes following two immunizations. *J. Immunol.* 150: 5647-5665.
208. Wasserman, G. M., S. Kumar, J. Ahlers, F. Ramsdell, J. A. Berzofsky, and L. H. Miller. 1993. An approach to development of specific T lymphocyte lines using preprocessed antigens in murine malaria *Plasmodium vinckei vinckei*. *Infect. Immun.* 61: 1958-1963.
209. Takahashi, H., Y. Nakagawa, K. Yokomuro, and J. A. Berzofsky. 1993. Induction of CD8⁺ CTL by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. *Internat. Immunol.* 5: 849-857.
210. Shirai, M., M. S. Vacchio, R. J. Hodes, and J. A. Berzofsky. 1993. Preferential V β usage by cytotoxic T cells crossreactive between two epitopes of HIV-1 gp160 and degenerate in class I MHC restriction. *J. Immunol.* 151: 2283-2295.
211. Yanuck, M., D. P. Carbone, C. D. Pendleton, T. Tsukui, S. F. Winter, J. D. Minna, and J. A. Berzofsky. 1993. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8⁺ cytotoxic T cells. *Cancer. Res.* 53: 3257-3261.
212. Takeshita, T., S. Kozlowski, R. D. England, R. Brower, J. Schneck, H. Takahashi, C. DeLisi, D. H. Margulies, and J. A. Berzofsky. 1993. Role of conserved regions of class I MHC molecules in the activation of CD8⁺ CTL by peptide and purified cell-free class I molecules. *Internat. Immunol.* 5: 1129-1138.
213. Kozlowski, S., M. Corr, M. Shirai, L. F. Boyd, C. D. Pendleton, J. A. Berzofsky, and D. H. Margulies. 1993. Multiple pathways are involved in the extracellular processing of major histocompatibility complex class I-restricted peptides. *J. Immunol.* 151: 4033-4044.
214. Williams, M. E., M. C. Kullberg, S. Barbieri, P. Caspar, J. A. Berzofsky, R. A. Seder, and A. Sher. 1993. Fc ϵ R⁺ cells are a major source of antigen induced IL-4 in spleens of mice infected with *Schistosoma mansoni* . *Eur. J. Immunol.* 23: 1910-1916.
215. Shirai, M., C. D. Pendleton, J. Ahlers, T. Takeshita, M. Newman, and J. A. Berzofsky. 1994. Helper-CTL determinant linkage required for priming of anti-HIV CD8⁺ CTL in vivo with peptide vaccine constructs. *J. Immunol.* 152: 549-556.

216. Clerici, M., A. V. Sison, J. A. Berzofsky, T. A. Rakusan, C. D. Brandt, M. Ellaurie, M. Villa, C. Colie, D. J. Venzon, J. L. Sever, and G. M. Shearer. 1993. Cellular immune factors associated with mother-to-infant transmission of HIV. *AIDS* 7:1427-1433.
217. Clerici, M., D. R. Lucey, J. A. Berzofsky, L. A. Pinto, T. A. Wynn, S. P. Blatt, M. J. Dolan, C. W. Hendrix, S. F. Wolf, and G. M. Shearer. 1993. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 *in vitro*. *Science* 262: 1721-1724.
218. Clerici, M., T. A. Wynn, J. A. Berzofsky, S. P. Blatt, C. W. Hendrix, A. Sher, R. L. Coffman, and G. M. Shearer. 1994. Role of interleukin-10 (IL-10) in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus (HIV-1). *J. Clin. Invest.* 93: 768-775.
219. Cease, K. B. and J. A. Berzofsky. 1994. Towards a vaccine for AIDS: the emergence of immunobiology-based vaccine development. *Annu. Rev. Immunol.* 12: 923-989.
220. Altuvia, Y., J. A. Berzofsky, R. Rosenfeld, and H. Margalit. 1994. Sequence features that correlate with MHC restriction. *Molec. Immunol.* 31: 1-19.
221. Berzofsky, J. A., J. D. Ahlers, M. Shirai, C. D. Pendleton, T. Takeshita, N. Dunlop, A. Minassian, M. Newman, and P. L. Nara. 1994. Construction of candidate synthetic peptide vaccines for HIV-1. In *Vaccines 94: Modern approaches to new vaccines including prevention of AIDS*. E. Norrby, F. Brown, R.M. Chanock, and H.S. Ginsberg, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. pp. 147-153.
222. Takahashi, H., T. Takeshita, S. Kozlowski, Y. Nakagawa, J. Ahlers, C. D. Pendleton, R. L. Moore, B. S. Fox, K. Yokomuro, D. H. Margulies, and J. A. Berzofsky. 1994. An immunodominant determinant of HIV-1 envelope recognized by both class-I-restricted CD8⁺ CTLs and class II-restricted CD4⁺ helper T cells shares similar MHC-binding sites. In *Vaccines 94: Modern approaches to new vaccines including prevention of AIDS*. E. Norrby, F. Brown, R.M. Chanock, and H.S. Ginsberg, editors. Cold Spring Harbor Laboratory Press, Cold Spring Harbor. pp. 181-188.
223. Clerici, M., J. M. Levin, H. A. Kessler, A. Harris, J. A. Berzofsky, A. L. Landay, and G. M. Shearer. 1994. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. *J. Amer. Med. Assoc.* 271:42-46.
224. Clerici, M. and J. A. Berzofsky. 1994. Cellular immunity and cytokines in HIV infection. *AIDS* 8: S175-S182.
225. Wiedenfeld, E. A., M. Fernandez-Viña, J. A. Berzofsky, and D. P. Carbone. 1994. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A *0201 peptide consensus motif. *Cancer Res.* 54:1175-1177.
226. Weissler, J. C., L. E. Rosenberg, and J. A. Berzofsky. 1994. The spring meetings: Back to the future. *J. Clin. Invest.* 93:457-458.

227. Shirai, M., H. Okada, M. Nishioka, T. Akatsuka, C. Wychowski, R. Houghten, C. D. Pendleton, S. M. Feinstone, and J. A. Berzofsky. 1994. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. *J. Virol.* 68:3334-3342.
228. Kozhich, A. T., Y. -I. Kawano, C. E. Egwuagu, R. R. Caspi, R. K. Maturi, J. A. Berzofsky, and I. Gery. 1994. A pathogenic autoimmune process targeted at a surrogate epitope. *J. Exp. Med.* 180: 133-140.
229. Bermas, B. L., M. Petri, J. A. Berzofsky, A. Waisman, G. M. Shearer, and E. Mozes. 1994. Autoantibodies in mice with experimentally induced systemic lupus erythematosus (SLE) and patients with SLE bind gp120 and peptides from the HIV-1 envelope. *AIDS Res. Hum. Retroviruses.* 10: 1071-1077.
230. Berzofsky, J. A. 1994. Presidential address to the American Society for Clinical Investigation, Baltimore, Maryland, 30 April, 1994: Cross-fertilization among fields: a seminal event in the progress of biomedical research. *J. Clin. Invest.* 94: 911-918.
231. Brower, R. C., R. England, T. Takeshita, S. Kozlowski, D. H. Margulies, J. A. Berzofsky, and C. DeLisi. 1994. Minimal requirements for peptide mediated activation of CD8⁺ CTL. *Molec. Immunol.* 31: 1285-1293.
232. Quakyi, I. A., J. Currier, A. Fell, D. W. Taylor, T. Roberts, R. A. Houghten, R. D. England, J. A. Berzofsky, L. H. Miller, and M. F. □ Good. 1994. Analysis of human T cell clones specific for conserved peptide sequences within malaria proteins: paucity of clones responsive to intact parasites. *J. Immunol.* 153: 2082-2092.
233. Nishimura, M., A. G. Kermode, M. Clerici, G. M. Shearer, J. A. Berzofsky, T. Uchiyama, S. Z. Wiktor, E. Pate, B. Maloney, A. Manns, W. Blattner, and S. Jacobson. 1994. Demonstration of human T lymphotropic virus type (HTLV-I)-specific T cell responses from seronegative and polymerase chain reaction-negative persons exposed to HTLV-I. *J. Infect. Dis.* 170:334-338.
234. Actor, J. K., M. A. Marshall, I. A. Eltoun, R. M. L. Buller, J. A. Berzofsky, and A. Sher. 1994. Increased susceptibility of mice infected with *Schistosoma mansoni* to recombinant vaccinia virus: association of viral persistence with egg granuloma formation. *Eur. J. Immunol.* 24: 3050-3056.
235. Meister, G. E., C. G. P. Roberts, J. A. Berzofsky, and A. S. DeGroot. 1995. Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from *Mycobacterium tuberculosis* and HIV protein sequences. *Vaccine* , 13: 581-591.
236. Takeshita, T., H. Takahashi, S. Kozlowski, J. D. Ahlers, C. D. Pendleton, R. L. Moore, Y. Nakagawa, K. Yokomuro, B. S. Fox, D. H. Margulies, and J. A. Berzofsky. 1995. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule. *J. Immunol.* 154: 1973-1986.

237. Berzofsky, J. A., J. D. Ahlers, M. Alexander-Miller, T. Tsukui, C. D. Pendleton, N. Dunlop, D. P. Carbone, and P. L. Nara. 1995. Developing synthetic peptide vaccines for HIV-1. In *Molecular approaches to the control of infectious diseases*. F. Brown, R. Chanock, H.S. Ginsberg, and E. Norrby, editors. Cold Spring Harbor Laboratory, Cold Spring Harbor, 135-142.
238. Berzofsky, J. A. and I. J. Berkower. 1995. Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994-95. *AIDS* 9: S143-157.
239. Shirai, M., T. Arichi, M. Nishioka, T. Nomura, K. Ikeda, K. Kawanishi, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky. 1995. Cytotoxic T lymphocyte (CTL) responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. *J. Immunol.* 154: 2733-2742.
240. Battagay, M., J. Fikes, A. M. Di Bisceglie, P. A. Wentworth, A. Sette, E. Celis, W. -M. Ching, A. Grakoui, C. M. Rice, K. Kurokohchi, J. A. Berzofsky, J. H. Hoofnagle, S. M. Feinstone, and T. Akatsuka. 1995. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus \square -encoded peptides binding to HLA-A2.1 molecules. *J. Virol.* 69:2462-2470.
241. Berzofsky, J. A. 1995. Designing peptide vaccines to broaden recognition and enhance potency. *Ann. N. Y. Acad. Sci.* 754: 161-168.
242. Malik, A., R. Houghten, G. Corradin, S. Buus, J. A. Berzofsky, and S. L. Hoffman. 1995. Identification of a nonameric H-2K^k-restricted CD8⁺ cytotoxic lymphocyte epitope on the *Plasmodium falciparum* circumsporozoite protein. *Infect. Immun.* 63: 1955-1959.
243. Pinto, L. A., J. Sullivan, J. A. Berzofsky, M. Clerici, H. A. Kessler, A. L. Landay, and G. M. Shearer. 1995. *Env*-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. *J. Clin. Invest.* 96: 867-876.
244. Cornette, J. L., H. Margalit, J. A. Berzofsky, and C. DeLisi. 1995. Periodic variation in side chain polarities of T cell antigenic peptides correlates with their structure and activity. *Proc. Nat. Acad. Sci. USA.* 92: 8368-8372.
245. England, R. E., M. C. Kullberg, J. L. Cornette, and J. A. Berzofsky. 1995. Molecular analysis of a heteroclitic T-cell response to the immunodominant epitope of sperm whale myoglobin: implications for peptide partial agonists. *J. Immunol.* 155: 4295-4306.
246. Shirai, M., M. Chen, T. Arichi, M. Nishioka, M. Newman, T. Nakazawa, S. M. Feinstone, and J. A. Berzofsky. 1996. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines. *J. Infect. Dis.* 173: 24-31.

247. Shearer, G. M., M. Clerici, A. Sarin, J. A. Berzofsky, and P. A. Henkart. 1995. Cytokines in immune regulation/pathogenesis in HIV infection. Ciba Foundation Symposium 195: 142-153 (Wiley, Chichester).
248. Seder, R. A., K. H. Grabstein, J. A. Berzofsky, and J. F. McDyer. 1995. Cytokine interactions in human immunodeficiency virus-infected individuals: Roles of interleukin (IL)-2, IL-12, and IL-15. *J. Exp. Med.* 182:1067-1078.
249. Kurokohchi, K., T. Akatsuka, C. D. Pendleton, A. Takamizawa, M. Nishioka, M. Battegay, S. M. Feinstone, and J. A. Berzofsky. 1996. Use of recombinant protein to identify a motif-negative human CTL epitope presented by HLA-A2 in the hepatitis C virus NS3 region. *J. Virol.* 70: 232-240.
250. Takahashi, H., Y. Nakagawa, G. Leggatt, Y. Ishida, T. Saito, K. Yokomuro, and J. A. Berzofsky. 1996. Inactivation of HIV-1 envelope-specific CD8⁺ cytotoxic T lymphocytes by free antigenic peptide: A self-veto mechanism? *J. Exp. Med.* 183: 879-889.
251. Ahlers, J. D., N. Dunlop, C. D. Pendleton, M. Newman, P. L. Nara, and J. A. Berzofsky. 1996. Candidate HIV-1 multideterminant cluster peptide-P18MN vaccine constructs elicit Th1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization. *AIDS Res. Hum. Retroviruses* 12: 259-272.
252. Kurokohchi, K., M. Carrington, D. L. Mann, T. B. Simonis, S. M. Feinstone, T. Akatsuka, and J. A. Berzofsky. 1996. Expression of HLA class I molecules and the transporter associated with antigen processing (TAP) in hepatocellular carcinoma. *Hepatology* 23: 1181-1188.
253. Kullberg, M. C., J. A. Berzofsky, D. Lj. Jankovic, S. Barbieri, M. E. Williams, P. Perlmann, A. Sher, and M. Troye-Blomberg. 1996. T-cell-derived IL-3 induces the production of IL-4 by non-B, non-T cells to amplify the Th2-cytokine response to a non-parasite antigen in *Schistosoma mansoni*-infected mice. *J. Immunol.* 156: 1482-1489.
254. Quakyi, I. A., L. H. Miller, M. F. Good, J. D. Ahlers, S. N. Isaacs, J. H. Nunberg, R. A. Houghten, D. B. Keister, J. E. Coligan, B. Moss, D. Alling, J. A. Berzofsky, and D. C. Kaslow. 1995. Synthetic Peptides from *P. falciparum* sexual stage 25-kDa protein induce antibodies that react with the native protein: the role of IL-2 and conformational structure on immunogenicity of Pfs25. *Peptide Research* 8: 335-344.
255. Ciernik, I. F., J. A. Berzofsky, and D. P. Carbone. 1995. Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53. *Hybridoma* 14:139-142.
256. Alexander-Miller, M. A., K. C. Parker, T. Tsukui, C. D. Pendleton, J. E. Coligan, and J. A. Berzofsky. 1996. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-1 envelope protein to human CTL. *Int. Immunol.* 8: 641-649.

257. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. *Proc. Natl. Acad. Sci. U. S. A.* 93: 4102-4107.
258. Roberts, C. G. P., G. E. Meister, B. T. Jesdale, J. Lieberman, J. A. Berzofsky, and A. S. DeGroot. 1996. Prediction of HIV peptide epitopes by a novel algorithm. *AIDS Res. Hum. Retroviruses* 12: 593-610.
259. Landay, A. L., M. Clerici, F. Hashemi, H. Kessler, J. A. Berzofsky, and G. M. Shearer. 1996. In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. *J. Infect. Dis.* 173: 1085-1091.
260. Ciernik, I. F., J. A. Berzofsky, and D. P. Carbone. 1996. Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope, and are lysed by mutant-specific CTL. *Clin. Cancer. Res.* 2: 877-882..
261. Ciernik, I. F., J. A. Berzofsky, and D. P. Carbone. 1996. Induction of cytotoxic T lymphocytes and anti-tumor immunity with DNA vaccines expressing single T cell epitopes. *J. Immunol.* 156: 2369-2375.
262. Gabrilovich, D. I., S. Nadaf, J. Corak, J. A. Berzofsky, and D. P. Carbone. 1996. Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors.. *Cellular Immunol.* 170: 111-119.
263. Clerici, M., A. Sarin, J. A. Berzofsky, A. L. Landay, H. A. Kessler, F. Hashemi, C. W. Hendrix, S. P. Blatt, J. Rusnak, M. J. Dolan, R. L. Coffman, P. A. Henkart, and G. M. Shearer. 1996. Antigen-stimulated apoptotic T cell death in HIV infection is selective for CD4⁺ T cells, modulated by cytokines and effected by lymphotoxin. *AIDS* 10: 603-611.
264. Tian, J. -H., L. H. Miller, D. C. Kaslow, J. Ahlers, M. F. Good, D. W. Alling, J. A. Berzofsky, and S. Kumar. 1996. Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. *J. Immunol.* 157: 1176-1183.
265. Alexander-Miller, M. A., G. R. Leggatt, A. Sarin, and J. A. Berzofsky. 1996. Role of antigen, CD8, and CTL avidity in high dose antigen induction of apoptosis of effector CTL. *J. Exp. Med.* 184: 485-492.
266. Tsukui, T., A. Hildesheim, M. H. Schiffman, J. Lucci III, D. Contois, P. Lawler, B. B. Rush, A. T. Lorincz, A. Corrigan, R. D. Burk, W. Qu, M. A. Marshall, D. Mann, M. Carrington, M. Clerici, G. M. Shearer, D. P. Carbone, D. R. Scott, R. A. Houghten, and J. A. Berzofsky. 1996. IL-2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology. *Cancer Res.* 56: 3967-3974.

267. Huang, X., M. C. Smith, J. A. Berzofsky, and J. J. Jr. Barchi. 1996. Structural comparison of a 15-residue peptide from the V3 loop of HIV-1_{IIIB} and an O-glycosylated analogue. *FEBS Letters* 393: 280-286.
268. Shirai, M., K. Kurokohchi, C. D. Pendleton, T. Arichi, L. F. Boyd, H. Takahashi, D. H. Margulies, and J. A. Berzofsky. 1996. Reciprocal CTL cross-reactivity interactions between two major epitopes within HIV-1 gp160. *J. Immunol.* , 157: 4399-4411.
269. Beretta, A., S. H. Weiss, G. Rappocciolo, R. Mayur, D. De Santis, J. Quirinale, A. Cosma, P. Robbioni, G. M. Shearer, J. A. Berzofsky, M. L. Villa, A. Siccardi, and M. Clerici. 1996. Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope. *J. Infect. Dis.* 173: 472-476.
270. Pinto, L. A., A. L. Landay, J. A. Berzofsky, H. A. Kessler, and G. M. Shearer. 1997. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. *Am. J. Med.* 102 (5B): 21-24.
271. Leggatt, G. R., M. A. Alexander-Miller, A. Kumar (née Malik), S. L. Hoffman, and J. A. Berzofsky. 1997. Cytotoxic T lymphocyte (CTL) adherence assay (CAA): A non-radioactive assay for murine CTL recognition of peptide-MHC class I complexes. *J. Immunol. Methods*, 201: 1-10.
272. Sarin, A., M. S. Williams, M. A. Alexander-Miller, J. A. Berzofsky, C. M. Zacharchuk, and P. A. Henkart. 1997. Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases. *Immunity* 6: 209-215.
273. Saito, T., G. J. Sherman, K. Kurokohchi, Z. -P. Guo, M. Donets, M. -Y. W. Yu, J. A. Berzofsky, T. Akatsuka, and S. M. Feinstone. 1997. Plasmid DNA-based immunization for hepatitis C virus structural proteins, immune responses in mice. *Gastroenterology* 112: 1321-1330.
274. Shirai, M., S. Kozlowski, D. H. Margulies, and J. A. Berzofsky. 1997. Degenerate MHC restriction reveals the contribution of class I MHC molecules in determining the fine specificity of CTL recognition of an immunodominant determinant of HIV-1 gp160 V3 loop. *J. Immunol.* 158: 3181-3188.
275. Ahlers, J. D., N. Dunlop, D. W. Alling, P. L. Nara, and J. A. Berzofsky. 1997. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: GM-CSF and TNF α synergize with IL-12 to enhance induction of CTL. *J. Immunol.* 158: 3947-3958.
276. Kozhich, A. T., R. R. Caspi, J. A. Berzofsky, and I. Gery. 1997. Immunogenicity and immunopathogenicity of an autoimmune epitope are potentiated by increasing MHC binding through residue substitution. *J. Immunol.* 158: 4145-4151.

277. Zhang, C., J. L. Cornette, J. A. Berzofsky, and C. DeLisi. 1997. The organization of human leukocyte antigen class I epitopes in HIV genome products: Implications for HIV evolution and vaccine design. *Vaccine* 15: 1291-1302.
278. Smith, M. C., C. D. Pendleton, V. E. Maher, M. J. Kelley, D. P. Carbone, and J. A. Berzofsky. 1997. Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular processing. *Internat. Immunol.* 9: 1085-1093.
279. Goletz, T. J., K. R. Klimpel, S. H. Leppla, J. M. Keith, and J. A. Berzofsky. 1997. Delivery of antigens to the MHC class I pathway using bacterial toxins. *Hum. Immunol.* 54: 129-136..
280. DeGroot, A. S., B. M. Jesdale, and J. A. Berzofsky. 1998. Prediction and determination of MHC ligands and T cell epitopes. In *Immunological Methods in Microbiology Vol. 25. Immunology of Infection*. S.H.E. Kaufmann and D. Kabelitz, editors. Academic Press, London, Chap. 3, pp. 79-106.
281. Hirunpetcharat, C., J. -H. Tian, D. C. Kaslow, N. van Rooijen, S. Kumar, J. A. Berzofsky, L. H. Miller, and M. F. Good. 1997. Complete protective immunity induced in mice by immunization with the 19kDa carboxyterminal fragment of the merozoite surface protein-1 (MSP119) of *Plasmodium yoelii* expressed in *Saccharomyces cerevisiae*: Correlation of protection with antigen-specific antibody titer, but not effector CD4⁺ T cells. *J. Immunol.* 159: 3400-3411.
282. DeGroot, A. S., G. E. Meister, J. L. Cornette, H. Margalit, C. DeLisi, and J. A. Berzofsky. 1997. Computer prediction of T-cell epitopes. In *New Generation Vaccines*. M.M. Levine, G.C. Woodrow, J.B. Kaper, and G.S. Cobon, editors. Marcel Dekker, Inc., New York. 127-138.
283. Ahlers, J. D., T. Takeshita, C. D. Pendleton, and J. A. Berzofsky. 1997. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. *Proc. Natl. Acad. Sci. U. S. A.* 94: 10856-10861.
284. Shirai, M., T. Arichi, T. Nakazawa, and J. A. Berzofsky. 1998. Persistent infection by *Helicobacter pylori* downmodulates virus-specific CD8⁺ cytotoxic T cell response and prolongs viral infection. *J. Infect. Dis.* 177: 72-80.
285. Goletz, T.J., K. R. Klimpel, N. Arora, S. H. Leppla, J. M. Keith, and J. A. Berzofsky. 1997. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. *Proc. Natl. Acad. Sci. U.S.A.* 94: 12059-12064.
286. Belyakov, I. M., M. A. Derby, J. D. Ahlers, B. L. Kelsall, P. Earl, B. Moss, W. Strober, and J. A. Berzofsky. 1998. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. *Proc. Natl. Acad. Sci.* 95:1709-1714.

287. Hildesheim, A., M. H. Schiffman, T. Tsukui, C. A. Swanson, J. Lucci, D. R. Scott, A. G. Glass, B. B. Rush, A. T. Lorincz, A. Corrigan, R. D. Burk, K. Helgesen, R. A. Houghten, M. E. Sherman, R. J. Kurman, J. A. Berzofsky, and T. R. Kramer. 1997. Immune activation in cervical neoplasia: Cross-sectional association between plasma soluble interleukin 2 receptor levels and disease. *Cancer Epidemiol. Biomark. Preven.* 6:807-813.
288. Leggatt, G. R. and J. A. Berzofsky. 1999. Cytotoxic T cell adherence assay (CAA). In *Methods in Molecular Biology Series : T cell protocols*. K. Kearse, editor. Humana Press, Totowa, NJ.,134: 277-281.
289. Belyakov, I. M., L. S. Wyatt, J. D. Ahlers, P. Earl, C. D. Pendleton, B. L. Kelsall, W. Strober, B. Moss, and J. A. Berzofsky. 1998. Induction of mucosal CTL response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing HIV 89.6 envelope protein. *J. Virol.* 72: 8264-8272.
290. Leggatt, G. R., A. Hosmalin, C. D. Pendleton, A. Kumar, S. Hoffman, and J. A. Berzofsky. 1998. The importance of pairwise interactions between peptide residues in the delineation of T cell receptor specificity. *J Immunol.* 161: 4728-4735:
291. Sarobe, P., C. D. Pendleton, T. Akatsuka, D. Lau, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky. 1998. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. *J. Clin. Invest.* 102: 1239-1248.
292. Alexander-Miller, M. A., M. A. Derby, A. Sarin, P. A. Henkart, and J. A. Berzofsky. 1998. Supra-optimal peptide/MHC causes a decrease in Bcl-2 and allows TNF- α \square receptor II-mediated apoptosis of CTL. *J. Exp. Med.* 188: 1391-1399.
293. Berzofsky, J. A., I. J. Berkower, and S. L. Epstein. 1999. Antigen-antibody interactions and monoclonal antibodies. In *Fundamental Immunology*. W.E. Paul, editor. Lippincott-Raven, Philadelphia. 75-110.
294. Berzofsky, J. A. and I. J. Berkower. 1999. Immunogenicity and antigen structure. In *Fundamental Immunology*. W.E. Paul, editor. Lippincott-Raven, Philadelphia. 651-699.
295. Goletz, T. J., C. L. Mackall, J. A. Berzofsky, and L. J. Helman. 1998. Molecular alterations in pediatric sarcomas: potential targets for immunotherapy. *Sarcoma* 2:77-87.
296. Tian, J.-H., M. F. Good, C. Hirunpetcharat, S. Kumar, I. T. Ling, D. Jackson, J. Cooper, J. Lukszo, J. Coligan, J. Ahlers, A. Saul, J. A. Berzofsky, A. A. Holder, L. H. Miller, and D. C. Kaslow. 1998. Definition of T cell epitopes within the 19kDa carboxyterminal fragment *Plasmodium yoelii* merozoite surface protein 1 (MSP1₁₉) and their role in immunity malaria. *Parasite Immunol.* 20: 263-278.
297. Shirai, M., T. Arichi, M. Chen, M. Nishioka, K. Ikeda, H. Takahashi, N. Enomoto, T. Saito, M. E. Major, T. Nakazawa, T. Akatsuka, S. M. Feinstone, and J. A. Berzofsky. 1999. T

- cell recognition of hypervariable region 1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: Preferential help for induction of antibodies to the hypervariable region.. *J. Immunol.* 162: 568-576.
298. Oscherwitz, J., F. M. Gotch, K. B. Cease, and J. A. Berzofsky. 1999. New insights and approaches regarding B and T cell epitopes in HIV vaccine design. *AIDS* , 13 (Suppl. A): S163-S174.
299. Suh, W-K., M. A. Derby, M. F. Cohen-Doyle, G. J. Schoenhals, K. Früh, J. A. Berzofsky, and D. B. Williams. 1999. Interaction of murine MHC class I molecules with tapasin and TAP enhances peptide loading and involves the heavy chain $\alpha 3$ domain. *J. Immunol.* 162: 1530-1540.
300. Belyakov, I. M., J. D. Ahlers, B. Y. Brandwein, P. Earl, B. L. Kelsall, B. Moss, W. Strober, and J. A. Berzofsky. 1998. The importance of local mucosal HIV-specific CD8⁺ cytotoxic T lymphocytes for resistance to mucosal-viral transmission in mice and enhancement of resistance by local administration of IL-12. *J. Clin. Invest.* 102: 2072-2081.
301. D'Amico, R., L. A. Pinto, P. Meyer, A. L. Landay, A. A. Harris, M. Clerici, J. A. Berzofsky, G. M. Shearer, and H. A. Kessler. 1999. Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed health care workers. *Infection Control and Hospital Epidemiology* , 20: 428-430.
302. McDyer, J. F., M. Dybul, T. J. Goletz, A. L. Kinter, E. K. Thomas, J. A. Berzofsky, A. S. Fauci, and R. A. Seder. 1999. Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: Evidence for CC-chemokine-dependent and -independent mechanisms. *J. Immunol.* , 162: 3711-3717.
303. Belyakov, I. M., B. Moss, W. Strober, and J. A. Berzofsky. 1999. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. *Proc. Natl. Acad. Sci. U. S. A.* 96: 4512-4517.
304. Berzofsky, J. A., J. D. Ahlers, M. A. Derby, C. D. Pendleton, T. Arichi, and I. M. Belyakov. 1999. Approaches to improve engineered vaccines for HIV and other viruses that cause chronic infections. *Immunological Reviews* 170: 151-172.
305. Matsui, S., J. D. Ahlers, A. O. Vortmeyer, M. Terabe, T. Tsukui, D. P. Carbone, L. A. Liotta, and J. Berzofsky. 1999. A model for CD8⁺ CTL tumor immunosurveillance and regulation of tumor escape by CD4⁺ T cells through an effect on quality of CTL. *J. Immunol.* 163: 184-193.
306. Maher, V. E., B. S. Worley, D. Contois, M. C. Smith, M. J. Kelley, M. Stipanov, S. N. Khleif, T. Goletz, L. van den Broeke, C. Mackall, L. J. Helman, D. P. Carbone, and J. A. Berzofsky. 2000. Mutant oncogene and tumor suppressor gene products and fusion

- proteins created by chromosomal translocations as targets for cancer vaccines. In *Peptide-based cancer vaccines*. W.M. Kast, editor. Landes Bioscience, Austin, pp. 17-39.
307. Chung, D. H., J. Dorfman, D. Plaksin, K. Natarajan, I. M. Belyakov, R. Hunziker, J. A. Berzofsky, W. M. Yokoyama, M. G. Mage, and D. H. Margulies. 1999. Natural killer (NK) and cytolytic T lymphocyte (CTL) recognition of a single chain H-2D^d molecule: distinct sites of H-2D^d interact with NK and T cell receptors. *J. Immunol.* 163: 3699-3708.

308. Pinto, L. A., J. A. Berzofsky, K. R. Fowke, R. F. Littles, F. Merced-Galindez, R. Humphreys, J. Ahlers, N. Dunlop, R. B. Cohen, S. M. Steinberg, P. Nara, G. M. Shearer, and R. Yarchoan. 1999. HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. *AIDS* 13: 2003-2012.
309. Berzofsky, J. A., L. J. Helman, and D. P. Carbone. 2000. Oncogene products and mutated proteins as tumor antigens. In *Biologic Therapy of Cancer: Principles and Practice* (3rd Ed.). S. A. Rosenberg, editor. Lippincott Williams & Wilkins, Philadelphia, 526-540.
310. Arichi, T., T. Saito, M. E. Major, I. M. Belyakov, M. Shirai, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky. 2000. Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV specific CTL induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model. *Proc. Natl. Acad. Sci. U.S.A.* 97: 297-302. (Retracted due to discovery of fraud by first author.)
311. Ciernik, I. F., P. Romero, J. A. Berzofsky, and D. P. Carbone. 1999. Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope. *Int. J. Rad. Oncolo. Biol. Phys.* 45:735-741.
312. Parra, M., G. Hui, A. Johnson, J. A. Berzofsky, T. Roberts, I. A. Quakyi, and D. W. Taylor. 2000. Characterization of conserved T and B cell epitopes in Plasmodium falciparum major merozoite surface protein-1 (MSP-1). *Infect. Immun.* 68: 2685-2691.
313. Berzofsky, J. A. 2000. Immunogenicity and Antigenicity. In *Samter's Immunologic Diseases* Sixth Edition. K.F. Austen, M.M. Frank, J.P. Atkinson, and H. Cantor, editors. Lippincott Williams & Wilkins, Baltimore, Chap. 7, pp. 65-82.
314. Berzofsky J.A., J.D. Ahlers, I.M. Belyakov. 2002. Design of Engineered Vaccines for HIV. In: Wong-Staal F, Gallo RC, editors. *AIDS Vaccine Research*. New York: Marcel Dekker, Inc. 173-206..
315. Nakagawa Y, T. Takeshita, J.A. Berzofsky, H. Takahashi. 2000. Analysis of mechanism for extracellular processing in the presentation of HIV-1 envelope protein derived peptide to epitope-specific CTL. *Immunology.* 101: 76-82..
316. Grene E, D.A. Newton, E.A. Brown, J.A. Berzofsky, S. Gattoni-Celli, G.M. Shearer. 2000. Semi-allogeneic cell hybrids stimulate HIV-1 envelope-specific cytotoxic T lymphocytes. *AIDS:* 14: 1497-1506.
317. Polakova, K., D. Plaksin, D.H. Chung, I.M. Belyakov, J.A. Berzofsky, and D.H. Margulies, 2000. Antibodies directed against the MHC-I molecule H-2D^d complexed with an antigenic peptide: similarities to a T cell receptor with the same specificity. *J. Immunol.* 165: 5703-5712.

318. Belyakov, I.M., J.D. Ahlers, J.D. Clements, W. Strober, and J.A. Berzofsky, 2000. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific cytotoxic T lymphocytes. *J. Immunol.* 165: 6454-6462.
319. Terabe, M., S. Matsui, N. Noben-Trauth, H. Chen, C. Watson, D. D. Donaldson, D. P. Carbone, W. E. Paul, and J. A. Berzofsky. 2000. NKT cell-mediated repression of tumour immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. *Nature Immunology* 1: 515-520.
320. Takahashi, M., Y. Nakagawa, J. A. Berzofsky, and H. Takahashi. 2001. Counter-regulation of cytolytic activity and cytokine production in human immunodeficiency virus (HIV)-1-specific murine CD8⁺ cytotoxic T lymphocytes by free antigenic peptide. *Int Immunol.* 13: 43-51.
321. Mackall, C., J. Berzofsky, and L. J. Helman. 2000. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. *Clin. Orthopaedics and Related Research* 373: 25-31.
322. Derby, M. A., M. A. Alexander-Miller, R. Tse, and J. A. Berzofsky. 2001. High avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low avidity CTL. *J. Immunol.*, 166: 1690-1697.
323. Shirai, M., R. Fujinaga, T. Masaki, and J. A. Berzofsky. 2001. Impaired development of HIV-1 gp160-specific CD8⁺ cytotoxic T cells by a delayed switch from Th1 to Th2 cytokine phenotype in mice with *Helicobacter pylori* infection. *Eur. J. Immunol.*, 31: 516-526.
324. Simon, R. M., S. M. Steinberg, M. Hamilton, A. Hildesheim, S. Khleif, L. W. Kwak, C. L. Mackall, J. Schlom, S. L. Topalian, and J. A. Berzofsky. 2001. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. *J. Clin. Oncol.* 19: 1848-1854.
325. McGettigan, J. P., H. D. Foley, I. M. Belyakov, J. A. Berzofsky, R. J. Pomerantz, and M. J. Schnell. 2001. Rabies virus-based vectors expressing HIV-1 envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelop proteins from different HIV-1 isolates. *J. Virol.* 75: 4430-4434.
326. Derby, M.A., J. Wang, D. H. Margulies, and J. A. Berzofsky. 2001. Two intermediate avidity CTL clones with a disparity between functional avidity and MHC tetramer staining. *Internat. Immunol.* 13: 817-824.
327. Ahlers, J. D., I. M. Belyakov, S. Matsui, and J. A. Berzofsky. 2001. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. *Internat. Immunol.* 13: 897-908.
328. Wong, E. C. C., V. E. Maher, K. Hines, J. Lee, C. S. Carter, T. Goletz, W. Kopp, C. L. Mackall, J. A. Berzofsky, and E. J. Read. 2001. Development of a clinical-scale method for generation of dendritic cells from peripheral blood monocytes for use in cancer immunotherapy. *Cytotherapy* 3: 19-29.

329. Chung, D. H., I. M. Belyakov, M. A. Derby, J. Wang, L. F. Boyd, J. A. Berzofsky, and D. H. Margulies. 2001. Competitive inhibition *in vivo* and skewing of the T cell repertoire of antigen-specific CTL priming by an anti-peptide-MHC mAb. *J. Immunol.* 167: 699-707.
330. Horner, A. A., S. K. Datta, K. Takabayashi, I. M. Belyakov, T. Hayashi, N. Cinman, M.-D. Nguyen, J. H. Van Uden, J. A. Berzofsky, D. D. Richman, and E. Raz. 2001. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. *J. Immunol.*,167: 1584-1591.
331. Ahlers, J. D., I. M. Belyakov, S. Matsui, and J. A. Berzofsky. 2001. Signals delivered through TCR instruct IL-12R expression: IL-12 and TNF α synergize for IL-12R expression at low antigen dose. *Internat. Immunol.* 13: 1433-1442.
332. Derby, M. A., J. T. Snyder, R. Tse, M. A. Alexander-Miller, and J. A. Berzofsky. 2001. An abrupt and concordant initiation of apoptosis: antigen-dependent death of CD8⁺ CTL. *Eur. J. Immunol.* 31: 2951-2959.
333. Worley, B. S., L. T. van den Broeke, T. J. Goletz, C. D. Pendleton, E. M. Daschbach, E. K. Thomas, F. M. Marincola, L. J. Helman, and J. A. Berzofsky. 2001. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. *Cancer Research* 61: 6868-6875.
334. Hel, Z., J. Nacsa, B. Kelsall, W.-P. Tsai, N. Letvin, R. W. Parks, E. Trynieszewska, L. Picker, M. G. Lewis, Y. Edghill-Smith, M. Moniuszko, R. Pal, L. Stevceva, J. D. Altman, T. M. Allen, D. Watkins, J. V. Torres, J. A. Berzofsky, I. M. Belyakov, W. Strober, and G. Franchini. 2001. Impairment of gag-specific CD8⁺ T-cell function in mucosal and systemic compartments of SIV_{mac251}- and SHIV_{ku2}- infected macaques. *J. Virol.*, 75: 11483-11495.
335. Marshall, M. A., D. Jankovic, V. E. Maher, A. Sher, and J. A. Berzofsky. 2001. Mice infected with *Schistosoma mansoni* develop a novel non-T lymphocyte suppressor population which inhibits virus-specific CTL induction via a soluble factor. *Microbes and Infection* 3: 1051-1061.
336. Belyakov, I. M., J. Wang, R. Koka, J. D. Ahlers, J. T. Snyder, R. Tse, J. Cox, J. S. Gibbs, D. H. Margulies and J. A. Berzofsky. 2001. Activating CTL precursors to reveal CTL function without skewing the repertoire by *in vitro* expansion. *Eur. J. Immunol.* 31: 3557-3566.
337. Berzofsky, J. A. 2001. Design of engineered vaccines for systemic and mucosal immunity to HIV. *Pathol. Biol.* 49: 466-467.
338. Dagher, R., L. Long, E.J. Read, S.F. Leitman, C.S. Carter, M. Tsokos, S. Kumar, T.J. Goletz, J.A. Berzofsky, L.J. Helman and C.L. Mackall. 2002. A pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing's sarcoma and alveolar rhabdomyosarcoma: an interinstitute NIH study. *Medical and Pediatric Oncology*, 38: 158-164.

339. Bukreyev, A., I. M. Belyakov, J. A. Berzofsky, B. R. Murphy, and P. L. Collins. 2001. Granulocyte-macrophage colony-stimulating factor expressed by a recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells. *J. Virol.*, 75: 12128-12140.
340. Ahlers, J.D., I. M. Belyakov, E. K. Thomas, and J. A. Berzofsky. 2001. High affinity T-helper epitope induces complementary helper and APC polarization, increased CTL and protection against viral infection. *J. Clin. Invest.* 108: 1677-1685.
341. Belyakov, I. M., Z. Hel, B. Kelsall, V. A. Kuznetsov, J. D. Ahlers, J. Nacsa, D. I. Watkins, T. M. Allen, A. Sette, J. Altman, R. Woodward, P. D. Markham, J. D. Clements, G. Franchini, W. Strober and J. A. Berzofsky. 2001. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. *Nature Medicine* 7: 1320-1326.
342. Berzofsky, J. A., J. D. Ahlers, and I. M. Belyakov. 2001. Strategies for designing and optimizing new generation vaccines. *Nature Reviews Immunology* 1: 209-219.
343. De Groot, A. S., H. Sbai, W. Martin, and J. A. Berzofsky. 2003. Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to epitope-driven vaccine design. In S. H. E. Kaufmann and D. Kabelitz, editors. *Methods in Microbiology: Immunology of Infection*, 2nd Edition. London: Academic Press. In press.
344. Biragyn, A., I. M. Belyakov, Y. H. Chow, D. S. Dimitrov, J. A. Berzofsky, and L. W. Kwak. 2002. DNA vaccines encoding HIV-1 gp120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses. *Blood*, 100: 1153-1159.
345. Mackall, C. L., T. J. Goletz, J. A. Berzofsky, and L. J. Helman. 2002. Toward new approaches: targeting tumor specific molecular alterations with immune based therapy. In C. S. Cooper, editor, *Translocations in Solid Tumors*. Georgetown, TX: Landes Bioscience. In press.
346. Ahlers, J. D., I. M. Belyakov, M. Terabe, R. Koka, D. D. Donaldson, E. K. Thomas, and J. A. Berzofsky. 2002. A push-pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L. *Proc. Natl. Acad. Sci. USA* 99: 13020-13025.
347. Allen, T.M., P. Jing, B. Calore, H. Horton, D.H. O'Connor, T. Hanke, M. Piekarczyk, R. Ruddersdorf, B.R. Mothe, C. Emerson, N. Wilson, J.D. Lifson, I.M. Belyakov, J.A. Berzofsky, C. Wang, D.B. Allison, D.C. Montefiori, R.C. Desrosiers, S. Wolinsky, K.J. Kunstman, J.D. Altman, A. Sette, A.J. McMichael, and D.I. Watkins. 2002. Effects of Cytotoxic T Lymphocytes (CTL) Directed against a Single Simian Immunodeficiency Virus (SIV) Gag CTL Epitope on the Course of SIVmac239 Infection. *J Virol* 76:10507-10511.
348. Ostrand-Rosenberg, S., V.K. Clements, M. Terabe, J.M. Park, J. Berzofsky, and S.K. Dissanayake. 2002. Resistance to metastatic disease in Stat6-deficient mice requires

- hematopoietic and non-hematopoietic cells and is IFN γ -dependent. *J. Immunol.* 169: 5796-5804.
349. Berzofsky, J. A., J. D. Ahlers, M. Terabe, and I. M. Belyakov. 2003. Enhancing mucosal and systemic T cell responses and efficacy of HIV/SIV vaccines. In, M. Vicari, B. Dodet, and M. Girard eds., *Retroviruses of Human AIDS and Related Animal Diseases: Proceedings of the XIIIth Cent Gardes Symposium*, Elsevier: Paris, pp. 89-93.
350. Oh, S., J.W. Hodge, J.D. Ahlers, , D.S. Burke, J. Schlom, and J.A. Berzofsky, 2003. Selective induction of high avidity CTL by altering the balance of signals from antigen presenting cells. *J Immunol.* 170: 2523-2530.
351. Takahashi, M., E. Osono, Y. Nakagawa, J. Wang, J. Berzofsky, D.H. Margulies, and H. Takahashi. 2002. Rapid induction of apoptosis in CD8⁺ HIV-1 envelope-specific murine CTLs by short exposure to antigenic peptide. *J Immunol* 169:6588-6593.
352. Oh, S., J. A. Berzofsky, D. S. Burke, T. A. Waldmann, and L. P. Perera. 2003. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. *Proc. Natl. Acad. Sci. USA* 100: 3392-3397.
353. Pinto, L.A., J. Edwards, P.E. Castle, C.D. Harro, D.R. Lowy, J.T. Schiller, D. Wallace, W. Kopp, J.W. Adelsberger, M.W. Baseler, J.A. Berzofsky, and A. Hildesheim. 2003. Cellular immune responses to HPV-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. *J. Infec. Diseases*, 188: 327-338.
354. Ahlers, J.D., I.M. Belyakov, and J.A. Berzofsky. 2003. Cytokine, chemokine and costimulatory molecule modulation to enhance efficacy of HIV vaccines. *Current Molecular Medicine* 3:85-94.
355. Snyder, J.T., M. A. Alexander-Miller, J. A. Berzofsky, and I. M. Belyakov: 2003. Molecular mechanisms and biological significance of CTL avidity. *Current HIV Research* 1: 287-294.
356. Belyakov, I.M., P. Earl, A. Dzutsev, V.A. Kuznetsov, M. Lemon, L.S. Wyatt, J.T. Snyder, J.D. Ahlers, G. Franchini, B. Moss, and J.A. Berzofsky. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. *Proc Natl Acad Sci U S A.*100: 9458-9463.
357. Okazaki, T., D.C. Pendleton, F. Lemonnier, and J.A. Berzofsky. 2003. Epitope-enhanced conserved HIV-1 peptide protects HLA-A2-transgenic mice against virus expressing HIV-1 antigen. *J. Immunol.* 171: 2548-2555.
358. Enghill-Smith, Y., D. Venzon, T. Karpova, J. McNally, J. Nacsa, W.-P. Tsai, E. Tryniszewska, M. Moniuszko, S.J. Snodgrass, J. Parrish, M.G. Lewis, J.A. Berzofsky, I.M. Belyakov, B. Moss, J. Tartaglia, M. Bray, V. Hirsh, H. Golding, and G. Franchini. 2003. Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised macaques. *J. Infec. Dis.*188: 1181-1191.

359. Terabe, M., J.M. Park, and B. J.A. 2004. Role of IL-13 in negative regulation of anti-tumor immunity. *Cancer Immunol and Immunotherapy*, 53: 79-85.
360. Terabe, M., S. Matsui, J.-M. Park, M. Mamura, N. Noben-Trauth, D.D. Donaldson, W. Chen, S.M. Wahl, S. Ledbetter, B. Pratt, J.J. Letterio, W.E. Paul, and J.A. Berzofsky. 2003. Transforming Growth Factor- β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. *J Exp Med*, 198: 1741-1752.
361. van den Broeke, L.T., E.M. Daschbach, E.K. Thomas, G. Andringa, and B. J.A. 2003. Dendritic cell induced activation of adaptive and innate antitumor immunity. *J Immunol.*, 171: 5842-5852.
362. Terabe, M., and Berzofsky, J.A. 2004. Immunoregulatory T cells in tumor immunity. *Current Opinion in Immunology* 16: 157-162.
363. Belyakov, I.M., and J.A. Berzofsky. 2004. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. *Immunity* 20: 247-253.
364. Belyakov, I.M., S.A. Hammond, J.D. Ahlers, G.M. Glenn, and J.A. Berzofsky. 2004. Transcutaneous immunization induces mucosal CTL and protective immunity by migration of primed skin dendritic cells. *Journal of Clinical Investigation* 113: 998-1007.
365. Oh, S., M. Terabe, C.D. Pendleton, A. Bhattacharyy, T.K. Bera, M. Epel, Y. Reiter, J. Phillips, W.M. Linehan, C. Kasten-Sportes, I. Pastan, and J.A. Berzofsky. 2004. Human CTL to wild type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells. *Cancer Research* 64: 2610-2618.
366. Berzofsky, J.A., I.J. Berkower, and S.L. Epstein. 2003. Antigen-antibody interactions and monoclonal antibodies. *In* Fundamental Immunology. W.E. Paul, editor. Lippincott Williams & Wilkins, Philadelphia. 69-105.
367. Berzofsky, J.A., and I.J. Berkower. 2003. Immunogenicity and antigen structure. *In* Fundamental Immunology. W.E. Paul, editor. Lippincott Williams & Wilkins, Philadelphia. 631-683.
368. Lee, W.J., K.P. Cantor, J.A. Berzofsky, S.H. Zahm, and A. Blair. 2004. Non-hodgkin's lymphoma among asthmatics exposed to pesticides. *Internat. J. Cancer* 111: 298-302.
369. Snyder, J.T., I.M. Belyakov, A. Dzutsev, F. Lemonnier, and J.A. Berzofsky. 2004. Protection against lethal virus challenge in HLA-A2 transgenic mice by peptide immunization with an HLA-A0201 restricted CD8⁺ T cell epitope of vaccinia and variola. *Journal of Virology* 78: 7052-7060.

370. Berzofsky, J.A. 2004. New strategies for designing and optimizing vaccines. *American Society for Microbiology News* 70 (5): 219-223.
371. Berzofsky, J.A., and I.M. Belyakov. 2004. Mucosal vaccines to induce cellular immunity against HIV and other viral infections. In *Vaccines*. C.A. de Quadros, editor. Pan American Health Organization, Washington, DC. 223-237.
372. Berzofsky, J.A., M. Terabe, S. Oh, I. M. Belyakov, J. D. Ahlers, J. E. Janik, and J. C. Morris. 2004. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. *J. Clin. Invest.* 113: 1515-1525.
373. Kuznetsov, V.A., Stepanov, J.A. Berzofsky, and I.M. Belyakov. 2004. Assessment of the relative therapeutic effects of vaccines on virus load and immune responses in small groups at several time points: An efficacy of mucosal and subcutaneous polypeptide vaccines in rhesus macaques exposed to SHIV. *J of Clinical Virology* 31S: S69-S82.
374. Berzofsky, J.A., J. Ahlers, J. Janik, J. Morris, S. Oh, M. Terabe, and I.M. Belyakov. 2004. Progress on new vaccine strategies against chronic viral infections. *J Clin Invest* 114:450-462.
375. Park, J.M., M. Terabe, L.T. van den Broeke, D.D. Donaldson, and J.A. Berzofsky. 2005. Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4⁺ NKT regulatory cells and IL-13. *Internat. J. Cancer* 114: 80-87. (Pub on line Oct. 2004)
376. Belyakov, I.M., J.D. Ahlers, and J.A. Berzofsky. 2004. Mucosal AIDS vaccines: current status and future directions. *Expert Rev. Vaccines* 3:Suppl. 65-73.
377. Sakai, Y., B.J. Morrison, J.D. Burke, J.M. Park, M. Terabe, J.E. Janik, G. Forni, J.A. Berzofsky, and J.C. Morris. 2004. Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice. *Cancer Research* 64: 8022-8028.
378. Oh, S., L.P. Perera, D.S. Burke, T.A. Waldmann, and J.A. Berzofsky. 2004. IL-15/IL-15R alpha-mediated avidity maturation of memory CD8⁺ T cells. *Proc Natl Acad Sci U S A*, 101: 15154-15159.
379. Pinto, L.A., M.T. Trivett, D. Wallace, J. Higgins, M. Baseler, M. Terabe, I.M. Belyakov,, J.A. Berzofsky, and Allan Hildesheim. 2005. Fixation and Cryopreservation of Whole Blood and Isolated Mononuclear Cells: Influence of Different Procedures on Lymphocyte Subset Analysis by Flow Cytometry. *Cytometry Part B (Clinical Cytometry)*: 63B: 47-55.
380. Zeng, R., R. Spolski, S.E. Finkelstein, S. Oh, P.E. Kovanen, C.S. Hinrichs, C.A. Pise-Masison, M.F. Radonovich, J.N. Brady, N.P. Restifo, J.A. Berzofsky, and W.J. Leonard. 2005. Synergy of IL-21 and IL-15 in Regulating CD8⁺ T-Cell Expansion and Function. *J Exp Med* 201: 139-148.

381. De Groot, A.S., H. Sbai, W. Martin, J. Sidney, A. Sette, and J.A. Berzofsky. 2004. High-throughput informatics and in vitro assays for T-cell epitope determination: application to the design of epitope-driven vaccines. *In New Generation Vaccines, Third Edition, Revised and Expanded*. M.M. Levine, J.B. Kaper, R. Rappauoli, M.A. Liu, and M.F. Good, editors. Marcel Dekker, Inc., New York. 179-196.
382. Park, J.M., M. Terabe, Y. Sakai, J. Munasinghe, G. Forni, J.C. Morris, and J.A. Berzofsky. 2005. Early Role of CD4+ Th1 cells and antibodies in HER-2 adenovirus-vaccine protection against autochthonous mammary carcinomas. *J Immunol* 174: 4228-4236..
383. De Groot, A.S., and J.A. Berzofsky. 2004. From genome to vaccine--new immunoinformatics tools for vaccine design. *Methods* 34:425-428.
384. Carbone, D.P., I.F. Ciernik, M.J. Kelley, M.C. Smith, S. Nadaf, D. Kavanaugh, V.E. Maher, M. Stipanov, D. Contois, B.E. Johnson, C.D. Pendleton, B. Seifert, C. Carter, E.J. Read, J. Greenblatt, L.E. Top, M.I. Kelsey, J.D. Minna, and J.A. Berzofsky. 2005. Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. *J. Clin. Oncol.* 23: 5099-5107..
385. Bukreyev, A., I.M. Belyakov, G.A. Prince, K.C. Yim, K.K. Harris, J.A. Berzofsky, and P.L. Collins. 2005. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a non-functional cytotoxic T lymphocyte response following primary infection but not following challenge with wild-type virus. *J Virol.* 79: 9515-9526.
386. Dong, Y., J. Qian, R. Ibrahim, J.A. Berzofsky, and S. Khleif. 2005. CTLs alone elicited by peptide vaccine targeting mouse VEGFR2 inhibit angiogenesis and tumor growth. *J Immunother.* 29: 32-40.
387. Zhang, H., K.S. Chua, M. Guimond, V. Kapoor, M.V. Brown, T.A. Fleisher, L.M. Long, D. Bernstein, B.J. Hill, D.C. Douek, J.A. Berzofsky, C.S. Carter, E.J. Read, L.J. Helman, and C.L. Mackall. 2005. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4(+)CD25(+) regulatory T cells. *Nat Med.*, 11: 1238-1243.
388. van den Broeke, L.T., C.D. Pendleton, C. Mackall, L.J. Helman, and J.A. Berzofsky. 2006. Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. *Cancer Research* 66: 1818-1823.
389. Wang, Y.E., C. Zhang, J.A. Berzofsky and C. DeLisi. 2005. Selecting stable molecular targets for treatment and prevention of AIDS. *Genome Informatics* 16: 254-261.
390. Terabe, M., J. Swann, E. Ambrosino, P. Sinha, S. Takaku, Y. Hayakawa, D.I. Godfrey, S. Ostrand-Rosenberg, M.J. Smyth, and J.A. Berzofsky. 2005. A nonclassical non-V α 14J α 18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. *J Exp Med* 202:1627-1633.

391. Belyakov, I.M., V.A. Kuznetsov, B. Kelsall, D. Klinman, M. Moniuszko, M. Lemon, P.D. Markham, P. Pal, J.D. Clements, M.G. Lewis, S. Strober, G. Franchini, and J.A. Berzofsky. 2006. Impact of vaccine-induced mucosal high avidity CD8⁺ CTL in delay of AIDS-viral dissemination from mucosa. *Blood* 107: 3258-3264. (published on-line 2005)
392. Qian, J., Y. Dong, Y.Y. Pang, R. Ibrahim, J. Berzofsky, J.T. Schiller, and S.N. Khleif. 2006. Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice. *Internat. J. Cancer*, 118: 3022-3029.
393. Okazaki, T., C. D. Pendleton, P. Sarobe, E. K. Thomas, S. Iyengar, C. Harro, D. Schwartz and J. A. Berzofsky. 2006. Epitope-enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine. *J. Immunol.*, 176: 3753-3759.
394. Pal, R., D. Venzon, S. Santra, V.S. Kalyanaraman, D.C. Montefiori, L. Hocker, L. Hudacik, N. Rose, J. Nacsa, E.-S. Y., I.M. Belyakov, J.A. Berzofsky, R. Washington Parks, P. Markham, N.L. Letvin, J. Tartaglia, and G. Franchini. 2006. Systemic Immunization with an ALVAC-HIV-1/Protein Boost Vaccine Strategy Protects Rhesus Macaques from CD4⁺ T Cell Loss and Reduces Both Systemic and Mucosal SHIVKU2 RNA Levels. *Journal of Virology* 80: 3732-3742.
395. Terabe, M., C. Khanna, S. Bose, F. Melchionda, A. Mendoza, C.L. Mackall, L. Helman, and J.A. Berzofsky. 2006. CD1d-restricted NKT cells can down-regulate tumor immunosurveillance independent of IL-4R-STAT6 or TGF- β . *Cancer Research* 66: 3869-3875.
396. Kawakami, K., M. Terabe, M. Kawakami, J.A. Berzofsky, and R.K. Puri. 2006. Characterization of a novel human tumor antigen IL-13R α 2 chain. *Cancer Research* 66:4434-4442.
397. Kotelkin, A., I.M. Belyakov, L. Yang, J.A. Berzofsky, P.L. Collins, and A. Bukreyev. 2006. The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T cell response as a consequence of suppressing the type I interferon response. *J Virol* 80: 5958-5967.
398. Kawakami, K., M. Terabe, M. Kioi, J.A. Berzofsky, and R.K. Puri. 2006. Intratumoral Therapy with IL13-PE38 Results in Effective CTL-mediated Suppression of IL-13R alpha 2-Expressing Contralateral Tumors. *Clin Cancer Res* 12: 4678-4686
399. Belyakov, I.M., A. Dzutsev, Q. Zhu, D. Isakov, D. Klinman, and J.A. Berzofsky. 2006. Enhancement of CD8⁺ T cell immunity in the lung by CpG ODN increases protective efficacy of a Modified Vaccinia Ankara vaccine against lethal poxvirus infection even in CD4-deficient host. *J Immunol* 177: 6336-6343.
400. Okazaki, T., M. Terabe, A.T. Catanzaro, C.D. Pendleton, R. Yarchoan, and J.A. Berzofsky. 2006. Possible therapeutic vaccine strategy against HIV escape from RT inhibitor studied in HLA-A2 transgenic mice. *J Virol* 80: 10645-10651.

401. Oh, S., B. Stegman, C.D. Pendleton, M.O. Ota, C.H. Pan, D.E. Griffin, D.S. Burke, and J.A. Berzofsky. 2006. Protective immunity provided by HLA-A2 epitopes for fusion and hemagglutinin proteins of measles virus. *Virology* 352:390-399.
402. Pinto, L.A., P.E. Castle, R.B. Roden, C.D. Harro, D.R. Lowy, J.T. Schiller, D. Wallace, M. Williams, W. Kopp, I.H. Frazer, J.A. Berzofsky, and A. Hildesheim. 2005. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. *Vaccine* 23:3555-3564.
403. Berzofsky, J.A., S. Oh, and M. Terabe. 2005. Peptide vaccines against cancer. *Cancer Treat Res* 123:115-136.
404. Pinto, L.A., R. Viscidi, C.D. Harro, T.J. Kemp, A.J. Garcia-Pineros, M. Trivett, F. Demuth, D.R. Lowy, J.T. Schiller, J.A. Berzofsky, and A. Hildesheim. 2006. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. *Virology* 353:451-462.
405. Ota, M.O., Z. Ndhlovu, S. Oh, S. Piyasirisilp, J.A. Berzofsky, W.J. Moss, and D.E. Griffin. 2007. The hemagglutinin protein is a primary target of the measles virus-specific HLA-A2-restricted CD8⁺ T cell response during measles and after vaccination. *J Infect Dis* 195: 1799-1807.
406. Dzutsev, A. H., I. M. Belyakov, D. V. Isakov, D. H. Margulies, and J. A. Berzofsky. 2007. Avidity of CD8 T-cells sharpens immunodominance. *Internat Immunol*, 19: 497-507.
407. Belyakov, I.M., D.V. Isakov, Q. Zhu, A.H. Dzutsev, and J.A. Berzofsky. 2007. A Novel Functional CTL Avidity/Activity Compartmentalization to the Site of Mucosal Immunization Contributes to Protection of Macaques Against SHIV Viral Depletion of Mucosal CD4⁺ T cells. *J. Immunol.* 178: 7211-7221.
408. Toubaji, A., S. Hill, M. Terabe, J. Qian, T. Floyd, M. Simpson, J.A. Berzofsky, and S.N. Khleif. 2007. The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. *Vaccine* 25: 5882-2891.
409. Perera, P.L., J. Mosca, S. Oh, J.A. Berzofsky, and T.A. Waldmann. 2007. Development of smallpox vaccine candidates with integrated IL-15 that demonstrate superior immunogenicity, efficacy and safety in mice. *J. Virol.* 81: 8774-8783.
410. Ambrosino, E., M. Terabe, R.C. Halder, J. Peng, S. Takaku, S. Miyake, T. Yamamura, V. Kumar, and J.A. Berzofsky. 2007. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: A new immunoregulatory axis. *J Immunol* 179: 5126-5136.
411. Terabe, M., and J.A. Berzofsky. 2007. NKT cells in immunoregulation of tumor immunity: cross-regulation between two subsets. *Trends in Immunol* 28: 491-496.

412. Garcia-Pineres, A.J. A. Hildesheim, R. Herrero, M. Trivett, M. Williams, I. Atmetlla, M. Ramirez, M. Villegas, M. Schiffman, A. C. Rodriguez, R. D. Burk, M. Hildesheim, E. Freer, J. Bonilla, C. Bratti, J. A. Berzofsky, and L. A. Pinto. 2006. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. *Cancer Research* 66: 11070-11076.
413. Belyakov, I.M., S. Kozlowski, M. Mage, J.D. Ahlers, L.F. Boyd, D.H. Margulies, and J.A. Berzofsky. 2007. Role of $\alpha 3$ domain of class I MHC molecules in the activation of high and low avidity CD8⁺ cytotoxic T lymphocytes. *International Immunology* 19: 1413-1420.
414. Park, J.M., M. Terabe, D.A. Donaldson, G. Forni, and J.A. Berzofsky. 2008. Natural Immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. *Cancer Immunol. Immunother.* 57: 907-912.
415. Wyatt, L.S., I.M. Belyakov, P.L. Earl, J.A. Berzofsky, and B. Moss. 2008. Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA. *Virology* 372: 260-272.
416. Berzofsky, J.A., I.J. Berkower, and S.L. Epstein. 2008. Chapter 5: Antigen-antibody interactions and monoclonal antibodies. In *Fundamental Immunology 6th Edition*. W.E. Paul, editor. Lippincott Williams & Wilkins, Philadelphia. 152-191.
417. Berzofsky, J.A., and I.J. Berkower. 2008. Chapter 21: Immunogenicity and antigen structure. In *Fundamental Immunology 6th Edition*. W.E. Paul, editor. Lippincott Williams & Wilkins, Philadelphia. 631-683.
418. Dzutsev, A.K., I. M. Belyakov, D. V. Isakov, S. J. Gagnon, D. H. Margulies, and J. A. Berzofsky. 2008. Estimation of low frequency antigen presenting cells with a novel RELISPOT assay. *J. Immunol. Methods* 333: 71-78.
419. Park, J.M., M. Terabe, J. C. Steel, G. Forni, Y. Sakai, J. C. Morris, and Jay A. Berzofsky. 2008. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/*neu* vaccine. *Cancer Research* 68: 1979-1987.
420. Berzofsky, J.A., and M. Terabe. 2008. NKT cells in tumor immunity: Opposing subsets define a new immunoregulatory axis. *J. Immunol.* 180: 3627-3635.
421. Berzofsky, J.A., and M. Terabe. 2008. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. *Cancer Immunology & Immunotherapy* 57: 1679-1683.
422. Ambrosino, E., J.A. Berzofsky, and M. Terabe. 2008. Regulation of tumor immunity: the role of NKT cells. *Expert Opinion on Biological Therapy* 8: 725-734.
423. Mackall, C.L., E.H. Rhee, E.J. Read, H.M. Khuu, S.F. Leitman, D. Bernstein, M. Tesso, L. M. Long, D. Grindler, M. Merino, W. Kopp, M. Tsokos, J.A. Berzofsky, and L. J. Helman. 2008. A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric

- Sarcomas. *Clinical Cancer Research*, 14: 4850-4858.
424. Fichtner-Feigl, S., M. Terabe, A. Kitani, C. A. Young, I. Fuss, E. K. Geissler, H.-J. Schlitt, J. A. Berzofsky, and W. Strober. 2008. Restoration of Tumor Immune Surveillance via Targeting of IL-13 Receptor- α_2 . *Cancer Research*, 68: 3467-3476.
 425. Oh, S., L. P. Perera, M. Terabe, L. Ni, T. A. Waldmann, and J. A. Berzofsky. 2008. IL-15 as a mediator of CD4⁺ help for CD8⁺ T cell longevity and avoidance of TRAIL-mediated apoptosis. *Proc. Natl. Acad. Sci. USA* 105: 5201-5206.
 426. Terabe, M., Y. Tagaya, Q. Zhu, L. Granger, M. Roederer, T. A. Waldmann, and J. A. Berzofsky. 2008. IL-15 expands unconventional CD8 $\alpha\alpha$ NK1.1⁺ T cells but not V α 14J α 18⁺NKT cells. *J. Immunol.* 180: 7276-7286.
 427. Nam, J-S., M. Terabe, M. Mamura, M.-J. Kang, H. Chae, C. Stuelten, E. Kohn, B. Tang, H. Sabzevari, M. R. Anver, S. Lawrence, D. Danielpour, S. Lonning, J. A. Berzofsky, and L. M. Wakefield. 2008. An anti-Transforming Growth Factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. *Cancer Research* 68: 3835-3843.
 428. Nam, J.-S. M. Terabe, M.-J. Kang, H. Chae, N. Voong, Y.-a. Yang, A. Laurence, A. Michalowska, M. Mamura, S. Lonning, J. A. Berzofsky, and L. M. Wakefield. 2008. Transforming Growth Factor β subverts the immune system into directly promoting tumor growth through interleukin 17. *Cancer Research*, 68:3915-3923.
 429. Wu, Z., H.-H. Xue, J. Bernard, R. Zeng, D. Issakov, J. Bollenbacher-Reilley, I. M. Belyakov, S. Oh, J. A. Berzofsky and W. J. Leonard. 2008. The IL-15 receptor α chain cytoplasmic domain is critical for normal IL-15R α function but is not required for trans-presentation. *Blood*, 112: 4411-4419.
 430. Belyakov, I. M., J. D. Ahlers, G. J. Nabel, B. Moss, and J. A. Berzofsky. 2008. Generation of functionally active HIV-1 specific CD8⁺ CTL in intestinal mucosa following mucosal, systemic, or mixed prime-boost immunization. *Virology* 381: 106-115.
 431. Epel, M., I. Carmi, S. Soueid-Baumgarten, SK. Oh, T. Bera, I. Pastan, J. Berzofsky, and Y. Reiter. 2008. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. *Eur J Immunol.* 38:1706-1720.
 432. Terabe, M. and J. A. Berzofsky. 2008. The role of NKT cells in tumor immunity. *Advances in Cancer Research* 101: 277-348.
 433. Hall, J.A., N. Bouladoux, C.M. Sun, E.A. Wohlfert, R.B. Blank, Q. Zhu, M.E. Grigg, J.A. Berzofsky, and Y. Belkaid. 2008. Commensal DNA Limits Regulatory T Cell Conversion and Is a Natural Adjuvant of Intestinal Immune Responses. *Immunity* 29: 637-649.

434. Zhu, Q., C. Egelston, A. Vivekanandhan, S. Uematsu, S. Akira, D. M. Klinman, I. M. Belyakov, and J. A. Berzofsky. 2008. Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. *Proc. Natl. Acad. Sci. USA*, 105: 16260-16265.
435. Berzofsky, J.A., and M. Terabe. 2009. The contrasting roles of NKT cells in tumor immunity. *Current Molecular Medicine* 9: 667-672.
436. Terabe, M., & J. A. Berzofsky. NKT cells and cancer: two subsets form a new immunoregulatory axis. *American Association of Cancer Research Educational Book* 2009.
437. Isakov, D., A. Dzutsev, I. M. Belyakov, and J. A. Berzofsky. 2009. Non-equilibrium and differential function between Intraepithelial and Lamina Propria TCR $\alpha\beta^+$ CD8 $\alpha\beta^+$ T Cells In The Small Intestinal Mucosa. *Mucosal Immunology*, 2: 450-461.
438. Oakley, M.S., V. Majam, B. Mahajan, N. Gerald, V. Anantharaman, J. M. Ward, L. J. Faucette, T. F. McCutchan, H. Zheng, M. Terabe, J. A. Berzofsky, L. Aravind, S. Kumar. 2009. Pathogenic roles of CD14, galectin 3, and Ox40 during experimental cerebral malaria in mice. *PLoS ONE*, 4: e6793.
439. Terabe, M., A. Ambrosino, S. Takaku, D. Venzon, S. Lonning, J. M. McPherson, and Jay A. Berzofsky. Synergistic enhancement of CD8 $^+$ T cell-mediated tumor vaccine efficacy by an anti-TGF- β monoclonal antibody. 2009. *Clinical Cancer Research* 15: 6560-6569.
440. Zhu, Q., C. Egelston, S. Gagnon, Y. Sui, I. M. Belyakov, D. M. Klinman, and J. A. Berzofsky. Using three TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. 2010. *J. Clin. Invest.* 120: 607-616.
441. Takaku, S., M. Terabe, E. Ambrosino, J. Peng, S. Lonning, J. M. McPherson, and J. A. Berzofsky. Blockade of TGF- β enhances tumor vaccine efficacy mediated by CD8 $^+$ T cells. 2010. *Internat. J. Cancer* 126: 1666-1674.
442. Sui, Y., Q. Zhu, S. Gagnon, A. Dzutsev, M. Terabe, M. Vaccari, D. Venzon, D. Klinman, W. Strober, B. Kelsall, G. Franchini, I. M. Belyakov, and J. A. Berzofsky. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. 2010. *Proc. Natl. Acad. Sci. USA*, 107: 9843-9848. (published on line, May, 2010).
443. Rahma, O. E., E. Ashtar, R. Ibrahim, A. Toubaji, B. Gause, V. E. Herrin, W.M. Linehan, S. M. Steinberg, F. Grollman, G. Grimes, S. A. Bernstein, J. A. Berzofsky and S. N. Khleif. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. 2010. *J. Translat. Med.*, 8:8-16.
444. O'Konek, J.J., M. Terabe, and J. A. Berzofsky. The role of NKT cells in the immune regulation of neoplastic disease. In: Rongfu Wang, Editor. *Innate and adaptive immune*

regulation and cancer immunotherapy. Springer, NY. In press. 2010.

445. De Groot, A.S., T. Cohen, M. Ardito, L. Moise, B. Martin, and J. A. Berzofsky. Use of bioinformatics to predict MHC ligands and T-cell epitopes: application to epitope-driven vaccine design. 2010. *Methods in Microbiology* 37: 35-66.
446. O'Konek, J., P. Illarionov, D. Stewart Khursigara, E. Ambrosino, L. Izhak, B. F. Castillo II, R. Raju, M. Khalili, H.-Y. Kim, A. R. Howell, G. S. Besra, S. A. Porcelli, J. A. Berzofsky and M. Terabe. 2011. Novel agonist of mouse and human iNKT cells reveals a new mechanism of tumor immunity. *J. Clin. Invest.* 121: 683-694.
447. Sui, Y. and J. A. Berzofsky. 2011. Vaccine strategies to prevent mucosal transmission of HIV-1. In *Novel Approaches to Vaccine Research*, 2011, Kathleen L. Hefferon, editor. ISBN: 978-81-308-0449-1. Research Signpost, Kerala. 137-180.
448. Lai, D., J. Zhu, T. Wang, J. Hu-Li, M. Terabe, J. A. Berzofsky, C. Clayberger, and A. M. Krensky. 2011. KLF13 sustains thymic memory-like CD8⁺ T cells in BALB/c mice by regulating IL-4-generating invariant natural killer T cells. *J. Exp. Med.* 208: 1093-1103. (online April, 2011)
449. O'Konek, J., J. A. Berzofsky, and M. Terabe. 2012. Immune regulation of tumor immunity by NKT cells. In Masaki Terabe and Jay A. Berzofsky, Editors. *Natural Killer T cells: Setting the Balance in the Regulation of Tumor Immunity*. Springer, NY. Pp 55-70.
450. Yu, H., A. Tawab-Amiri, A. Dzutsev, M. Sabatino, K. Aleman, R. Yarchoan, M. Terabe, Y. Sui, and J. A. Berzofsky. 2011. IL-15 *ex vivo* overcomes CD4⁺ T cell deficiency for the induction of human antigen-specific CD8⁺ T cell responses. *J. Leuk. Biol.* 90: 205-214. (online April, 2011).
451. Rahma O.E., E. Achta, M. Czystowska, M. E. Szajnik, E. Wieckowski, S. Bernstein¹, V. E. Herrin, M. A. Shams, S. M. Steinberg, M. Merino, W. Gooding, C. Visus, A. B. DeLeo, J. K. Wolf, J. G. Bell, J. A. Berzofsky, T. L. Whiteside, and S. N. Khleif. 2012. A Gynecologic Oncology Group phase II trial comparing p53 peptide subcutaneous injection and intravenous pulsed dendritic cells in high-risk ovarian cancer patients. *Cancer Immunology Immunotherapy* 61: 373-384.
452. Nakashima, H., M. Terabe, J. A. Berzofsky, S. R. Husain¹, and R. K. Puri. 2011. A Novel combination immunotherapy for cancer by IL-13 receptor alpha2 targeted DNA vaccine and immunotoxin in murine tumor models. *J. Immunol.* 187: 4935-4946.
453. Isakov, D., A. Dzutsev, J. A. Berzofsky, and I. M. Belyakov. 2011. Lack of IL-7 and IL-15 signaling affects interferon-gamma production by, more than survival of, small intestinal intraepithelial memory CD8⁺ T cells. *Eur. J. Immunol.* 41: 3513-3528.
454. Terabe, M., and J. A. Berzofsky (editors). *Natural Killer T cells: Balancing the regulation of tumor immunity*. 2012. Springer, New York. ISBN 978-1-4614-0612-9.

455. Sui, Y., S. Gagnon, A. Dzutsev, Q. Zhu, H. Yu, A. Hogg, Y. Wang, Z. Xia, I. M. Belyakov, D. Venzon, D. Klinman, W. Strober, B. Kelsall, G. Franchini, and J. A. Berzofsky. 2011. TLR agonists and/or IL-15 adjuvanted mucosal SIV-vaccine reduced gut CD4⁺ memory T cell loss in SIVmac251-challenged rhesus macaques. *Vaccine* 30: 59-68.
456. Berzofsky, J. A. 2011. A push-pull vaccine strategy using Toll-like receptor ligands, IL-15, and blockade of negative regulation to improve the quality and quantity of T cell immune responses. *Vaccine*, doi: 10.1016/j.vaccine.2011.11.034.
457. Berzofsky, J. A., M. Terabe, and L. V. Wood. 2011. Strategies to use immune modulators in therapeutic vaccines against cancer. *Seminars in Oncology* 39: 348-357.
458. Berzofsky, J. A., and I. J. Berkower. 2012. Antigen-antibody interactions and monoclonal antibodies. In *Fundamental Immunology* 7th edition. W.E. Paul, editor. Lippincott Williams & Wilkins, Philadelphia. In press.
459. Berzofsky, J. A., and I. J. Berkower. 2012. Immunogenicity and antigen structure. In *Fundamental Immunology* 7th edition. W.E. Paul, editor. Lippincott Williams & Wilkins, Philadelphia. In press.
460. Zhu, Q., J. Talton, G. Zhang, T. Cunningham, Z. Wang, R. C. Waters, J. Kirk, B. Eppler, D. M. Klinman, I. M. Belyakov, Y. Sui, S. Gagnon, R. J. Mumper, and J. A. Berzofsky. 2012. Large intestine-targeted nanoparticle-releasing oral vaccine to control genitorectal viral infection. *Nature Medicine* 18: 1291-1296.
461. Berzofsky, J. A. 2012. Improving immunotherapy: Revisiting the immunologist's little secret. *Science Translational Medicine*, 4 (120): 1-3.
462. Sui, Y.*, S. Gordon*, G. Franchini**, and J. A. Berzofsky**. 2013. Non-human primate models for HIV/AIDS vaccine development. *Current Protocols in Immunology*, 12.14.1-12.14.30. (*; **, Contributed equally).
463. Izhak, L., E. Ambrosino, S. Kato, S. T. Parish, J. J. O'Konek, H. Weber, Z. Xia, D. Venzon, J. A. Berzofsky, and M. Terabe. 2013. Delicate balance among three types of T cells in concurrent regulation of tumor immunity. *Cancer Research* 73: 1514-1523.
464. Ben-Sasson, S. Z., A. Hogg, J. Hu-Li, P. Wingfield, X. Chen, M. Crank, S. Caucheteux, M. Ratner-Hurevich, J. A. Berzofsky, R. Nir-Paz, and W. E. Paul. 2013. IL-1 enhances expansion, effector function, tissue localization and memory response of antigen-specific CD8 T cells. *J. Exp. Med.* 210: 491-502.
465. Zhu, Q, and J. A. Berzofsky. 2013. Oral vaccines: directed safe passage to the front line of defense. *Gut Microbes* 4: 1-7.
466. Izhak, L., J. A. Berzofsky, and M. Terabe. 2013. Balance is a key for happiness. *Oncoimmunology*, e24211.

467. Huang, Y.-H., M. Terabe, C. D. Pendleton, D. Stewart Khursigara, T. Bera, I. Pastan, and J. A. Berzofsky. 2013. Identification and enhancement of HLA-A2.1-restricted CTL epitopes in a new human cancer antigen-POTE. *PLOS ONE* 8 (6): e64365.
468. O'Konek, J. J., S. Kato¹, S. Takao, Liat Izhak, Z. Xia, P. Illarionov, G. S. Besra, M. Terabe and J. A. Berzofsky. 2013. β -mannosylceramide activates type I natural killer T cells to induce tumor immunity without inducing long-term functional anergy. *Clinical Cancer Research*, 19: 4404-4411.
469. Berzofsky, J.A., L. V. Wood, and M. Terabe. 2013. Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer. *Expert Review of Vaccines*, 12: 1115-1118.
470. Vargas-Inchaustegui, D.A., P. Xiao, A. E. Hogg, T. Demberg, K. McKinnon, D. Venzon, E. Brocca-Cofano, J. DiPasquale, E. M. Lee, L. Hudacik, R. Pal, Y. Sui, J. A. Berzofsky, L. Liu, S. Langermann, and M. Robert-Guroff. 2013. Immune Targeting of PD-1^{hi} Expressing Cells During and After Antiretroviral Therapy in SIV-infected Rhesus Macaques. *Virology*, 447: 274-284.
471. Terabe, M., and J. A. Berzofsky. 2014. The immunoregulatory role of type I and type II NKT cells in cancer and other diseases. *Cancer Immunology, Immunotherapy*, 63: 199-213.
472. Morris, J. C., A. R. Tan, T. E. Olencki, G. I. Shapiro, B. J. Dezube, M. Reiss, F. J. Hsu, J. A. Berzofsky, and D. P. Lawrence. 2014. Phase I Study of GC1008 (Fresolimumab): A Human Anti-transforming Growth Factor-beta (TGF β) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma. *PLoS One*, Mar 11;9(3):e90353. doi: 10.1371/journal.pone.0090353.
473. Berzofsky, J. A., and G. Franchini. 2015. Human/simian immunodeficiency virus transmission and infection at mucosal sites. In *Mucosal Immunology*, 4th Edition, Mestecky, J., W. Strober, M. W. Russell, B. L. Kelsall, H. Cheroutre, and B.N. Lambrecht, editors. Elsevier, Amsterdam, 1481-1492.
474. Sui, Y., A. Hogg, Y. Wang, B. Frey, H. Yu, Z. Xia, D. Venzon, K. McKinnon, J. Smedley, M. Gathuka, D. Klinman, B. F. Keele, S. Langermann, L. Liu, G. Franchini, and J. A. Berzofsky. 2014. Mucosal adjuvants and myeloid cells modulate viral load reduction in SIVmac251 infection of macaques. *J. Clin. Invest.* 124: 2538-2549. (published on line May 2014 doi:10.1172/JCI73518).
475. Chen, Z., L. Ozbun, N. Chong, A. Wallecha, J. A. Berzofsky, and S. N. Khleif. 2014. Episomal expression of truncated listeriolysin O in LmddA-LLO-E7 vaccine enhances antitumor efficacy by preferentially inducing expansion of CD4⁺Foxp3⁻ and CD8⁺ T cells. *Cancer Immunology Research* 2: 911-922.
476. Vargas-Inchaustegui, D., I. Tuero, V. Mohanram, T. Musich, P. Pegu, A. Valentin, Y. Sui, M. Rosati, J. Beal, D. J. Venzon, V. Kulkarni, C. Alicea, G. R. Pilkington, N. P. M. Liyanage, T. Demberg, S. N. Gordon, Y. Wang, A. E. Hogg, B. Frey, L. J. Patterson, J.

- DiPasquale, D. Montefiori, N. Sardesai, S. G. Reed, J. A. Berzofsky, G. Franchini, B. K. Felber, G. N. Pavlakis, and M. Robert-Guroff. 2014. Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggest novel combinatorial approaches for enhancing responses. *Clinical Immunology* 153: 308-322.
477. Abu-Eid, R., R. N. Samara, L. Ozbun, K. M. Friedman, J. A. Berzofsky, M. Mkrtychyan, and S. N. Khleif. 2014. Selective inhibition of regulatory T cells by targeting PI3K-Akt pathway. *Cancer Immunology Research* 2: 1080-1089. Doi: 10.1158/2326-6066.CIR-14-0095.
478. Valentin, A., K. McKinnon, J. Li, M. Rosati, V. Kulkarni, G. R Pilkington, J. Bear, C. Alicea, D. A Vargas-Inchaustegui, L. J. Patterson, P. Pegu, N. P.M. Liyanage, S. N Gordon, M. Vaccari, Y. Wang, A. E Hogg, B. Frey, Y. Sui, S. G Reed, N. Y. Sardesai, J. A. Berzofsky, G. Franchini, M. Robert-Guroff, B. K Felber, and G. N. Pavlakis. 2014. Comparative Analysis of SIV-specific Cellular Immune Responses Induced by Different Vaccine Platforms in Rhesus Macaques. *Clinical Immunology* 155: 91-107. Doi: 10.1016/j.clim.2014.09.005.
479. Soto-Pantoja, D. R., M. Terabe, A. Ghosh, L. A. Ridnour, W. G. DeGraff, D. A. Wink, J. A. Berzofsky, and D. D. Roberts. 2014. CD47 in the tumor microenvironment limits cooperation between anti-tumor T cell immunity and radiation therapy. *Cancer Research* 74: 6771-6783. Doi: 10.1158/0008-5472.CAN-14-0037-T.
480. Robertson, F. C., J. A. Berzofsky, and M. Terabe. 2014. NKT cell networks in the regulation of tumor immunity. *Frontiers in Immunology* 5: 553 article 543. Doi: 10.3389/fimmu.2014.00543.
481. Lacouture, M. E., J. C. Morris, D. P. Lawrence, A. R. Tan, T. E. Olencki, G. I. Shapiro, B. J. Dezube, J. A. Berzofsky, F. J. Hsu, and J. Guitart. 2015. Cutaneous lesions associated with neutralization of TGF β by the monoclonal antibody GC1008. *Cancer Immunology, Immunotherapy*, 64: 437-446. DOI 10.1007/s00262-015-1653-0 (Jan, 2015).
482. Wang, Y. Y. Sui, S. Kato, A. E. Hogg, J. C. Steel, J. C. Morris and J. A. Berzofsky. 2015. Vaginal type-II mucosa is an inductive site for primary CD8⁺ T cell mucosal immunity. *Nature Communications* 6:6100; DOI: 10.1038/ncomms7100. Pub online Jan 20, 2015.
483. Kapanadze, T., J. Medina-Echeverz, J. Gamrekelashvili, J. M. Weiss, R. H. Wilttrout, V. Kapoor, N. Hawk, M. Terabe, J. A. Berzofsky, M. P. Manns, E. Wang, F. M. Marincola, F. Korangy, T. F. Greten. 2015. Tumor induced CD11b⁺ Gr-1⁺ myeloid derived suppressor cells exacerbate immune mediated hepatitis in mice in a CD40-dependent manner. *Eur. J. Immunol.*, 45: 1148-1158.
484. Jing, W., Y. Shirota, D. Bayik, H. Shirota, D. Tross, J. L. Gulley, L. Wood, J. A. Berzofsky, and D. Klinman. 2015. Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells. *J. Immunol.*, 194: 4215-4221.

485. Rahma, O.E., V. E. Herrin, R. A. Ibrahim, A. Toubaji, S. Bernstein, O. Dakheel, S. M. Steinberg, R. Eid, M. Mkrtychyan, J. A. Berzofsky and S. N. Khleif. 2014. Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer. *J. Translational Med.* 12: 353-362.
486. Berzofsky, J.A., L. V. Wood, and M. Terabe. 2015. Strategies for improving vaccines to elicit T cells to treat cancer. In: *Developments in T cell based cancer immunotherapies*. E. Wang, P. Ascierto, and D. Stroncek, editors. Springer, New York. Chapter 2, 29-52.
487. Terabe, M., and J.A. Berzofsky. 2015. NKT cells in tumor immunity. In: *Encyclopedia of Immunobiology*. M. Ratcliffe, editor. Elsevier. In press.
488. Solaymani-Mohammadi, S., O.Lakhdari, I. Minev, S. Shenouda, B. F. Frey, R. Billeskov, S. M. Singer, J. A. Berzofsky, L. Eckmann, and M. F. Kagnoff. 2016. Lack of the programmed death-1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules. *J. Leukocyte Biol.* 99: 475-482.
489. Sui, Y., E. M. Lee, Y. Wang, A. Hogg, B. Frey, D. Venzon, R. Pal, and J. A. Berzofsky. 2016. Early SIV dissemination after intra-rectal SIVmac251 challenge was associated with proliferating virus-susceptible cells in the colorectum. *J. AIDS* 71: 353-358.
490. Yu, H., Y. Sui, Y. Wang, N. Sato, B. Frey, Z. Xia, T. A Waldmann, and J. A Berzofsky. 2015. Interleukin-15 constrains mucosal T helper 17 cell generation: influence of mononuclear phagocytes. *PLoS One* 10: e0143001. DOI:10.1371/journal.pone.0143001.
491. Parchment, R. E., A. R. Voth, J. H. Doroshov, and J. A. Berzofsky. 2016. Immunopharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. *Seminars in Oncology* 43: 501-513.
492. Zdanov, S. M. Mandapathil, R. Abu Eid, S. Adamson-Fadeyi, W. Wilson, J. Qian, A. Carnie, N Tarasova, M. Mkrtychyan, J. A. Berzofsky, T. L. Whiteside, and S. N. Khleif. 2016. Mutant KRAS conversion of conventional T cells into regulatory T cells. *Cancer Immunology Research* 4: 354-365.
493. Wood, L. V., T. Fojo, B. D. Roberson, M. S. B. Hughes, W. Dahut, J. L. Gulley, R. A. Madan, P. M. Arlen, M. Sabatino, D. F. Stroncek, L. Castiello, J. B. Trepel, M.-J. Lee, H. L. Parnes, S. M. Steinberg, M. Terabe, J. Wilkerson, I. Pastan, and J. A. Berzofsky. 2016. TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with stage D0 prostate cancer. *OncImmunity*, DOI: 10.1080/2162402X.2016.1197459.
494. Castiello, L., M. Sabatino, J. Ren, M. Terabe, H. Khuu, L.V. Wood, J.A. Berzofsky, and D.F. Stroncek. 2017. Expression of CD14, IL-10 and tolerogenic signature in dendritic cells inversely correlate with response to TARP vaccination in prostate cancer patients.

Clinical Cancer Research, 23: 3352-3364.

495. Gulley, J. L., J. A. Berzofsky, M. O. Butler, A. Cesano, B. A. Fox, S. Gnjatic, S. Janetzki, S. Kalavar, V. Karanikas, S. N. Khleif, I. Kirsch, P. P. Lee, C. Maccalli, H. Maecker, J. Schlom, B. Seliger, J. Siebert, D. F. Stroncek, M. Thurin, J. Yuan, and L. H. Butterfield. 2017. Immunotherapy Biomarkers 2016: Overcoming the Barriers. *Journal for ImmunoTherapy of Cancer*, 5:29.
496. Billeskov, R., Y. Wang, S. Solaymani-Mohammadi, B. Frey, S. Kulkarni, P. Andersen, E. M. Agger, Y. Sui, and J. A. Berzofsky. 2017. Low antigen dose in adjuvant-based vaccination selectively induces CD4 T cells with enhanced functional avidity and protective efficacy. *J. Immunol.*, 198: 3494-3506.
497. Terabe, M., Clark, K., Robertson, F.C., De Ravin, E., Bloom, A., Venzon, D., Kato, S., Mirza, A.M., Berzofsky, J.A. 2017. Blockade of only TGF-beta 1 & 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy. *OncImmunity*, 6:5, e1308616, DOI: 10.1080/2162402X.2017.1308616.
498. Morales-Kastresana, A., Telford, W., Musich, T., McKinnon, K., Clayborne, C., Braig, Z., Rosner, A., Demberg, T., Watson, D., Karpova, T.S., Freeman, G.J., DeKruyff, R.H., Pavlakakis, G., Terabe, M., Robert-Guroff, M., Berzofsky, J.A., Jones, J. 2017. Labeling extracellular vesicles for nanoscale flow cytometry. *Scientific Reports*, 7: 1878 | DOI:10.1038/s41598-017-01731-2.
499. Sui, Y., B. Frey, Y. Wang, R. Billeskov, S. Kulkarni, K. McKinnon, T. Rourke, L. Fritts, C. J. Miller, J. A. Berzofsky. 2017. Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques. *PLoS Pathogens*, 13(5): e1006395.
500. Leshem, Y., Liu, X., Bera, T., Terabe, M., Berzofsky, J.A., Bossenmaier, B., Niederfellner, G., O'Brien, J., Tai, C., Reiter, Y., Pastan, I. 2017. Combining local immunotoxins targeting mesothelin with CTLA-4 blockade synergistically eradicates murine cancer by promoting anti-cancer immunity. *Cancer Immunol Research*, 5: 685-694.
501. Hogg, A., Y. Sui, S. Z. Ben-Sasson, W. E. Paul, and J. A. Berzofsky. 2017. Role of CD4 T cell helper subsets in immune response and deviation of CD8 T cells in mice. *Eur J Immunol*. 47: 2059-2069.
502. Dzutsev, A., Hogg, A., Y. Sui, S. Solaymani-Mohammadi, H. Yu, B. Frey, Y. Wang, and J. A. Berzofsky. 2017. Differential T cell homing to colon vs small intestine is imprinted by local CD11c⁺ antigen presenting cells that determine homing receptors. *J. Leuk. Biol.* 102: 1381-1388. (doi:10.1189/jlb.1A1116-463RR).
503. Speir, M., A. Authier-Hall, C. R. Brooks, K. J. Farrand, B. J. Compton, R. J. Anderson, A. Heiser, T. L. Osmond, C. W. Tang, J. A. Berzofsky, M. Terabe, G. F. Painter, I. F. Hermans, and R. Weinkove. 2017. Glycolipid-peptide conjugate vaccines enhance CD8⁺ T cell responses against human viral proteins. *Scientific Reports* 7:14273.

504. Berzofsky, J. A., M. Terabe, J. B. Trepel, I. Pastan, D. F. Stroncek, J. C. Morris, and L. W. Wood. 2017. Cancer vaccine strategies: translation from mice to human clinical trials. *Cancer Immunology, Immunotherapy*, DOI 10.1007/s00262-017-2084-x.
505. Frey, B., J. Jiang, Y. Sui, L. F. Boyd, B. Yu, G. Tatsuno, R. Billeskov, S. Solaymani-Mohammadi, P. W. Berman, D. H. Margulies, and J. A. Berzofsky. 2018. Effects of cross-presentation, antigen processing, and peptide binding in HIV evasion of T cell immunity. *J. Immunol.* 200: 1853-1864.
506. Kato, S., J. A. Berzofsky, and M. Terabe. 2018. Possible therapeutic application of targeting type II NKT cell-mediated suppression of tumor immunity. *Frontiers in Immunology*, 9: article 314.
507. O'Konek, J. J., E. Ambrosino, A. C. Bloom, L. Pasquet, C. Massilamany, Z. Xia, M. Terabe, and J. A. Berzofsky. 2018. Differential regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin. *OncImmunity*, e1439305 published on line April 9, 2018.
508. Maeng, H., M. Terabe, and J. A. Berzofsky. 2018. Cancer vaccines: Translation from mice to human clinical trials. *Current Opinion in Immunology* 51:111-122.
509. Jin, P., W. Chen, J. Ren, S. Chen, L. Wood, Y. Zhao, A. Remaley, C. Pham, S. Lian, S. Liu, H. Liu, S. Highfill, J. A. Berzofsky and D. Stroncek. 2018. Plasma from some cancer patients inhibits adenoviral Ad5f35 vector transduction of dendritic cells. *Cytotherapy*, 20: 728-739.
510. Ma, C., M. Han, B. Heinrich, Q. Fu, Q. Zhang, M. Sandhu, D. Agdashian, F. Korangy, M. Terabe, J. A. Berzofsky, V. Fako, T. Ritz, T. Longerich, C. M. Theriot, J. A. McCulloch, S. Roy, W. Yuan, V. Thovarai, S. K. Sen, M. Ruchirawat, X. Wei Wang, G. Trinchieri, and T. F. Greten. 2018. Gut microbiome-controlled bile acid metabolism regulates liver cancer via NKT cells. *Science*, 360: 876.
511. Paquin-Proulx, D., B. C. Greenspun, L. Pasquet, B. Strunz, S. Aleman, K. Falconer, M. Terabe, J. A. Berzofsky, J. K. Sandberg, E. Melum, D. F. Nixon, and N. K. Björkstom. 2018. IL13R α 2 identifies tissue-resident IL-22 producing PLZF⁺ innate T cells in the human liver. *Eur. J. Immunol.*, 48: 1329-1335.
512. Sui, Y., A. Dzutsev, D. Venzon, B. Frey, V. Thovarai, G. Trinchieri, and J. A. Berzofsky. 2018. Influence of gut microbiome on mucosal immune activation and SHIV viral transmission in naïve macaques. *Mucosal Immunology*, 11: 1219-1229.
513. Welsh, J. A., J. Kepley, A. Rosner, P. Horak, J. A. Berzofsky, and J. C. Jones. 2018. Prospective use of high-refractive index materials for single molecule detection in flow cytometry. *Sensors*, 18(8). pii: E2461. doi: 10.3390/s18082461.

514. Terabe, M., and J. A. Berzofsky. 2018. Tissue-specific roles of NKT cells in tumor immunity. *Frontiers in Immunology*, 9:1838. doi: 10.3389/fimmu.2018.01838.
515. Billeskov, R., B. Beikzadeh, and J. A. Berzofsky. 2018. The effect of antigen dose on T cell-targeting vaccine outcome. *Human Vaccines & Immunotherapeutics*, DOI: 10.1080/21645515.2018.1527496.
516. Sui, Y., G. Lewis, Y. Wang, K. Berckmueller, B. Frey, A. Dzutsev, D. Vargas-Inchaustegui, V. Mohanram, T. Musich, S. Shen, A. DeVico, T. Fouts, D. Venzon, J. Kirk, C. Waters, J. Talton, J. Clements, G. D. Tomaras, G. Franchini, M. Robert-Guroff, G. Trinchieri, R. C. Gallo, and J. A. Berzofsky. 2019. Mucosal vaccine efficacy against intrarectal SHIV acquisition in the absence of anti-Env antibody. *J. Clin. Invest.*, 129:1314-1328, Published on line Feb 2019, doi.org/10.1172/JCI122110.
517. Morales-Kastresana, A., T. A. Musich, J. A. Welsh, W. Telford, T. Demberg, J. C. S. Wood, E. J. Felton, M. Bigos, C. D. Ross, A. Kachynski, A. Dean, J. Van Dyke, J. Tigges, V. Toxavidis, D. R. Parks, W. R. Overton, A. H. Kesarwala, G. J. Freeman, A. Rosner, S. P. Perfetto, L. Pasquet, M. Terabe, K. McKinnon, V. Kapoor, J. B. Trepel, A. Puri, H. Kobayashi, B. Yung, X. Chen, P. Guion, P. Choyke, S. J. Knox, I. Ghiran, M. Robert-Guroff, J. A. Berzofsky, J. C. Jones. 2019. High-fidelity detection and sorting of nanoscale vesicles in viral disease and cancer. *J. Extracellular Vesicles*, 8: 1, 1597603. DOI: 10.1080/20013078.2019.1597603. Published on line 19 June, 2019.
518. Solaymani-Mohammadi, S., and J. A. Berzofsky. 2019. IL-21 collaborates with interferon- γ for the optimal expression of interferon-stimulated genes and enhances protection against enteric microbial infection. *PLoS Pathogens*, 15: e1007614. <https://doi.org/10.1371/journal.ppat.1007614>.
519. Maeng, H., and J. A. Berzofsky. 2019. Strategies for developing and optimizing cancer vaccines. *F1000Research* 2019 (F1000 Faculty Review), published May 13, 2019. 654(<https://doi.org/10.12688/f1000research.18693.1>)
520. Vaccari, M., S. Fourati, D.R. Brown, I. Silva de Castro, M. Bissa, L. Schifanella, M. N. Doster, K. E. Foulds, M. Roederer, R. A. Koup, Y. Sui, J. A. Berzofsky, R.-P. Sekaly, and G. Franchini. 2019. Myeloid cell crosstalk regulates the efficacy of the DNA/ALVAC/gp120 HIV vaccine candidate. *Frontiers in Immunology*, 10:1072. doi: 10.3389/fimmu.2019.01072. eCollection 2019.
521. Bloom, A. C., L. Bender, S. Tiwary, L. Pasquet, K. Clark, T. Jiang, Z. Xia, A. Morales-Kastresana, J. C. Jones, I. Walters, M. Terabe, and J. A. Berzofsky. 2019. Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. *OncImmunity*, in press.

Manuscripts submitted:

1. Dzutsev, A., L. Koo, A. Hogg, R. Goldszmid, J. Kabat, Y. Sui, S. Gagnon, I. M. Belyakov, O. Schwartz, G. Trinchieri and J. A. Berzofsky. CD103⁺ migratory dendritic cells scout the colon luminal space, take up bacteria and transport them to colonic lymphoid patches.
2. Patterson, L. J., K. McKinnon, S. Parish, D. Venzon, I. Tuero, D. Vargas-Inchaustegui, L. Hudacik, R. Pal, J. A. Berzofsky, M. Robert-Guroff and M. Terabe. Expanded functional NKT cells and B cells in the bone marrow are associated with control of SIV infection in the rhesus macaque model of AIDS.
3. Clark, K., A. Bloom, D. J. Venzon, M. Suzuki, L. Pasquet, B. Compton, S. L. Cardell, S. A. Porcellini, G. Painter, J. A. Berzofsky, and M. Terabe. Characterizing β -mannosylceramide presentation by CD1d as an iNKT cell agonist.
4. Kato, S., L. Pasquet, Y. Mikami, H. Liu, T. Adams, H. Yang, D. J. Venzon, J. O'Shea, S. O. Sharrow, T. Davies-Hill, Z. Xia, D. Kovalovsky, M. Lee, M. Suzuki, E. S. Jaffe, M. Terabe, and J. A. Berzofsky. Characterizing the elusive lung sulfatide-reactive type II NKT cells.
5. Tiwary, S., J. A. Berzofsky, and M. Terabe. Altered lipid tumor environment and its potential effects on NKT cell function in tumor immunity.
6. Berzofsky, J. A., P. B. Olkhanud, and M. Terabe. Complementary approaches to study NKT cells in cancer.

Patent Applications Filed, Patents Issued & Technology Transfer

Patents & Patent Applications

1. Berzofsky, J. A., and Kawamura, H. A method of producing improved immune response. Filed August 7, 1985. Application No. 06/763,218. CIP 07/338,362. Patent 5,283,323 issued February 1, 1994.
2. Berzofsky, J. A., DeLisi, C., Margalit, H., Cornette, J. L., Cease, K. B., and Spouge, J. L. Method to predict antigenic sites recognized by T lymphocytes such as for design of vaccines. Filed December 31, 1986. Application No. 06/948,255. CIP 07/005,885.
3. Berzofsky, J. A., Ouyang, C. S., DeLisi, C., Margalit, H., Cornette, J. L., and Cease, K. B. Synthetic peptides which induce cellular immunity to the AIDS virus and AIDS viral proteins. Filed December 30, 1986. Application No. 06/947,935. CIP 07/492,318. Patent 5,081,226 issued January 14, 1992.
4. Good, M. F., Berzofsky, J. A., and Miller, L. H. Improved malarial immunogen. Filed February 26, 1987. Application No. 07/019,000. Patent Number 4,886,782 issued December 12, 1989.
5. Berzofsky, J. A., Takahashi, H., Hosmalin, A., Germain, R. N., and Moss, B. A synthetic antigen evoking anti-HIV response. Filed January 26, 1988. Application No. 07/148,692.
6. Good, M. F., Kumar, S., Berzofsky, J. A., and Miller, L. H. Synthetic vaccine against *P. falciparum* malaria. Filed July 7, 1988. Application No. 07/216,088. Patent 5,028,425 issued July 2, 1991.
7. Berzofsky, J. A., Hale, P. M., Hosmalin, A., Margalit, H., Spouge, J. L., and Cornette, J. L. Synthetic vaccine against AIDS virus. Filed July 21, 1988. Application No. 07/222,684. Patent 5,030,449 issued July 9, 1991.
8. Berzofsky, J. A., Kurata, A., Palker, T. J., and Haynes, B. F. Immunodominant sites of HTLV-I envelope protein. Filed September 1, 1989. Application No. 07/401,441. Patent 5,622,703 issued April 22, 1997. Patent 5,695,762 issued Dec. 9, 1997.
9. Berzofsky, J. A., Hosmalin, A., Clerici, M., Germain, R. N., Shearer, G. M., Moss, B., and Pendleton, C. D. Peptides stimulating cytotoxic T cells immune to HIV RT. Filed March 9, 1990. Application No. 07/489,825. Patent 5,336,758 issued August 9, 1994.
10. Berzofsky, J.A. Multideterminant peptide antigens that stimulate helper T lymphocyte response to HIV in a range of human subjects. Filed August 29, 1991. Application No. 07/751,998. Patent 5,939,074 issued August 17, 1999.

11. Berzofsky, J.A., Takahashi, H., and Germain, R.N. Method to induce cytotoxic T lymphocytes specific for a broad array of HIV-1 isolates using hybrid synthetic peptides. Filed September 18, 1991. Application No. 07/760,530.
 - a. Patent 5,711,947 issued January 27, 1998; Patent 5,820,865 issued October 13, 1998.
12. Berzofsky, J.A., Takeshita, T., Shirai, M., Pendleton, C.D., Kozlowski, S., and Margulies, D.H. Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope. Filed March 6, 1992. Application No. 07/847,311. Patent 5,976,541 issued November 2, 1999.
13. Shearer, G.M., Berzofsky, J.A., and Clerici, M. Test of HIV-specific T lymphocyte function that detects exposure to HIV antigens and possibly early HIV infection. Filed May 14, 1992. Application No. 07/882,078.
14. Berzofsky, J.A., Shirai, M., Akatsuka, T., and Feinstone, S.M. Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells. Filed June 10, 1992. Application 07/894,063. Patent 5,980,899 issued Nov. 9, 1999.
15. Berzofsky, J.A., Yanuck, M., Takahashi, H., Carbone, D.P., and Minna, J.D. Novel Immunotherapeutic Methods and Vaccines. Filed March 15, 1993. Application No. 08/031,494.
16. Berzofsky, J.A., Ahlers, J.D., Pendleton, C.D., Nara, P., and Shirai, M. Composite synthetic peptide construct eliciting neutralizing antibodies and cytotoxic T lymphocytes against HIV. Filed May 14, 1993. Application No. 08/060,988. U. S. Patent 5,932,218 issued August 3, 1999. European Patent 0701572 B1, issued August 11, 1999. Divisional: Multideterminant peptides that elicit helper T lymphocyte, cytotoxic T lymphocyte, and neutralizing antibody responses against HIV-1. U.S. Patent 6,294,322 B1 issued Sept. 25, 2001.
17. Berzofsky, J.A., Feinstone, S., and Shirai, M. Hepatitis C virus core peptide for stimulation of cytotoxic T lymphocytes and diagnosis of HCV exposure. Filed April 8, 1994. Application No. 08/224,973. European patent 0754193 issued June 14, 2000.
18. Goletz, T.J., Berzofsky, J.A., and Helman, L.J. Novel immunotherapeutic methods and vaccines. Filed September 15, 1995. Application No. 08/528,129. Notice of allowance April 14, 1999. U.S. Patent 5,997,869 issued December 7, 1999.
19. Klimpel, K., Goletz, T.J., Arora, N., Leppla, S.H., and Berzofsky, J.A. Targeting antigens to the MHC class I processing pathway with an Anthrax toxin fusion protein. Filed September 17, 1996. Application No. 60/025,270. US Patent 6,592,872 issued July 15, 2003.
20. Berzofsky, J.A., Belyakov, I.M., Derby, M.A., Kelsall, B.L., and Strober, W. Mucosal cytotoxic T lymphocyte responses. Filed September 11, 1997. Application 60/058,523.

Divisional 10/815,340 filed April 15, 2004. Patent 6,749,856 issued June 15, 2004.
European Patent 1011720 issued Dec. 29, 2004.

21. Berzofsky, J.A., Sarobe, P., Major, M., Feinstone, S.H. Modified HCV peptide vaccine. Filed Aug. 21, 1998. Application 60/097,446. Application 09/763,260 filed Oct. 19, 2001 as continuation. US Patent 6,685,944 issued February 3, 2004. US Patent 7,074,410 issued July 22, 2006. US Patent 7,341,726 issued March 11, 2008.
22. Berzofsky, J. A., M. Terabe, D. D. Donaldson, S. Matsui, N. Noben-Trauth, and W. E. Paul. Method and composition for enhancing an immune response. Filed October 20, 2000. Application 90/693,600. Exclusively licensed.
23. Terabe, M., S. Matsui, , J.A. Berzofsky. Methods to Prevent Tumor Recurrence by Blockage of TGF-Beta. Application US 60/421,286. Filed October 25, 2002. PCT International Application PCT/US03/34023 Filed October 24, 2003. Australian Patent 2003284994 issued February 25, 2010. Certificate of European Letters Patent 1556071 issued January 19, 2011.
24. Morris, J., J.A. Berzofsky, Y. Sakai, J.-M. Park, M. Terabe. Methods for Prophylaxis and Treatment of HER-2/neu Tumors. Provisional application filed 2002.
25. Perera, L. P., T. A. Waldmann, S. Oh, J. A. Berzofsky. Recombinant Vaccinia Viruses Expressing IL-15 and Methods of Using the Same. Application #: U.S. Provisional 60/433,703. Filed December 16, 2002. US Patent 8,663,622 issued March 4, 2014. Canadian Patent application 2,510,309 allowed March 18, 2014. European Patent 1575601 issued July 1, 2015.
26. Berzofsky, J. A., and T. Okazaki. Enhanced HIV-1 Vaccines and Methods for Their Use. U.S. Provisional Application 60/459,507, filed March 31, 2003. US Patent application 10/551,405 filed Sept. 29, 2005, allowed Dec. 30, 2009. US Patent 7,731,971 Enhanced CTL epitope-containing HIV-1 reverse transcriptase polypeptides, issued June 8, 2010. US Patent 8,877,914 Compositions comprising nucleic acids encoding HIV-1 reverse transcriptase epitopes, issued November 4, 2014.
27. Berzofsky, J.A., I. Pastan, S. Oh. Immunogenic Peptides and Peptide Derivatives for Prostate and Breast Cancer Treatment. Application # 60/476,467. Filed June 5, 2003. National Stage US Patent Application 10/559,329 filed December 2, 2005. Divisional Application 12/430,837 filed April 27, 2009. US Patent 7,541,035 issued June 2, 2009. US Patent 8,043,623 issued October 25, 2011.
28. Berzofsky, J.A., J. T. Snyder, II, A. Dzutsev, and I. M. Belyakov. Peptides for the induction of an immune response to vaccinia virus and their use. Application 60/512,039. Filed October 16, 2003.
29. Berzofsky, J.A., I. H. Pastan, and M. Terabe. Immunogenic peptides of XAGE-1. Application # 60/529,025. Filed December 12, 2003. International PCT/US2004/041639 filed December 13, 2004.

30. Berzofsky, J.A., and T. Okazaki. Epitope-Enhancement of a Human CD4 HIV Epitope. Application # 60/567,073, filed on April 30, 2004
31. Catanzaro, A., R. Yarchoan, J. A. Berzofsky, T. Okazaki, J. T. Snyder, and S. Broder. Vaccines and Methods for Prevention and Treatment of Drug-Resistant HIV-1 and Hepatitis B Virus. Application 60/655,984 pending, filed Feb. 22, 2005. US Patent 9,474,793 issued October 25, 2016.
32. Terabe, M., S. Takaku, and J. A. Berzofsky. Synergistic effect of TGF-beta blockade and immunogenic agents on tumors. U.S. Patent Application No. 60/654,329, filed February 17, 2005. US 11/816,410.
33. Berzofsky, J.A., L. T. van den Broeke, C. Mackall, and L. J. Helman. Immunogenic Peptides and Methods of Use for Treating and Preventing Cancer: A peptide epitope and improvement thereof inducing T cell immunity to alveolar rhabdomyosarcoma in HLA-B7-positive individuals. U.S. provisional patent application no. 60/733,319 filed on November 3, 2005; PCT/ US2006/41462 filed October 24, 2006. US Patent application 12/092,449 filed May 2, 2008. US Patent 7,867,977 issued January 11, 2011. US Patent 8,614,304 B2 issued December 24, 2013. US Patent 9,206,245 B2 issued December 8, 2015.
34. Khleif, S.N. and J. A. Berzofsky. Methods and Composition for Co-stimulation of Immunological Responses to Peptide Antigens. Provisional Application 60/189,396 filed March 15, 2000. US Patent Application No. 09/810,310, filed March 14, 2001. European Patent EP1877087.
35. Khleif, S.N and J. A. Berzofsky. Human Papillomavirus Immunoreactive Peptides. Provisional US Patent Application No. 60/278,520 filed March 23, 2001; PCT/US2002/09261 filed March 22, 2002. US National Stage application 10/472,661 filed September 22, 2003. US Patent 7,189,513 issued March 13, 2007. Australian Application No. AU2002258614 filed March 22, 2002. European Patent application EP2002/728570 filed March 22, 2002; European Patent EP14250391. Canadian application CA244197 filed March 22, 2002. US Patent 7,507,538 issued March 24, 2009.
36. Strober, W., S. Fichtner-Feigl, M. Terabe, A. Kitani, I. Fuss, J. A. Berzofsky. Treatment Of Primary Tumors and Tumor Metastases with TNF-alpha Antagonists. U.S. Patent Application No. 60/962,668 filed July 31, 2007.
37. Berzofsky, J.A., I. M. Belyakov and Q. Zhu. Immunostimulatory Combinations of TLR Ligands and Methods of Use. US Provisional Patent Application Serial No. 60/995,212 filed September 24, 2007. European Patent 2200639 issued 30 March, 2016. US Patent 9,421,254 issued August 23, 2016.

38. Berzofsky, J.A., Q. Zhu, and J. Talton. Oral Delivery of a Vaccine to the Large Intestine to Induce Mucosal Immunity. US Provisional Patent Application Serial No. 61/238,361 filed August 31, 2009.
39. Berzofsky, J.A., J. O'Konek, M. Terabe, P. Illarionov, G. Besra. Beta-Mannosylceramide and Stimulation of NKT cell Anti-tumor Immunity. US Provisional Application Serial No. 61/313,508 filed March 12, 2010. US Patent 8,835,613 issued September 16, 2014. Divisional patent 9,168,291 issued October 27, 2015. US Patent 9,517,243 issued December 13, 2016.
40. Berzofsky, J.A., Y-H. Huang, M. Terabe, and I. H. Pastan. Immunogenic POTE peptides and methods of use. US patent application #61/313,559 filed March 12, 2010. US Patent 8,871,902 B2 issued October 28, 2014.
41. Berzofsky, J.A., L. V. Wood, B. D. Roberson and M. Terabe. Multi-epitope TARP peptide vaccine and uses thereof. US Provisional application 61/915,948 filed December 13, 2013. PCT /US2014/070114 filed December 12, 2014. Patent 14831120.2 in Europe issued May 8, 2019. US Patent 14/102,996 issued May 14, 2019.
42. Petit, R. A. Wallecha, Z. Chen, J.A. Berzofsky, S. Khleif. Methods and compositions for increasing T-effector cell to regulatory T cell ratio. US Patent Application 2014 61/948,453 filed March 5, 2014. PCT/US 2015 018915 filed March 5, 2015.
43. Berzofsky, J.A., S. N. Khleif, R. Petit, A. Wallecha, and Z. Chen. Listeria-based immunogenic compositions for eliciting anti-tumor responses. U.S. Provisional Application #62/026,221 filed July 18, 2014. PCT Application PCT/US2015/040922 filed July 15, 2015.
44. Berzofsky, J.A., L.V. Wood, B.D. Roberson, J.C. Steel, M.K. Brenner, M. Terabe, and J.C. Morris. Compositions and methods for the treatment of HER2-expressing solid tumors. U.S. Provisional Application #62/248,964 filed October 30, 2015. PCT Application PCT/US2016/059680 filed October 31, 2016.
45. Jones, Jennifer C., Aizea Morales Kastresana, J.A. Berzofsky. Molecular Nanotags. US Provisional Patent Application Serial No. 62/411,324, filed October 21, 2016.
46. Johnson, Kenya, M. Mkrtichyan, Eric Jacobson, Frank K. Bedu-Addo, Samir N. Khleif, J.A. Berzofsky. Cationic Lipid Vaccine Compositions and Methods of Use. US Provisional Application Serial No. 61/660,172, filed June 13, 2012. PCT/US2013/045578 application filed June 13, 2013. US National Stage application 14/407,419, filed December 11, 2014.
47. Jones, Jennifer C., J.A. Berzofsky, Joshua A. Welsh, Katherine McKinnon. Exo-Clean Method for Removing Proteins and Unbound Labels from Extracellular Vesicle Preparations. US Provisional Application Serial No. 62/612,040 filed December 29, 2017. PCT/US2018/067913 filed Dec. 28, 2018.

48. Jones, Jennifer C., Joshua A. Welsh, William G. Telford, J.A. Berzofsky, Ariel Rosner. Optical Configuration Methods for Spectral Scatter Flow Cytometry. US Provisional Application Serial No. 62/575,988, filed October 23, 2017. PCT/US2018/057128 filed Oct 23, 2018.
49. Lise H. Pasquet, Jay A. Berzofsky, Amy R. Howell, Masaki Terabe, Kaddy Camara, Stuart K. Richardson. Activators of Type II NKT Cells and Methods of Use Thereof. US Provisional Application Serial No. 62/648,167, filed March 26, 2018. PCT/US2019/238890 filed March 25, 2019.
50. Jennifer C. Jones, Joshua A. Welsh, Jay A. Berzofsky. Biomarker Analysis for High-Throughput Diagnostic Multiplex Data. US Provisional Application Serial No. 62/650,162, filed March 29, 2018. PCT/US2019/024975 filed March 29, 2019.

CRADAs

NIH CRADA 01361 with Genzyme Corporation (2003-2013). Co-principal Investigator
 NIH CRADA 02287 with NanoTherapeutics Corp (2007-date). Principal Investigator.
 NIH CRADA 02519 with Amplimmune, Inc. (2010-date). Principal Investigator
 NIH CRADA 02829 with Xoma, Inc (2013 to date). Co-principal investigator.
 NIH CRADA 02891 with Beckman-Coulter (2014 to date). Co-principal investigator.
 NIH CRADA 02927 with Intensity Therapeutics (2014 to date). Principal investigator.
 NIH CRADA 02525 with Osel, Inc. (2010 to date). Principal Investigator since Dec, 2011.
 NIH Collaborative MTA 34624 with Glycosyn (part of Callaghan Innovative Research Limited)
 NIH CRADA 03039 with PDS Biotechnology, Inc. (2016 to date)
 NIH CRADA 03048 with RareCyte, Inc. (2016 to date)
 NIH CRADA 03176 with NextCure, Inc. (2017 to date)

Clinical Protocols/Trials

94-C-0031: Detection of immunologic responses and vaccination against tumor specific mutant ras and p53 peptides in patients with cancer.

PI: Jay A. Berzofsky, M.D., Ph.D.

99-C-0023: A phase I/II trial of vaccination with mutant ras peptide-pulsed dendritic cells in the treatment of HLA-A2.1-positive patients with colorectal cancer.

PI: Jay A. Berzofsky, M.D., Ph.D.

99-C-0142: Phase II trial of individualized mutant p53 peptide-pulsed cultured autologous dendritic cells in the adjuvant treatment of patients with locally advanced non-small cell lung cancer after standard therapy.

PI: Jay A. Berzofsky, M.D., Ph.D.

06-C-0200: A phase I study of the safety and efficacy of GC1008: a human anti-transforming growth factor-beta (TGF-beta) monoclonal antibody in patients with advanced renal cell carcinoma or malignant melanoma.

PI: John C. Morris, M.D. (formerly with Metabolism Branch, NCI, now at U of Cincinnati)

Lead AI: Jay A. Berzofsky, M.D., Ph.D.

09-C-0139: A pilot study of vaccination with epitope-enhanced TARP peptide and TARP peptide-pulsed dendritic cells in the treatment of Stage D0 prostate cancer.

PI: Jay A. Berzofsky, M.D., Ph.D.

Lead AI: Lauren V. Wood, M.D.

09-C-0024: A phase I study of quadrivalent human papilloma virus (HPV) (Types 6, 11, 16, 18) recombinant vaccine in HIV-infected and HIV-negative pre-adolescents, adolescents and young adults.

PI: Lauren V. Wood, M.D.

Lead Associate Investigator: Jay A. Berzofsky, M.D., Ph.D.

13-C-0016: A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults with Tumors with 1-3+ HER2/neu Expression.

PI: Hoyoung Maeng, M.D.

Lead AI: Jay A. Berzofsky, M.D., Ph.D.

15-C-0075: A randomized, placebo-controlled phase II study of multi-epitope TARP peptide autologous dendritic cell vaccination in men with Stage D0 prostate cancer.

PI: Hoyoung Maeng, M.D.

Lead AI: Jay A. Berzofsky, M.D. Ph.D.

15-C-0076: A pilot study of long term TARP vaccination using a multi-epitope TARP peptide autologous dendritic cell vaccination in previously vaccinated men on NCI 09-C-0139.

PI: Hoyoung Maeng, M.D.

Lead AI: Jay A. Berzofsky, M.D., Ph.D.

Jay A. Berzofsky
Speaking and Chairmanship Invitations
1990-2014

1990

- 27 Jan.-3 Feb., 1990 UCLA Symposium on Cellular Immunity and the Immunotherapy of Cancer, Park City, Utah. Invited plenary session speaker.
- 5 Feb., 1990 Walter Reed Army Institute of Research AIDS Conference, Washington, D.C., Invited speaker.
- 2 March, 1990 University of Pennsylvania School of Medicine, Philadelphia, PA, seminar speaker.
- 1-7 April, 1990 UCLA Symposium on HIV and related Retroviruses, Keystone, CO. Invited plenary session speaker.
- 3-7 June, 1990 American Association of Immunologists, FASEB, Meeting, New Orleans, LA. Invited symposium chairperson (Antigen Processing and Presentation) and symposium speaker.
- 20-24 June, 1990 Sixth International Conference on AIDS, San Francisco, CA. Invited plenary session speaker on Vaccines.
- 8-12 July, 1990 Symposium on Antigen Presenting Cells organized by the University of Vienna, Baden bei Wien, Austria. Invited speaker.
- 11-17 Aug., 1990 Laboratory of Tumor Cell Biology Meeting on AIDS and Human Retroviruses, Bethesda, Md. Invited speaker and session chairperson.
- 9-12 Sept., 1990 European Federation of Immunological Societies Meeting, Edinburgh, Scotland, U.K. Invited plenary session speaker.
- 19 Oct., 1990 University of Massachusetts Medical School, Worcester, MA. Invited seminar speaker.
- 29-30 Oct., 1990 NCI Cancer Vaccine Workshop, Bethesda, MD. Invited speaker.
- 15-16 Nov., 1990 New Horizons in Immunology Symposium, organized by *Nature*, Boston, MA. Invited speaker.
- 4 Dec., 1990 National Academy of Sciences Institute of Medicine Meeting on Malaria, Washington, D. C. Invited speaker.

1991

- 12-17 March, 1991 Keystone Symposium on Immunotoxins, Denver, CO. Invited Plenary Speaker.
- 17 April, 1991 Harvard Medical School, Immunology Program, Boston, MA. Invited speaker.
- 3-6 May, 1991 Association of American Physicians, Seattle, WA. HIV session speaker.
- 17-18 May, 1991 Columbia University/Progenics Conference on AIDS, Arden House, NY. Invited speaker.
- 16-21 June, 1991 7th International Conference on AIDS, Florence, Italy. Invited speaker.
- 1-8 Sept., 1991 Laboratory of Tumor Cell Biology Retrovirus Meeting, Bethesda, MD. Invited speaker and session chairperson.
- 19-23 Sept., 1991 Cold Spring Harbor Vaccine Conference, Cold Spring Harbor, NY. Invited opening speaker.
- 15-19 Oct., 1991 Queensland Institute for Medical Research, Bancroft Center Opening Symposium, Brisbane, Queensland, Australia. Invited Plenary Keynote Speaker.
- 15 Nov., 1991 NIH Technology Transfer Symposium, Bethesda, MD. Invited speaker.
- 22 Nov., 1991 University of Virginia School of Medicine, Dept. of Microbiology, Charlottesville, VA. Invited speaker.

1992

- 10 January, 1992 Uniformed Services University of the Health Sciences, Bethesda, MD. Immunology course guest lecturer on Ir genes, antigen processing and presentation.
- 4 February, 1992 National Cancer Institute, Experimental Immunology Branch, Bethesda, MD. Invited guest seminar speaker.
- 12 February, 1992 National Institute of Diabetes, Digestive, and Kidney Diseases, Laboratory of Chemical Biology, Bethesda, MD. Invited seminar speaker.
- 27 Mar.-4 Apr., 1992 Keystone Symposium on Prevention and Treatment of AIDS, Keystone, CO. Invited plenary speaker.

- 27 May, 1992 Columbia University College of Physicians and Surgeons, New York, NY. 31st Michael Heidelberger Award and Lecture.
- 5 June, 1992 Tufts University School of Medicine, Department of Medicine, Boston, MA. Invited Grand Rounds speaker.
- 13 July, 1992 National Cancer Institute, Laboratory of Tumor Cell Biology, Bethesda, MD. Invited seminar speaker.
- 9-16 Aug., 1992 National Cancer Institute, LTCB Annual Symposium on Human Retroviruses, Bethesda, MD. Invited speaker and session chairperson.
- 23-28 Aug., 1992 8th International Congress of Immunology, Budapest, Hungary. Invited chairperson of Workshop on Antigen Processing and Presentation, and speaker.
- 29-31 Aug., 1992 Symposium on Prediction and Recognition of Antigenic Determinants, Eötvös University, Budapest, Hungary. Invited plenary speaker & chair.
- 21-22 Sept., 1992 NIH Research Festival, Bethesda, MD. Invited chairperson and speaker.
- 19-20 Oct., 1992 University of Texas Medical Branch, Galveston, TX. McLaughlin Visiting Professor.
- 20-23 Oct., 1992 54th Annual MD Anderson Symposium on the Immunobiology of Cancer, Houston, TX. Invited plenary speaker.

1993

- 21-24 Jan., 1993 New York Academy of Sciences Symposium on the Specific Immune Treatment of Cancer, Washington, DC. Invited plenary speaker.
- 8-14 Feb., 1993 Keystone Symposium on Antigen Processing and Presentation, Taos, NM, Invited plenary speaker.
- 17-24 March, 1993 Joint Keystone Symposia on Cellular Immunity and Immunotherapy of Cancer, and on the Molecular Immunology of Virus Infections, Taos, NM. Invited joint plenary session speaker.
- 19-29 April, 1993 CBER-FDA Workshop on HIV Vaccines, Bethesda, MD. Invited speaker.
- 28-30 July, 1993 FDA Workshop on Combination Vaccines, Bethesda, MD. Invited speaker.
- 22-28 Aug., 1993 Laboratory of Tumor Cell Biology Annual Retrovirus Meeting, Bethesda, MD. Invited speaker and chairperson.

- 20-24 Sept., 1993 Cold Spring Harbor Symposium on Vaccines including the Prevention and Treatment of AIDS, Cold Spring Harbor, NY. Invited opening plenary speaker.
- 1-4 Nov., 1993 National Cooperative Vaccine Development Meeting on Advances in AIDS Vaccine Development, Division of AIDS, NIAID, Alexandria, VA. Invited speaker.
- 5-7 Nov., 1993 Project Inform/Immune Restoration Think Tank on HIV Treatment, Baltimore, MD. Invited Discussant.
- 10 Dec., 1993 Institute of Medicine Symposium "Towards an Understanding of the Correlates of Protective Immunity to HIV Infection," Washington, DC. Invited participant.
- 1994**
- 23-30 Jan., 1994 Keystone Symposium on HIV, Hilton Head Island, SC. Invited plenary speaker.
- 13-30 Feb., 1994 Keystone Symposium on Human Tumor Viruses, Taos, NM. Invited plenary speaker.
- 29 Apr.-2 May, 1994 American Society for Clinical Investigation, Baltimore, MD. Presidential address.
- 18-19 July, 1994 Conference on Novel HIV Vaccine Strategies, Washington, D.C. Invited plenary speaker.
- 19-21 Sept., 1994 NIH Research Festival, Bethesda, MD. Invited speaker.
- 25-30 Sept., 1994 Laboratory of Tumor Cell Biology Annual Retrovirus Meeting, Bethesda, MD. Invited speaker and chairperson.
- 5-9 Oct., 1994 Cold Spring Harbor Meeting on Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor, NY. Invited keynote speaker.
- 1995**
- 16-23 Jan., 1995 Keystone Symposium on Molecular Aspects of Viral Immunity, Keystone, CO. Invited plenary speaker.
- 25-27 Jan., 1995 Jennifer Jones Simon Foundation Workshop on Cancer Immunotherapy, Los Angeles, CA. Invited discussant.

- 29 Jan-2 Feb, 1995 American Society for Microbiology 2nd National Conference on Human Retroviruses & Related Infections, Washington, DC. Invited speaker.
- 9 Feb., 1995 National Cancer Institute, Pediatric Oncology Branch, NIH, Bethesda, MD. Invited seminar speaker.
- 3-5 Mar., 1995
AIDS and Second International Conference on Engineered Vaccines for Cancer, San Francisco, CA. Invited plenary speaker.
- 19 May, 1995 University of Michigan, Dept. of Medicine, Ann Arbor, MI. Ground Rounds speaker.
- 23-29 July, 1995 9th International Congress of Immunology, San Francisco, CA. Invited plenary symposium chairperson and speaker.
- 27 Aug-2 Sept, 1995 Laboratory of Tumor Cell Biology Annual Retrovirus Meeting, Bethesda, MD. Invited chairperson and speaker.
- 6-9 Sept., 1995 Queensland Institute for Medical Research Golden Jubilee Symposium, Brisbane, Australia. Invited plenary speaker.
- 10-23 Sept., 1995 Australasian Society for Immunology Visiting Speaker, Melbourne, Canberra, & Sydney, Australia, and Dunedin & Auckland, New Zealand.
- 10 Nov., 1995 Emory University, Dept. of Microbiology and Immunology, Atlanta, GA. Invited seminar speaker.
- 30 Nov-3 Dec, 1995 First International Antigen Processing and Presentation Conference: Fundamental Mechanisms and their Application, Los Angeles, CA. Invited speaker.
- 16-19 Dec., 1995 Winter Advanced Course in Immunology and Infectious Disease, Tsuruoka, Japan. Invited faculty member/speaker.
- 1996**
- 26-27 Feb., 1996 IBC Vaccine Technology Conference, Washington, DC. Invited speaker
- 25 Mar., 1996 CHI Symposium on New Cancer Strategies: p53 Diagnostics and Therapy, Washington, DC. Invited speaker.
- 26 Mar., 1996 Institute of Medicine Vaccine Workshop, Washington, DC. Invited speaker.
- 17-20 Apr., 1996 British Society for Immunology Jenner Bicentenary Symposium, Bristol, UK. Invited plenary speaker.

- 7-13 Sept., 1996 Institute of Human Virology Annual Retrovirus Meeting, Baltimore, MD.
Invited speaker.
- 1-3 Oct., 1996 NIH Intramural Immunology Retreat, Airlie, VA. Invited workshop chair.
- 25-27 Oct., 1996 University of Rome Cancer Immunotherapy Symposium, Rome, Italy.
Invited speaker.
- 23-27 Nov., 1996 Japan Immunology Society Jenner Bicentenary Symposium, Yokohama,
Japan. Invited plenary speaker.

1997

- 22 Jan., 1997 AIDS Malignancies Working Group Symposium, Washington, DC.
Invited speaker.
- 1-7 Feb., 1997 Keystone Symposium on Cellular Immunology and Immunotherapy of
Cancer, Copper Mountain, CO. Invited plenary speaker.
- 3-4 Mar., 1997 University of Alabama at Birmingham, Dept. of Medicine Trainee
Research Symposium, Invited Keynote Speaker.
- 23-25 Mar., 1997 Symposium on Immunogenicity of Proteins, Genentech, South San
Francisco, CA. Invited speaker.
- 9 Apr., 1997 NCI Grand Rounds Speaker, Bethesda, MD (Construction of Engineered
Vaccines for HIV).
- 13-19 Apr., 1997 Keystone Symposium on Tolerance and Autoimmunity, Keystone, CO.
Invited workshop chair.
- 30 Apr.-2 May, 1997 2nd National Symposium on Basic Aspects of Vaccines, Bethesda, MD.
Invited session chairperson and plenary speaker.
- 15-21 Sept., 1997 Institute of Human Virology Annual Meeting, Baltimore, MD. Invited
State-of-Art Lecturer.

1998

- 14 Jan., 1998 NIDR Invited Lecture, Bethesda, MD.
- 5-8 March, 1998 UCLA Symposium "Towards an HIV Vaccine: Immunopathogenesis of
HIV Infection," Palm Springs, CA. Invited plenary speaker.
- 13-19 March, 1998 Keystone Symposium on HIV Pathogenesis and Treatment, Park City,
Utah. Invited speaker.

- 27 March, 1998 Georgetown University Lombardi Cancer Center, Washington, D.C. Invited speaker.
- 3 June, 1998 Wistar Institute, University of Pennsylvania, Philadelphia, PA. Invited speaker.
- 16 June, 1998 Bio'98 Symposium, New York, NY. Invited symposium speaker.
- 23-29 Aug., 1998 Institute of Human Virology Annual Meeting, Baltimore, MD. Invited State-of-Art Lecturer
- 18-22 Oct., 1998 5th International Union of Biochemistry and Molecular Biology Conference on the Biochemistry of Health and Disease, Jerusalem, Israel. Invited Symposium Speaker.
- 25 Oct., 1998 Weizmann Institute of Science, Rehovot, Israel, Invited seminar speaker.
- 26 Oct., 1998 University of London Medical School, Guy's Hospital, Invited seminar speaker.
- 1-6 Nov., 1998 10th International Congress of Immunology, New Delhi, India. Invited Symposium Speaker.
- 18-20 Nov., 1998 NMHCC Conference on Functional Antigenics, Washington, D.C. Invited speaker.
- 10-11 Dec., 1998 FDA-NCI Workshop on Tumor Vaccines, Bethesda, MD. Invited speaker.

1999

- 7-13 Jan., 1999 Keystone Symposium on HIV Vaccine Development, Keystone, CO. Invited speaker
- 16 March, 1999 University of Pittsburgh School of Medicine, Invited seminar speaker
- 12-17 April, 1999 Keystone Symposium on DNA Vaccines, Snowbird, Utah. Co-organizer and invited plenary speaker.
- 21-23 April, 1999 5th National Symposium on the Basic Aspects of Vaccines, Bethesda, MD. Invited plenary session chair and speaker.
- 6 May, 1999 Workshop on Alloimmunization as a Strategy for Vaccine Design against HIV/AIDS, Bethesda, MD. Invited speaker.
- 7-9 June, 1999 6th International Symposium on Hepatitis C and Related Viruses, Bethesda, MD. Invited plenary speaker.
- 30 Aug-3 Sept 1999 Institute of Human Virology Annual Meeting, Baltimore, MD. Invited State-of-Art Lecturer
- 8-10 Sept., 1999 International Congress on Cytokines, Bethesda, MD. Invited speaker.
- 13 Dec., 1999 Hôpital Cochin INSERM Unit, Paris, France. Invited seminar speaker.
- 13-15 Dec., 1999 Club Francophone des Cellules Dendritiques Symposium, Paris, France. Invited plenary speaker.

2000

- 21-27 Jan., 2000 Keystone Symposium on Cellular Immunology and Immunotherapy of Cancer, Santa Fe, NM, Invited Workshop Chairperson and speaker.
- 8-12 March, 2000 2nd Sabin Vaccine Foundation Walker's Cay Colloquium on Immunotherapy of Cancer, Invited Speaker
- 6 April, 2000 New York Blood Center, New York, NY. Invited seminar speaker.
- 3-5 May, 2000 6th National Symposium on the Basic Aspects of Vaccines, Bethesda, MD. Invited plenary session chair and speaker.
- 11 May, 2000 NIH Cytokine Symposium, Bethesda, MD. Invited Speaker
- 12-16 July, 2000 Mid-Summer Symposium on Hepatitis C Virus Vaccines, Jamaica. Invited speaker and session organizer/chair

- 10-15 Sept., 2000 Inst. of Human Virology Annual Mtg, Baltimore, MD. Invited State-of-Art Lecturer
- 22 Sept., 2000 NCI Symposium on Bench to Bedside and Back, Basic and Translational Biomedical Research, Bethesda, MD. Organizer and Chair.
- 2 Nov., 2000 NIH Collaborative Meeting on HIV Vaccines, Bethesda, MD. Invited Speaker.
- 7-8 Dec., 2000 Forum for Collaborative HIV Research/ George Washington University Workshop on Immune-Based Therapies and HIV Disease, Washington, DC. Invited discussant.
- 2001**
- 10 January, 2001 Institute of Human Virology, Baltimore, MD. Invited seminar speaker.
- 17-18 Jan., 2001 Genetics Institute, Cambridge, MA. Invited seminar speaker.
- 22-27 Jan., 2001 Keystone Symposium on the Interface between Innate and Adaptive Immunity, Keystone, CO. Invited plenary session speaker.
- 4-8 Feb., 2001 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL. Invited symposium speaker.
- 7-10 Mar., 2001 3rd Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy, Sabin Vaccine Institute, Walker's Cay, Bahamas. Invited speaker.
- 28 Mar.-3 Apr., 2001 Keystone Symposium on AIDS Vaccines in the New Millenium, Keystone, CO. Invited plenary session speaker.
- 1 May, 2001 Vaccine Research Center, NIH, Bethesda, MD. Invited seminar speaker.
- 2-4 May, 2001 7th National Symposium on Basic Aspects of Vaccines, Bethesda, MD. Organizing committee.
- 4-7 May, 2001 Federation of Clinical Immunology Societies (FOCIS) Meeting, Boston, MA. Invited plenary session speaker.
- 2 July, 2001 Celera Genomics, Inc., Rockville, MD. Invited seminar speaker.
- 22-28 July, 2001 11th International Congress of Immunology, Stockholm, Sweden. Invited workshop chair.
- 27 Aug. 2001 IDEC Pharmaceuticals, La Jolla, CA. Invited seminar speaker.
- 9-13 Sept., 2001 International Meeting of the Institute of Human Virology, Baltimore, MD. Invited plenary session speaker.

- 27-31 Oct., 2001 13th Cent Gardes Symposium on Retroviruses of Human AIDS and Related Animal Diseases, Annecy, France. Invited speaker.
- 28 Nov.- 2 Dec., 2001 3rd Midwinter Symposium on Hepatitis C Virus, Barbados. Invited speaker and chairperson.
- 18 Dec., 2001. Pulmonary Branch, National Heart, Lung, & Blood Institute Seminar, Bethesda, MD. Invited speaker.
- 2002**
- 16-22 Jan., 2002 Keystone Symposium on T Lymphocyte Activation, Differentiation, and Death, Keystone, CO. Invited plenary speaker.
- 6-10 March, 2002 Fourth Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy, Walkers Cay, Bahamas. Invited speaker.
- 5-11 April, 2002 Keystone Symposium on HIV-1 Protection and Control by Vaccination, Keystone, CO. Invited plenary speaker.
- 10-15 April, 2002 Keystone Symposium on Gene-Based Vaccines, Breckenridge, CO. Co-organizer and invited plenary speaker.
- 22-24 April, 2002 International Meeting on Cytokines as Natural Adjuvants: Perspectives for Vaccine Development, Rome, Italy. Invited plenary speaker.
- 1-3 May, 2002 8th National Symposium on Basic Aspects of Vaccines, Bethesda, MD. Organizing committee
- 10 May, 2002 International Immunological Readouts Meeting (Workshop), Bethesda, MD. Invited speaker.
- 26 June, 2002 American Association of Immunologists Introductory Course in Immunology, Tufts University, Medford, MA. Invited lecturer.
- 27-31 July, 2002 FASEB Summer Research Conference on Therapeutic and Preventive AIDS Vaccines, Tuscon, AZ. Invited plenary speaker.
- 9-13 Sept., 2002 International Meeting of the Institute of Human Virology, Baltimore, MD. Invited plenary session speaker.
- 23-25 Oct., 2002 DNA Vaccines 2002, Royal College of Physicians, Edinburgh, Scotland. Invited plenary speaker.
- 26-29 Oct., 2002 XIIIth Cent Gardes Meeting on HIV and AIDS Vaccines, Annecy, France. Invited plenary speaker.

- 5-8 Nov., 2002 2nd International Workshop on CD1 Antigen Presentation and NK T Cells, Woods Hole, MA. Invited speaker.
- 18-23 Nov., 2002 BioSecurity 2002: Vaccines: The Paradigm Quake, Las Vegas, NV. Invited speaker.
- 25-27 Nov., 2002 Pan American Health Organization Centennial Celebration Conference on Vaccines, Washington, DC. Invited plenary speaker.

2003

- 7 Jan., 2003 NIH Academy, Invited speaker.
- 15-19 Jan., 2003 AACR Special Conference in Cancer Research: The TGF- β superfamily—roles in the pathogenesis of cancer and other diseases, La Jolla, CA. Invited plenary speaker.
- 23-24 Jan., 2003 AAI/NCI Workshop on Cancer Immunology, Bethesda, MD. Invited participant.
- 27 Jan., 2003 University of Chicago Committee on Immunology Seminars, Chicago, IL. Invited speaker
- 17-23 Feb., 2003 Keystone Symposium on Basic Aspects of Tumor Immunology, Keystone, CO. Invited speaker.
- 5-8 March, 2003 Sabin Vaccine Institute 5th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy, Walker's Cay, Bahamas. Invited speaker.
- 13 March, 2003 Experimental Transplantation Branch, CCR, NCI, Bethesda, MD. Invited seminar speaker.
- 28 Mar-4 Apr., 2003 Keystone Symposium on HIV Vaccine Development, Banff, Alberta, Canada. Invited speaker.
- 23-24 April, 2003 Kunkel Society of Rockefeller University Annual Meeting, New York, NY. Invited plenary speaker.
- 30 Apr.-2 May, 2003 9th WRAIR National Symposium on Basic Aspects of Vaccines, Bethesda, MD. Organizing committee
- 15-19 May, 2003 3rd Annual Meeting of the Federation of Clinical Immunological Societies (FOCIS), Paris, France. Invited speaker.
- 20 May, 2003 American Society for Microbiology Annual Meeting, Washington, DC. Invited symposium speaker.

- 1-2 June, 2003 Nobel Forum on Vaccines and Immunotherapy, Stockholm, Sweden. Invited plenary speaker.
- 29 Sept.-3 Oct., 2003 International Meeting of the Institute of Human Virology, Baltimore, MD. Invited plenary session speaker, special lecture.
- 14-17 Oct., 2003 MD Anderson 56th Annual Symposium on Fundamental Cancer Research: Cancer Immunity: Challenges for the Next Decade, Houston, TX. Invited plenary speaker.
- 1 Dec., 2003 USDA Agricultural Research Service National Immunology Conference, Bethesda, MD. Invited Keynote Speaker.

2004

- 6-11 Jan., 2004 Keystone Symposium on Rational Design of Vaccines and Immunotherapeutics, Keystone, CO. Invited plenary speaker.
- 25-30 Mar, 2004 Keystone Symposium on Immune Evasion, Taos, NM. Invited plenary speaker.
- 17-21 Apr, 2004 American Association of Immunologists Annual Meeting, Washington, DC. Invited Symposium Chairperson and Speaker.
- 29-30 Apr, 2004 10th WRAIR National Symposium on Basic Aspects of Vaccines, Bethesda, MD. Invited Symposium Chairperson and Speaker.
- 13-15 June, 2004 International Workshop on Cancer Vaccines, Siena, Italy. Invited plenary speaker.
- 15-18 June, 2004 International Colloquium on Innate and Adaptive Immunity after Transcutaneous or Mucosal Vaccination, Veyrier du Lac, France. Invited plenary speaker.
- 18-24 July, 2004 12th International Congress of Immunology and 4th Annual Conference of the Federation of Clinical Immunological Societies, Montreal, Canada. Invited minisymposium speaker.
- 6 Sept., 2004 Queensland Institute of Medical Research, Brisbane, Australia. Invited seminar speaker.
- 8-13 Sept, 2004 3rd International Workshop on NKT Cells and CD1-mediated Antigen Presentation, Heron Island, Australia. Invited plenary speaker.

- 10-13 Oct, 2004 International Symposium on Tumor Escape and Its Determinants, Salzburg, Austria. Invited plenary speaker.
- 31 Oct-4 Nov, 2004 International Meeting of the Institute of Human Virology, Baltimore, MD. Invited Symposium Chairperson and Speaker.
- 17 Nov, 2004 The 2004 Tadeusz J. Wiktor Memorial Lecture, Wistar Institute, University of Pennsylvania, Philadelphia, PA.

2005

- 19-24 March, 2005 Keystone Symposium on Basic Aspects of Tumor Immunology, Keystone, CO. Invited Speaker and workshop chair.
- 29 Aug-2 Sept, 2005 International Meeting of the Institute of Human Virology, Baltimore, MD. Invited Symposium Chairperson and Featured Speaker
- 19-21 Sept, 2005 NIH Immunology Interest Group Retreat, Airlie, VA. Invited session chair and organizer.
- 22-23 Sept, 2005 International NCI Symposium on Translational Immunology Related to Cancer, Bethesda, MD. Organizer, Session Chair, and Plenary Speaker.
- 24 Oct., 2005 Albert Einstein College of Medicine, Bronx, NY. Invited seminar speaker.
- 10-11 Nov, 2005 CHAVI Conference on Mucosal Immunity and Vaccines, Duke University, Durham, NC. Invited plenary speaker.
- 16-19 Nov, 2005 First International Dead Sea Conclave on HIV and Cancer Vaccines, Dead Sea, Jordan Valley Marriott Resort and Conference Center, Jordan. Invited session chair and plenary speaker.
- 13-14 Dec, 2005 Boston University International Conference on Biodefense, Boston, MA. Invited plenary speaker.
- 16 Dec, 2005 Laboratory of Experimental Immunology, Frederick Cancer Research and Development Center, CCR, NCI. Invited seminar speaker.

2006

- 5-7 Feb, 2006 Hasumi Foundation International Symposium on Cancer Vaccines, Bethesda, MD. Invited Plenary Speaker.

- 9 Feb, 2006 NCI Symposium on Inflammation and Colon Cancer, Bethesda, MD. Invited panel discussant.
- 5-9 March, 2006 American Association for Asthma, Allergy, and Immunology Annual Meeting, Miami Beach, FL. Invited Plenary Speaker.
- 26-29 May, 2006 International Symposium on Cancer Vaccines, Naples, Italy. Invited Plenary Speaker.
- 4-8 Oct., 2006 International Conference on NKT Cells and CD1, Siena, Italy. Invited speaker.
- 30 Oct., 2006 Symposium on IL-15 and Immunotherapy, Bethesda, MD. Invited speaker.
- 17-21 Nov, 2006 10th International Meeting of the Institute of Human Virology, Baltimore, MD. Invited plenary speaker and session chair.
- 2007**
- 25-28 Jan, 2007 Symposium on Immune Suppression in Cancer, Moffitt Cancer Research Center, Tampa, FL. Invited plenary speaker.
- 1 Feb, 2007 International Society for Cutaneous Lymphoma, Herschel Zackheim Memorial Lecture and Award.
- 8-9 Feb, 2007 FDA-NCI Cancer Immunotherapy workshop, Organizer and session Chair
- 15-19 Feb, 2007 American Association for the Advancement of Sciences (AAAS) Annual Meeting, San Francisco, CA. Chair-elect of Medical Sciences Section.
- 17-18 March, 2007 Symposium on Two Decades of Predictive Biology, Boston University, Boston, MA. Invited plenary speaker
- 21-23 March, 2007 Symposium on Viruses, Genes and Cancer, Venice, Italy. Invited plenary speaker.
- 12-14 April, 2007 International Cancer Vaccine Symposium, Vienna, Austria. Invited plenary speaker.
- 12-14 April, 2007 Third Vienna Vaccines Conference, Baden, Austria. Invited plenary speaker.
- 18-22 May, 2007 94th Annual Meeting of the American Association of Immunologists, Miami Beach, FL. Invited symposium speaker.
- 12-13 July, 2007 NCI Immunotherapy Workshop, Bethesda, MD. Invited speaker.

- 23 July, 2007 Viral Immunology Symposium, Johns Hopkins University School of Public Health, Baltimore, MD. Invited plenary speaker.
- 9-11 Sept. 2007 Nobel Forum on Progress in Vaccines against Cancer, Stockholm, Sweden. Invited plenary speaker.
- 27 Sept, 2007 University of Pittsburgh, Pittsburgh, PA. Invited seminar speaker.
- 9-10 Oct., 2007 NCI Center of Excellence in Immunology Symposium on Cancer and Inflammation, Bethesda, MD. Organizing committee and session chair.
- 28-30 Oct., 2007 ANRS and NIH Symposium on Mucosal Immunity and HIV/AIDS Vaccines, Annecy, France. Invited plenary speaker.
- 1-2 Nov., 2007 NCI Symposium on HIV and AIDS Research, Bethesda, MD. Organizing committee and speaker and session chair.
- 4 Dec., 2007 NCI Center for Cancer Research Grand Rounds, Bethesda, MD. Invited speaker.
- 2008**
- 15-18 Feb, 2008 American Association for the Advancement of Science Annual Meeting, Boston, MA. Invited symposium chair and speaker.
- 6 March, 2008 National Heart, Lung, and Blood Institute, Hematology Branch, Bethesda, MD. Invited seminar speaker.
- 17 March, 2008 Nippon Medical School, Dept. of Immunology, Tokyo, Japan. Invited seminar speaker.
- 18 March, 2008 RIKEN Research Institute, RIKEN Research Center for Allergy and Immunology, Yokohama, Japan. Invited seminar speaker.
- 18 March, 2008 St. Marianna University Medical School, Dept of Rheumatology, Kawasaki, Japan. Invited seminar speaker.
- 19-21 March, 2008 National Institute for Neuroscience, Department of Immunology, Tokyo, Japan. Visiting Professor.
- 2 June, 2008 Institute of Human Virology, University of Maryland, Baltimore, MD. Invited seminar speaker.
- 5 June, 2008 International Symposium on Mucosal Dendritic Cells: From Basic Science to HIV Infection, Paris, France. Invited plenary speaker.

- 13 June, 2008 National Cancer Institute/ Institute of Human Virology Joint Retreat, Bethesda, MD. Invited speaker.
- 17 June, 2008 National Cancer Advisory Board, NCI, Bethesda, MD. Invited speaker.
- 20 June, 2008 Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD. Invited seminar speaker.
- July 24, 2008 NIAID Laboratory of Cellular and Molecular Immunology, Bethesda, MD. Invited course speaker.
- 11-12 Sept., 2008 National Cancer Institute Symposium on Cancer Immunology and Immunotherapy: Realizing the Promise. Bethesda, MD. Invited plenary speaker.
- 13 Sept., 2008 Institute of Human Virology Annual Meeting, Baltimore, MD. Invited session chair and plenary speaker.
- 30 Oct., 2008 University of Miami School of Medicine, Department of Microbiology and Immunology, Miami, FL. Invited seminar speaker.
- 7-9 Nov., 2008 National Cancer Institute Translational Science Meeting, Washington, DC. Invited speaker.
- 14-16 Nov., 2008 Workshop on Vaccines in the Management of Cancer: Where are we heading?, University of Torino, Turin, Italy. Invited speaker.
- 2009**
- 11-16 Jan, 2009 Keystone Symposium on Mobilizing Cellular Immunity for Cancer Therapy, Snowbird, Utah. Invited plenary speaker.
- 23-27 March, 2009 5th International Symposium on CD1 and NKT cells, Kamakura, Japan. Invited plenary speaker.
- 30 April, 2009 Cancer & Inflammation Program Retreat, NCI, Gettysburg, PA. Invited speaker.
- 9-11 May, 2009 Institute of Human Virology Symposium “25 Years after discovering HIV as the cause of AIDS”, Baltimore, Maryland. Invited plenary speaker.
- 20 May, 2009 International Symposium on Immune Regulation, Toronto, Canada. Invited plenary speaker.
- 23 Oct, 2009 Institut Cochin, INSERM, Paris, France. Invited seminar speaker.

- 27-28 Oct, 2009 International Symposium on Critical Frontiers between Immunity and Gene Therapy, Pamplona, Spain. Invited plenary speaker.
- 5-6 Nov, 2009 NCI Translates Symposium, Vienna, Virginia. Invited session speaker.
- 6 Nov, 2009 NCI Prostate SPORE meeting: Translational Clinical Trials in Prostate Cancer, Vienna, Virginia. Invited speaker.
- 19 Nov, 2009 University of Maryland, College Park, MD. Invited seminar speaker.
- 3 Dec, 2009 Lankenau Institute for Medical Research, Philadelphia, PA. Invited seminar speaker.

2010

- 7-12 Feb, 2010 Keystone Symposium on Molecular & Cellular Biology of Immune Escape in Cancer, Keystone, CO. Invited speaker.
- 21-26 March, 2010 Keystone Symposium on HIV Vaccines, Banff, Alberta, Canada. Invited speaker.
- 6 April, 2010 NCI-Prostate Cancer Foundation Symposium on Therapy of Prostate Cancer. Bethesda, MD. Invited speaker.
- 3-4 June, 2010 NCI Symposium on Mucosal Transmission of HIV/SIV and its Prevention by Vaccines and Other Modalities, Bethesda, MD. Invited speaker.
- 17-18 Aug, 2010 Cambridge Healthtech Institute Symposium on Vaccines and Adjuvants, Cambridge, MA. Invited Keynote Speaker.
- 22-27 Aug, 2010 14th International Congress of Immunology, Kobe, Japan. Invited Workshop Chair and Speaker.
- 23-24 Sept, 2010 NCI Symposium on Immunity, Inflammation and Cancer, Bethesda, MD. Invited plenary speaker.
- 4-8 October, 2010 Institute of Human Virology Annual Meeting, Tropea, Calabria, Italy. Invited plenary speaker.
- 2-4 Dec., 2010 Workshop on Immune Correlates of Vaccine Protection, Seattle, WA. Invited panel participant.
- 12-13 Dec, 2010 2nd Annual SEHA Research Conference, Abu Dhabi, UAE. Invited speaker.

2011

- 9-14 Jan, 2011 Keystone Symposium on NK and NKT cell Biology, Breckenridge, CO. Invited plenary session speaker.
- 28-30 April, 2011 Fifth Semmering Symposium: Vaccines—The Key Paradigm for the 21st Century's Health Care Strategy, Baden, Vienna, Austria. Invited plenary speaker.
- 21 June, 2011 Japan Society for Promotion of Science Conference, Washington, DC. Invited Discussant.
- 23-26 June, 2011 Federation of Clinical Immunological Societies Annual Meeting, Washington, DC. Invited plenary session chair.
- 28-29 July, 2011 NCI Translates conference, Washington, DC. Invited speaker.
- 12-14 Sept, 2011 NIH-wide Immunology Retreat, Cambridge, MD. Invited session chair and speaker.
- 22-23 Sept, 2011 NCI Symposium: Cancer Immunology and Immunotherapy: Building on Success. Bethesda, MD. Invited plenary speaker.
- 30 Oct–Nov 2, 2011 13th Annual International Meeting of the Institute of Human Virology, Baltimore, MD. Invited to give plenary special lecture.
- Nov 30–Dec 2, 2011 Japan AIDS Research Society Annual Meeting, Tokyo, Japan. Invited plenary speaker.
- 2012**
- Jan 10, 2012 Laboratory of Molecular Immunology, NHLBI, NIH, Bethesda, MD. Invited seminar speaker.
- Feb 5-10, 2012 Keystone Symposium on Cytokines & IL-17, Keystone, CO. Invited plenary speaker.
- April 24, 2012 Yale Cancer Center, Yale University School of Medicine, New Haven, CT. Invited Grand Rounds speaker and Iris Fisher Memorial Lecture.
- May 23-25, 2012 CIMT Cancer Immunotherapy Conference, Mainz, Germany. Invited plenary speaker.
- June 14, 2012 Georgia Health Sciences University Cancer Center, Augusta, GA. Invited Grand Rounds speaker.
- June 19, 2012 Center of Excellence in Immunology, NCI, Bethesda, MD. Invited seminar speaker.

Oct 14-17, 2012 Institute of Human Virology 14th Annual International Meeting, Baltimore, MD. Invited plenary speaker.

Oct 24-27, 2012 Viruses, Genes and Cancer International Symposium, Venice, Italy. Invited plenary speaker.

2013

14-17 March, 2013 World Immune Regulation Meeting VII, Davos, Switzerland. Invited plenary speaker.

16-18 April, 2013 World Vaccine Congress Washington 2013, National Harbor, MD. Invited plenary speaker.

2 May, 2013 National Cancer Institute Medical Oncology Branch, Bethesda, MD. Invited seminar speaker.

20-22 May, 2013 American Association of Pharmaceutical Scientists 2013 Biotechnology Conference, San Diego, CA. Invited plenary speaker.

29-31 May, 2013 Ninth Elsinore Meeting on Infection & Immunity, Elsinore, Denmark. Invited plenary speaker.

22-27 Aug, 2013 15th International Congress of Immunology, Milan, Italy. Invited workshop speaker.

3-4 Sept, 2013 NIH Immunology Interest Group Workshop, Bethesda, MD. Invited session chair.

8-12 Sept, 2013 15th Annual Meeting of the Institute of Human Virology, Moscow, Russia. Invited plenary speaker.

19-10 Sept, 2013 Center of Excellence in Immunology Symposium on Cancer, Inflammation, Microbiota and Cancer, Bethesda, MD. Invited plenary speaker.

30 Sept-2 Oct, 2013 21st Annual Cancer Research Institute International Cancer Immunotherapy Symposium: Cancer Immunotherapy 2013: Dynamics of Host-Tumor Interaction, New York, NY. Invited plenary speaker.

28 Oct-1 Nov, 2013 Cold Spring Harbor Asia Conference on Tumor Immunology and Immunotherapy, Suzhou, China. Invited plenary speaker.

1-2 November, 2013 22nd Asia Pacific Cancer Conference, Tianjin, China. Invited speaker.

4-6 November, 2013 Chinese Academy of Medical Sciences, Beijing, China. Invited seminar speaker and visiting professor.

2014

30 Jan, 2014 Johns Hopkins School of Public Health, Baltimore, MD. Invited seminar speaker.

10-14 March, 2014 Keystone Symposium on Immune Evolution in Cancer, Whistler, BC, Canada. Invited plenary speaker.

24-26 March, 2014 World Vaccine Congress Washington 2014, Washington, DC. Invited speaker.

27 March, 2014 Division of Viral Products, CBER, FDA, Bethesda, MD. Invited seminar speaker.

1 April, 2014 Cell Signaling Technology, Boston, MA. Invited seminar speaker.

9 April, 2014 La Jolla Institute for Allergy & Immunology, La Jolla, CA. Invited seminar speaker.

20 June, 2014 NCI Cancer & Inflammation Program Seminar, Frederick, MD. Invited speaker

15 Sept 2014 16th Annual International Meeting of the Institute of Human Virology, Baltimore, MD. Invited plenary speaker.

5-7 Oct, 2014 Cent Gardes Conference on HIV Vaccines, Fondation Mérieux, Veyrier du Lac, Annecy, France. Invited speaker

9-10 Oct, 2014 NCI CEI Symposium on Cancer Immunotherapy, Bethesda, MD. Invited session chair.

20-21 Oct, 2014 FDA Conference on Immunomodulators and Cancer Risk Assessment, White Oak, MD. Invited speaker.

31 Oct-3 Nov, 2014 PCS Global Cancer Conference, Athens, Greece. Invited Keynote Speaker.

1-4 Dec, 2014 AACR Tumor Immunology & Immunotherapy Conference, Orlando, FL. Invited speaker.

2015

- 28-30 Jan, 2015 13th Annual Conference on Cytokines and Inflammation GTCBio, San Diego, CA. Invited speaker.
- 8-13 Feb, 2015 Keystone Symposium on Tumor Immunology, Banff, Canada. Invited speaker.
- 7-9 Apr, 2015 World Vaccine Congress 2015, Washington, DC. Invited speaker.
- 28 May-1 June, 2015 American Society for Clinical Oncology (ASCO), Chicago, IL. Invited speaker.
- 16-18 Sept, 2015 Cancer: Inflammation and Immunity International Conference, Finalborgo, Italy. Invited speaker.
- 28-30 Sept, 2015 Computation as a Driver of Translational Medicine International Conference, Catania, Italy. Invited speaker.
- 25-27 Oct, 2015 Cent Gardes Conference on HIV Vaccines, Fondation Mérieux, Veyrier du Lac, Annecy, France. Invited speaker.
- 2-4 Nov, 2015 Vaccines R&D 2015, Baltimore, Maryland. Invited Keynote Speaker.
- 3 Nov, 2015 Ras Immunotherapy Workshop, Bethesda, Maryland. Invited speaker.
- 15-19 Nov, 2015 CD1-MR1 International Conference, Lorne, Melbourne, Australia. Invited speaker.
- 30 Nov, 2015 Institute of Human Virology, Baltimore, Maryland. Invited seminar speaker.
- 9 Dec, 2015 NCI Cancer & Inflammation Program Annual Retreat, Bethesda, Maryland. Invited Keynote speaker.

2016

- 11 Feb, 2016 Wake Forest University School of Medicine, Winston Salem, NC. Invited seminar speaker.
- 29 Feb-1 Mar, 2016 Institute of Medicine, National Academy of Medicine, National Academy of Sciences, Forum on Clinical Development and Use of Immunotherapy for Cancer Treatment. Washington, DC. Invited speaker.
- 20-25 March, 2016 Keystone Symposium on HIV Vaccines, Olympic Valley, CA. Invited plenary session chair and workshop speaker.
- 29-31 March, 2016 World Vaccine Congress, Washington, DC. Invited speaker.

- 1 April, 2016 SITC-NCI Symposium on Immunotherapy Biomarkers, Bethesda, MD. Invited speaker.
- 8-10 April, 2016 Cancer Vaccine Conference, Siena, Italy. Invited plenary speaker.
- 9 May, 2016 Center for Biologics Evaluation and Research, FDA, White Oak, MD. Invited seminar speaker.
- 9 June, 2016 International Institute for Nanotechnology, Northwestern University, Evanston, IL. Invited seminar speaker.
- 27 June, 2016 Yellow Berets to Grey Hair Symposium in Honor of Alan N. Schechter's 50+ Years at NIH, NIH, Bethesda, MD. Invited speaker.
- 21-26 Aug, 2016 International Congress of Immunology 2016, Melbourne, Australia. Symposium speaker.
- 14-16 Nov, 2016 Viruses, Inflammation and Cancer Conference, Venice, Italy. Invited plenary speaker.
- 2017**
- 19-24 March, 2017 Keystone Symposium on Cancer Immunology and Immunotherapy. Whistler, BC, Canada. Invited speaker and workshop chair.
- 28-29 March, 2017 Cambridge Healthtech Institute Symposium on Peptide Vaccines in Cancer, Boston, MA. Invited plenary speaker.
- 10-12 April, 2017 World Vaccine Congress 2017, Washington, DC. Invited speaker.
- 24-27 April, 2017 5th Cancer Immunotherapy & ImmunoMonitoring International Congress (CITIM). Prague, Czech Republic. Invited plenary speaker.
- 19-22 July, 2017 18th International Congress of Mucosal Immunology. Washington, DC. Invited session chair.
- 29-30 Aug, 2017 CHI 5th Annual Immuno-Oncology Summit. Boston, MA. Invited Keynote Speaker.
- 26-27 Sept., 2017 Inaugural Charles River World Congress on Animal Models in Drug Discovery & Development, Boston, MA. Invited Keynote Speaker.
- 12-13 Oct, 2017 NCI Center of Excellence in Immunology Symposium on Cancer Immunology and Immunotherapy, Bethesda, MD. Invited session chair.
- 22-26 Oct, 2017 Cold Spring Harbor Asia International Symposium on Cancer Immunology & Immunotherapy, Suzhou, China. Invited plenary speaker.

- 3-7 Nov, 2017 International Workshop on CD1 and MR1, Napa, California. Invited plenary speaker.
- 13-15 Nov, 2017 3rd International Conference on Vaccines R&D 2017, Reston, VA. Invited Keynote speaker.

2018

- 9 Feb, 2018 NCI Cancer & Inflammation Program Seminar, NCI Frederick. Invited speaker.
- 3-5 April, 2018 World Vaccine Congress, Washington, DC. Invited Keynote speaker.
- 25 April, 2018 Lung-MAP ImmunoOncology Conference, Bethesda, MD. Invited discussant.
- 5-6 July, 2018 European Academy of Tumor Immunology Annual Meeting, Paris, France. Invited to receive the 2018 EATI Honorary Lecture and Career Award “for his important contribution to tumor immunotherapy.”
- 28-30 Aug, 2018 Third Annual Personalized Cancer Vaccines meeting, Boston, MA. Invited speaker.
- 22-25 Oct, 2018 Institute of Human Virology Annual Meeting, Baltimore, MD. Invited plenary speaker.
- 13-15 Nov, 2018 Vaccines R&D International Conference, Baltimore, MD. Invited keynote speaker.

2019

- 16 Jan, 2019 Suppressor cells and TB/HIV. NIAID Conference, Rockville, MD. Invited speaker.
- 18 Jan, 2019 Division of AIDS, NIAID, seminar series, Rockville, MD. Invited seminar speaker.
- 1 Feb, 2019 University of Cincinnati School of Medicine, Cincinnati, OH, Invited Hematology & Oncology Division Grand Rounds speaker.
- 12-14 April, 2019 First International Congress of Bio-Immunotherapy of Cancer, Reggio Calabria, Italy. Invited plenary speaker.
- 8-9 August, 2019 Immuno-Oncology Summit: Personalized Cancer Vaccines, Boston, MA, Invited speaker.

- 1-5 Sept, 2019 EMBO Workshop: CD1-MR1: Beyond MHC-restricted lymphocytes, Oxford, UK. Invited plenary speaker.
- 17-18 Oct, 2019 NCI Symposium: Cancer & Inflammation: From Micro to Macro, Bethesda, MD. Invited session chair.
- 19-23 Oct, 2019 17th International Congress of Immunology, Beijing, China. Invited speaker.
- 18-20 Nov, 2019 Vaccines R&D. Boston, MA. Invited plenary speaker.
- 20 Nov, 2019 Society for Neuro-Oncology Think Tank, Phoenix, AZ. Invited plenary speaker.